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Immunomodulatory	  monoclonal	   antibodies	   (mAbs)	  indicated	   for	   the	   treatment	   of	  
cancer,	   inflammatory	   and	   autoimmune	   diseases	   or	   to	   prevent	   organ	   transplant	  
rejection,	  mostly	  target	  cell	  surface	  molecules	  expressed	  by	  immune	  cells	  including	  
T	  cells.	  The	  presence	  of	   immunosuppressive	  molecules	  during	  disease	  progression	  
can	   hinder	   the	   activity	   of	   immune	   cells.	   Tumour-­‐induced	   immunosuppression	  
enables	  disease	  progression	  and	  various	  strategies	  are	  being	  developed	  to	  enhance	  
the	   anti-­‐tumour	   responses	   of	   cytotoxic	   T	   cells.	   Activation	   of	   effective	   effector	  
responses	  require	  resetting	  of	  metabolic	  activity	   to	   fit	  energy	  and	  anabolic	  needs.	  
While	   the	   benefits	   of	   exploiting	   immunomodulatory	   mAbs	   for	   therapy	   are	  
substantial,	   it	   is	   also	   clear	   that	   use	   of	   these	   biologics	   may	   be	   accompanied	   by	  
adverse	   effects	   such	   as	   cytokine	   release,	   immunosuppression,	   infections	   and	  
autoimmunity.	  Significant	  focus	  in	  recent	  times	  has	  been	  on	  assessing	  the	  potential	  
of	   immunomodulatory	  mAbs	   to	   induce	   enhanced	   cytokine	   release	   but	  much	   less	  
attention	   has	   been	   paid	   to	   other	   aspects	   of	   T	   cell	   biology	   including	   non-­‐
physiological	   activation	   phenotype/functions,	   migration	   characteristics	   and	  
metabolism.	   An	   improved	   understanding	   of	   these	   parameters	   may	   assist	   in	  
accurately	  predicting	  the	  propensity	  of	  new	  mAbs	  to	  induce	  serious	  adverse	  effects.	  	  
Superagonistic	   CD28-­‐specific	   monoclonal	   antibody	   (CD28SA)	   is	   one	   such	  
immunomodulatory	  monoclonal	   antibody	   which	   is	   a	   potent	   stimulator	   of	   T	   cells,	  
originally	  intended	  for	  the	  management	  of	  B	  cell	  chronic	  lymphocytic	  leukaemia	  and	  
rheumatoid	   arthritis.	   Human	   volunteers	   who	   received	   humanized	   CD28SA	  
(TGN1412)	   as	   part	   of	   a	   first-­‐in-­‐man	   trial	   experienced	   life-­‐threatening	   cytokine	  
release	   syndrome.	   Follow-­‐up	   studies	   revealed	   aberrant	   activation	   of	   effector	  
memory	   T	   cells	   (TEM)	   contributed	   towards	   the	   adverse	   reaction.	   The	  
biopharmaceutical	   industry	   is	   actively	   pursuing	   development	   of	   T	   cell	  
immunostimulatory	   mAbs	   and	   there	   is	   a	   significant	   need	   to	   improve	   the	  
understanding	   of	   and	   accurately	   predict	   the	   propensity	   of	   a	   new	   mAb	   to	   drive	  
excessive	  T	  cell	  activation.	  	  Therefore,	  one	  of	  the	  main	  aims	  of	  the	  study	  discussed	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in	  this	  thesis	  was	  to	  determine	  mechanism/s	  underlying	  the	  hyperactive	  phenotype	  
of	  CD28SA-­‐activated	  TEM.	  Observations	   in	   the	   current	   study	   revealed	  activation	  of	  
TEM	  by	  CD28SA	  upregulated	  the	  expression	  of	  activation	  markers	  such	  as	  CD137	  and	  
HLA-­‐DR,	  but	  failed	  to	  express	  co-­‐inhibitory	  receptor,	  PD-­‐1.	  This	  led	  to	  the	  lack	  of	  PD-­‐
1-­‐mediated	  regulation	  of	  aberrant	  TEM	  activation.	  In	  addition,	  CD28SA-­‐activated	  TEM	  
expressed	   elevated	   levels	   of	   LFA-­‐1	   and	   CCR5	   receptors,	   and	   displayed	   increased	  
migratory	  capacity.	  Subsequent	  studies	  highlighted	  increased	  metabolic	  demand	  of	  
CD28SA-­‐activated	   TEM.	   The	   hyperactive	   cells	   with	   increased	   proliferative	   capacity	  
exhibited	   distinct	   metabolic	   profile	   characterized	   by	   increased	   glycolysis	   and	  
lipogenesis.	   These	   findings	   have	   profound	   implications	   for	   strategies	   aiming	   at	  
understanding	  and	  predicting	  the	  safety	  profile	  of	  immunostimulatory	  mAbs.	  
Deployment	   of	   immunosuppressive	   strategies,	   including	   TGF-­‐β	   secretion	   by	  
tumours	   to	   render	   immunostimulatory	   mAbs-­‐mediated	   anti-­‐tumour	   responses	  
ineffective	   is	   well	   studied.	   The	   other	   study	   discussed	   in	   this	   thesis	   aimed	   to	  
delineate	   the	   effects	   of	   oxidative	   stress	   in	   TGF-­‐β-­‐induced	   suppression	   of	   antigen-­‐
specific	   cytotoxic	   T	   cell	   responses.	   This	   study	   showed	   antigen-­‐specific	   T	   cells	  
exposed	   to	   TGF-­‐β	   down	   regulate	   CD25	   and	   LAG-­‐3	   (co-­‐inhibitory	   T	   cell	   receptor)	  
expression,	   secrete	   lower	   levels	   of	   IL-­‐2	   and	   IFN-­‐γ,	   and	   reduced	   glycolysis.	   In	  
addition,	  mitochondrial	   reactive	   oxygen	   species	   (MitoROS)	   scavenger	   rescued	   the	  
effector	  functions	  such	  as	  proliferation	  and	  IFN-­‐γ	  secretion	  of	  stimulated	  T	  cells	  that	  
were	   inhibited	   by	   TGF-­‐β.	   Our	   findings	   demonstrate	   that	   relief	   of	   TGF-­‐β-­‐induced	  
oxidative	  stress	  restores	  the	  effector	  function	  of	  CD8+	  cytotoxic	  T	  cells.	  Based	  on	  the	  
current	  findings	  it	  would	  be	  potentially	  beneficial	  to	  supplement	  immunotherapies	  
with	  antioxidants	  to	  counteract	   the	   immunosuppressive	  effects	  of	   tumour-­‐derived	  
TGF-­‐β	   to	   help	   restore	   CD8+	   T	   cell-­‐mediated	   anti-­‐tumour	   function.	   The	   findings	  
presented	   in	   this	   thesis	   may	   help	   with	   defining	   key	   T	   cell	   biomarkers	   based	   of	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ACC:	  Acetyl-­‐CoA	  carboxylase	  
ACL:	  ATP	  citrate	  lyase	  
ADAM:	  A	  Disintegrin	  And	  Metalloproteinase	  
ADAP:	  Adhesion-­‐	  and	  Degranulation-­‐promoting	  Adapter	  Protein	  
ADP:	  Adenosine	  diphosphate	  
AKT:	  Protein	  Kinase	  B	  
AKT:	  RAC-­‐alpha	  serine/threonine-­‐protein	  kinase	  
AMPK:	  Adenosine	  monophosphate-­‐activated	  protein	  kinase	  
ANOVA:	  Analysis	  of	  variance	  
AP-­‐1:	  Activator	  protein	  1	  
AP-­‐1:	  Activator	  protein	  1	  
APAP:	  N-­‐acetyl-­‐para-­‐aminopheno	  
APC:	  Antigen	  presenting	  cell	  
ARE:	  Antioxidant	  response	  elements	  
ATM:	  	  Ataxia	  telangiectasia	  mutated	  
ATP:	  Adenosine	  triphosphate	  
	  
BCA:	  Bicinchoninic	  Acid	  
BSA:	  Bovine	  serum	  albumin	  
BTLA:	  B-­‐	  and	  T-­‐lymphocyte	  attenuator	  
	  
Ca2+:	  Calcium	  ion	  
CCL:	  Chemokine	  (C-­‐C	  motif)	  ligand	  	  
CCR:	  C-­‐C	  chemokine	  receptor	  	  
CD:	  Cluster	  of	  differentiation	  	  
CD28SA:	  CD28	  Superagonistic	  antibody	  	  
CDK:	  Cyclin-­‐dependent	  kinases	  
cDNA:	  complementary	  DNA	  
CK2:	  Casein	  kinase	  2	  
CoA:	  Coenzyme	  A	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CPT1:	  Carnitine	  palmitoyltransferase	  I	  	  
CREB:	  cAMP	  responsive	  element	  binding	  protein	  
CTL:	  Cytotoxic	  T	  lymphocytes	  




DC:	  Dendritic	  cell	  
DNA:	  Deoxyribonucleic	  acid	  
	  
EDTA:	  Ethylenediaminetetraacetic	  acid	  
ELISA:	  Enzyme-­‐linked	  immunosorbent	  assay	  
ELISpot:	  Enzyme-­‐Linked	  ImmunoSpot	  
Erk:	  Extracellular	  signal-­‐regulated	  kinases	  
	  
FA:	  Fatty	  acids	  
FADH2:	  Flavin	  adenine	  dinucleotide	  
FAO:	  Fatty	  acid	  oxidation	  	  
FAS:	  Fatty	  acid	  synthase	  	  
FBS:	  Fetal	  bovine	  serum	  
FCS:	  Fetal	  calf	  serum	  
FOXP3:	  Forkhead	  box	  P3	  
	  
GADS:	  GRB2-­‐related	  adaptor	  downstream	  of	  Shc	  
GAPDH:	  Glyceraldehyde-­‐3-­‐phosphate	  dehydrogenase	  
GITR:	  Glucocorticoid-­‐induced	  tumour-­‐necrosis-­‐factor-­‐receptor-­‐related	  protein	  
GLUT1:	  Glucose	  transporters-­‐1	  
	  
H2O:	  Water	  
H2O2:	  Hydrogen	  peroxide	  
HBSS:	  Hanks	  balanced	  salt	  solution	  
HDMEC:	  Human	  dermal	  microvascular	  endothelial	  cells	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HEPES:	  4-­‐(2-­‐hydroxyethl)-­‐1-­‐piperazineethanesulfonic	  acid	  
HLA:	  Human	  leukocyte	  antigen	  
Hr:	  Hour	  
HRP:	  horseradish	  peroxidase	  
	  
ICAM-­‐1:	  Intercellular	  Adhesion	  Molecule	  1	  
IFN-­‐γ:	  Interferon-­‐γ	  	  
IL:	  Interleukin	  	  
IP:	  Inositol	  triphosphate	  
IS:	  immunological	  synapse	  
ITAM:	  Immunoreceptor	  tyrosine-­‐based	  activation	  motif	  
ITIM:	  Immunoreceptor	  tyrosine-­‐based	  inhibitory	  motif	  
Itk:	  Interleukin-­‐2-­‐inducible	  T-­‐cell	  kinase	  
ITSM:	  Immunoreceptor	  tyrosine	  based	  Switch	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1. Introduction	  	  
The	   immune	   system	   is	   a	   vast	   dynamic	   communication	   network	   of	   distinct	  
populations	  of	  cells	  and	  chemical	  signals	  distributed	  in	  blood	  and	  tissue	  throughout	  
the	  body	  to	  monitor	  tissue	  homeostasis,	  protect	  against	  invading	  pathogens	  and	  to	  
eliminate	  damaged	  cells	  [1].	  	  
Cells	  of	   the	   immune	  system	  are	  categorised	  as	   innate	  or	  adaptive,	  based	  on	   their	  
antigen	   specificity	   and	   timing	   of	   activation.	   Innate	   immune	   cells	   recognise	   and	  
respond	  to	  invaders	  first,	  using	  generic	  germline-­‐encoded	  receptors	  that	  recognize	  
conserved	  patterns	  on	  different	  classes	  of	  pathogens.	  Among	  this	  first	  line	  defence	  
of	  cells	  are	  natural	  killer	  (NK)	  cells,	  macrophages,	  neutrophils,	  basophils,	  eosinophils	  
and	   mast	   cells,	   which	   secrete	   inflammatory	   mediators	   such	   as	   cytokines	   and	  
chemokines,	  and	  engulf	   foreign	  antigens	  via	  phagocytosis	   [1].	  Dendritic	  cells	   (DCs)	  
and	  macrophages	   are	   termed	  antigen	  presenting	   cells	   (APCs)	   as	   they	   can	   take	  up	  
antigens	  and	  migrate	  to	  lymphoid	  organs	  where	  they	  can	  present	  their	  antigens	  to	  
adaptive	   immune	  cells.	   	   In	  contrast	   to	   innate	  cells,	  an	   individual	  adaptive	   immune	  
cell	  specifically	  recognizes	  a	  unique	  antigen	  by	  using	  somatically	  generated	  antigen-­‐
specific	   receptors,	   which	   are	   formed	   as	   a	   consequence	   of	   random	   gene	  
rearrangements.	  Among	  the	  adaptive	  immune	  cells	  are	  B	  lymphocytes,	  CD4+	  helper	  
T	   lymphocytes	   and	   CD8+	   cytotoxic	   T	   lymphocytes	   (CTLs).	   Helper	   T	   lymphocytes	  
provide	   necessary	   signals	   for	   B	   cells	   to	   proliferate	   and	   differentiate	   into	   either	  
antibody-­‐secreting	   effector	   cells	   or	   memory	   cells.	   Helper	   T	   lymphocytes	   also	  
contribute	  to	  the	  activation	  of	  cytotoxic	  T	  cells	  by	  stimulating	  DCs	  to	  produce	  more	  
costimulatory	   proteins	   [1].	   Activated	   cytotoxic	   T	   cells	   utilize	   contact-­‐dependent	  
pathways	   such	   as	   the	   granule	   exocytosis	   pathway	   and	   the	   Fas-­‐Fas	   ligand	   (FasL)	  
pathway,	  and	  contact-­‐independent	  pathways	  such	  as	  Interferon-­‐γ	  (IFN-­‐γ)	  secretion,	  
to	  induce	  target	  cell	  killing	  [2].	  	  
The	  adaptive	  immune	  response	  is	  mediated	  mainly	  through	  B	  and	  T	  lymphocytes.	  T	  
lymphocytes	  differentiate	  in	  the	  thymus	  and	  migrate	  to	  secondary	  lymphoid	  organs	  
such	  as	  the	  lymph	  nodes	  and	  spleen.	  Here	  the	  T	  lymphocytes	  play	  a	  prominent	  role	  
to	  sense,	  monitor	  and	  respond	  to	  the	  presence	  of	  foreign	  antigens	  that	  have	  been	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previously	   engulfed	   by	   highly	   phagocytic	   immature	   DCs	   at	   sites	   of	   infection	   and	  
brought	   in	   to	   the	   secondary	   lymphoid	   organs.	   Mature	   DCs	   display	   these	   foreign	  
antigens	   as	   proteasome-­‐processed	   peptides	   in	   the	   context	   of	   major	  
histocompatibility	  complex	  (MHC)	  glycoproteins.	  In	  the	  secondary	  lymphoid	  tissues	  
(e.g.	  lymph	  nodes,	  tonsils	  and	  spleen)	  mature	  DCs	  activate	  T	  cells	  when	  the	  peptide-­‐
MHC	   complex	   engages	   the	   T	   cell	   receptor	   complex	   (TCR)	   expressed	   by	   CD8+	   and	  
CD4+	  T	  cell	  subsets.	  The	  TCR	  serve	  as	  highly	  variable	  receptor	  molecules	  that	  enable	  
T	  cells	  to	  recognize	  and	  respond	  to	  foreign	  peptides	  [1].	  Intracellular	  peptides	  (e.g.	  
derived	  from	  viral	  proteins)	  bind	  to	  MHC	  class	  I	  molecules	  and	  are	  recognized	  by	  the	  
CD8+	   T	   cell	   subtype,	   while	   extracellular	   peptides	   (e.g.	   derived	   from	   bacterial	  
proteins)	  bind	  to	  MHC	  class	  II	  molecules	  and	  are	  recognized	  by	  CD4+	  T	  cells.	  	  
1.1. T	  cell	  subsets	  	  
The	  CD4	  helper	  T	  cells	  (TH)	  are	  more	  heterogeneous	  than	  the	  CD8	  cytotoxic	  T	  cells	  
(CTL)	   and	   can	   further	   differentiate	   into	   different	   phenotypes	   depending	   on	   the	  
cytokines	   in	   the	   local	   environment.	   The	   different	   TH	   subsets	   have	   a	   defined	  
signature	   cytokine	   profile	   and	   distinct	   transcription	   factors	   that	   regulate	   their	  
development	  (figure	  1.1).	  TH1	  cells	  produce	  IFN-­‐γ	  and	  Interleukin	  (IL)-­‐2	  and	  express	  
the	   transcription	   factor	   T-­‐bet.	   TH2	   cells	   produce	   IL-­‐4,	   IL-­‐5	   and	   IL-­‐13	   and	   express	  
GATA3.	  Th17	  cells	  produce	  IL-­‐17	  and	  IL-­‐22	  and	  express	  ROR-­‐γ t.	  Treg	  can	  be	  divided	  
into	  different	  subsets	  based	  on	  the	  expression	  of	  FoxP3	  and/or	  the	  production	  of	  IL-­‐
10,	  transforming	  growth	  factor-­‐β	  (TGF-­‐β)	  and	  IL-­‐35	  [3].	  	  
Following	  activation	  all	   T	   cells	  differentiate	   into	  different	   subsets	  of	  memory	  cells	  
categorized	  based	  on	  their	  homing	  capacities	  and	  effector	  functions,	  namely	  central	  
memory	  cells	   (TCM)	  and	  effector	  memory	  cells	   (TEM)	   (figure	  1.2).	  TCM	  express	  CCR7	  
and	  secrete	  IL-­‐2	  but	   lack	  the	  capacity	  to	  produce	  IFN-­‐γ.	  TEM	   lack	  CCR7	  and	  express	  
characteristic	   sets	   of	   chemokine	   receptors	   and	   adhesion	   molecules	   that	   enable	  





Figure	  1.1:	  CD4	  and	  CD8	  T	  cell	  subtypes	  	  
Mature	  DCs	  activate	  T	  cells	  when	  the	  peptide-­‐MHC	  complex	  engages	  the	  TCR	  expressed	  by	  CD8+	  and	  
CD4+	  T	  cell	  subsets.	  These	  subsets	  differentiate	  into	  different	  phenotypes	  depending	  on	  the	  cytokine	  
milieu	  and	  can	  be	  characterized	  by	  their	  cytokine	  profile	  and	  by	  transcription	  factors.	  (Adapted	  from	  
Broere	  et	  al.,	  2011	  [5]).	  	  
	  
CD8+	  cytotoxic	  T	  cells	  are	  regarded	  as	  the	  main	  mediators	  of	  anti-­‐tumour	   immune	  
response.	   Among	   the	   cytotoxic	   effector	   functions,	   the	   secretion	   of	   IFN-­‐γ	   is	  
considered	   the	  most	   successful	   in	   T	   cell-­‐mediated	   tumour	   rejection	   [6].	   The	   anti-­‐
tumour	   activities	   of	   IFN-­‐γ	   include	   the	   induction	   of	   MHC	   expression	   and	   antigen	  
presentation,	   the	   induction	   of	   additional	   inflammatory	   cytokine	   production,	   and	  
inhibit	   tumour	   angiogenesis	   [6].	   However,	   tumour-­‐specific	   CD8+	   T	   cell	   responses	  
tend	   to	   be	   weak	   and	   susceptible	   to	   suppression	   in	   the	   tumour-­‐promoting	  
microenvironment.	   	   Mechanism	   utilised	   by	   tumour	   cells	   to	   inactivate	   immune	  
responses	   include	   the	   secretion	   of	   inhibitory	   cytokines	   such	   as	   TGF-­‐β.	   	   Tumour-­‐
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derived	   TGF-­‐β	   suppresses	   CD8+	   cytotoxic	   function	   through	   an	   anti-­‐cytotoxic	  
program	  of	  transcriptional	  repression	  [7].	  
	  
Figure	  1.2:	  CD4	  and	  CD8	  T	  cell	  subtypes	  based	  on	  function	  
Immature	  DCs	  (iDC)	  take	  up	  foreign	  peptides/antigens	  in	  peripheral	  tissue	  and	  migrate	  to	  secondary	  
lymphoid	   tissues.	   Here	   as	   matured	   DCs	   (mDC),	   the	   processed	   peptide	   in	   the	   context	   of	   an	  MHC	  
molecule	  is	  presented	  to	  naïve	  T	  cells.	  Upon	  activation	  naïve	  T	  cells	  proliferate	  and	  differentiate	  into	  
effector	   or	  memory	   T	   cells,	   and	  will	  migrate	   to	   peripheral	   tissue	   to	   exert	   their	   effector	   functions.	  
Memory	  T	  cells	   can	  develop	   into	  effector	   (Th:	  CD4+/CCR7-­‐CD45RO-­‐,	  CTL:	  CD8+/	  CCR7-­‐CD45RO-­‐)	  and	  
effector	  memory	  cells	  (TEM:	  CCR7
-­‐	  CD45RO+)	  that	  will	  migrate	  to	  peripheral	  tissues	  or	  central	  memory	  
T	   cells	   (TCM:	   CCR7
+	   CD45RO+).	   CCR7	   is	   a	   chemokine	   receptor,	   CD62L	   (L-­‐selectin)	   is	   an	   adhesion	  
receptor,	  while	  CD45RO	  is	  a	  marker	  of	  memory	  T	  cells.	  (Adapted	  from	  Broere	  et	  al.,	  2011	  [5]).	  	  
	  
To	  study	  antigen-­‐specific	  T	  cell	  responses,	  TCR	  transgenic	  mice	  are	  one	  of	  the	  most	  
useful	  tools.	  In	  TCR	  transgenic	  mice	  the	  majority	  of	  T	  cells	  that	  develop	  express	  TCRs	  
with	   known	   antigen	   specificity	   and	   can	   thus	   be	   used	   to	   study	   antigen-­‐specific	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immune	  responses.	   In	  this	  thesis	  we	  used	  a	  TCR	  transgenic	  mouse	  model	  wherein	  
the	   TCR	   (F5-­‐TCR)	   of	   the	   CD8+	   T	   cells	   can	   specifically	   be	   activated	   by	   an	   antigenic	  
peptide,	  NP68.	  
1.2. T	  cell	  activation	  	  
The	   binding	   of	   the	   peptide-­‐MHC	   complex	   to	   the	   TCR	   initiates	   the	   formation	   of	  
microclusters	   at	   distinct	   contact	   areas	   between	   the	   T	   cell	   and	   the	   APC.	   These	  
microclusters	   represent	   essential	   membrane-­‐associated	   platforms	   where	   TCR-­‐
mediated	   signalling	   is	   initiated	   and	   maintained,	   before	   the	   formation	   of	   the	  
immunological	   synapse	   (IS)	   [8].	   TCR	  engagement	   is	   translated	   into	   changes	   in	   the	  
TCR-­‐associated	   CD3	   subunits	   that	   allow	   tyrosines	   within	   their	   immunoreceptor	  
tyrosine-­‐based	   activation	  motifs	   (ITAMs)	   to	   be	   phosphorylated	   by	   CD4-­‐	   and	   CD8-­‐
p56	  Lck	  complexes.	  This	  event	  represents	  the	  start	  of	  assembly	  of	  the	  TCR	  signalling	  
machinery	   or	   TCR	   signalosome	  which	   consists	   of	   a	   complex	  modular	   architecture	  
made	   up	   of	   three	   independent	   signalling	   modules	   whose	   connectivity	   and	   inter-­‐
regulation	   are	   increased	   upon	   TCR	   stimulation.	   These	   are	   the	   src-­‐family	   protein	  
tyrosine	  kinase	  (PTK)	  regulation	  module,	  the	  signal	  triggering	  module	  which	  consist	  
of	   the	   ITAM	  motifs	  associated	  with	   the	  TCR	  complex	  and	   the	  PTK	  ZAP70,	  and	   the	  
signal	  diversification	  and	  regulation	  module	   that	   includes	  components	  such	  as	   ITK	  
and	  Vav1	  [9].	  Following	  the	  phosphorylation	  of	  CD3	  ITAMs	  by	  the	  src-­‐family	  PTK	  Lck,	  
ZAP	  70	  is	  recruited.	  Activated	  ZAP70	  in	  turn	  phosphorylates	  the	  adaptor	  protein	  LAT	  
which	   then	  nucleates	   the	   assembly	  of	   a	  multiprotein	   complex	   that	   bridges	   T	   cell-­‐
specific	   signalling	  events	   to	   the	  general	   signalling	  pathways	   that	  are	   involved	   in	  T	  
cell	  development	  and	  function.	  Phosphorylation	  of	  LAT	  creates	  binding	  sites	  for	  PLC-­‐
γ	   (leads	   to	   the	   generation	   of	   diacylglycerol	   (DAG)	   and	   inositol	   triphosphate	   (IP3)	  
which	   activate	   the	   nucleotide	   exchange	   factor	   RasGRP1	   and	   trigger	   Ca2+	   flux,	  
respectively),	   Gads	   (binds	   SLP-­‐76	   which	   when	   phosphorylated	   interacts	   with	   the	  
cytosolic	   adaptor	   protein	   Nck	   and	   with	   the	   nucleotide	   exchange	   factor	   Vav1,	   to	  
induce	   cytoskeletal	   reorganization,	   and	  also	   increases	   cell	   adhesion	  by	   interacting	  
with	  the	  adaptor	  protein	  ADAP)	  and	  Grb2	  (binds	  Sos	  and	  leads	  to	  Ras	  activation	  and	  
subsequent	  activation	  of	  MAPKs,	  Rac,	  and	  ultimately	   several	   transcription	   factors)	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[10].	   These	   signalling	   events	   lead	   to	   effector	   functions	   such	   as	   cell	   migration,	  
cytokine	  synthesis	  and	  cell	  division.	  	  
1.3. Regulation	  of	  T	  cell	  activation	  	  
The	   process	   of	   T	   cell	   activation	   consists	   of	   an	   orchestration	   of	   various	   functional	  
modules	   such	   as	   actin	   polymerization,	   cell	   surface	   receptor	   patterning,	   calcium	  
fluxing,	   immunological	   synapse	   formation,	   enhanced	   adhesion	   and	   gene	  
transcription.	   These	   modules	   are	   mediated	   by	   a	   number	   of	   signalling	   proteins	  
through	   inducible	   phosphorylation,	   enzyme	   activation	   and	   protein-­‐protein	   &	  
protein-­‐lipid	   interactions.	   This	   complex	   and	  dynamic	   interplay	  of	   signalling	   events	  
governs	   the	  decisions	   the	  T	   cell	  makes	   in	   terms	  of	   gene	  expression,	  proliferation,	  
differentiation,	   survival	   and	   migration.	   These	   outcomes	   are	   influenced	   by	   the	  
magnitude,	   duration	   and	   context	   of	   the	   activation	   signals	   [11].	   Additional	   cell	  
surface	  glycoproteins	  provide	  contextual	   information	   that	   influence	  TCR-­‐mediated	  
activation	  signals	  and	  can	  be	  classified	  as	  either	  co-­‐stimulatory	  or	  co-­‐inhibitory.	  The	  
overall	  balance	  between	  these	  positive	  and	  negative	  signals	  directs	  the	  magnitude	  
of	   the	   T	   cell	   response.	   TCR	   signalling	   is	   modulated	   by	   four	   different	   families	   of	  
costimulatory	  and	  coinhibitory	  molecules:	  (1)	  B7-­‐CD28	  family	  including	  CD28,	  CTLA-­‐
4,	  PD-­‐1	  and	  BTLA;	  (2)	  CD2/signalling	  lymphocyte	  activation	  molecule	  (SLAM)	  family	  
including	   SLAM	   (CD150),	   2B4	   (CD244),	   and	   CD48;	   (3)	   Ig	   family	   including	   TIM-­‐3,	  
CD160	   and	   LAG-­‐3;	   and	   (4)	   TNF-­‐receptor	   superfamily	   including	   CD137,	   GITR	   and	  
CD27.	   In	  addition	   to	  costimulatory	  and	  coinhibitory	   receptors,	   the	  cytokine	  milieu	  
plays	  an	  important	  role	  in	  the	  promotion	  of	  activation,	  differentiation,	  proliferation,	  
or	  cell	  death	  of	  T	  cells.	  The	  major	  stimulatory	  cytokine	  for	  T	  cells	   is	   IL-­‐2,	  while	  the	  
major	  inhibitory	  cytokine	  is	  TGF-­‐β.	  
1.3.1. 	  CD28	  co-­‐stimulatory	  receptor	  	  
The	   primary	   TCR	   signal	   provides	   the	   minimal	   scaffold	   for	   the	   recruitment	   of	  
essential	  signalling	  molecules	  that	  then	  form	  nexus	  points	  to	  other	  major	  signalling	  
pathways	   such	   as	   the	  MAPK/Erk	   pathways.	   Signalling	   molecules	   recruited	   by	   co-­‐
stimulatory	  receptors	  such	  as	  CD28	  add	  to	  this	  central	  scaffold	  and	  act	  as	  amplifiers,	  
enabling	   signalling	   thresholds	   to	   be	   overcome	   when	   TCR	   occupancy	   is	   low	   or	   to	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maximize	  amplitude	  of	  T	  cell	  activation	  when	  TCRs	  are	  fully	  occupied	  [12].	  CD28	  is	  
expressed	  by	  T	  cells	  and	  binds	  to	  ligands	  B7.1	  (CD80)	  and	  B7.2	  (CD86)	  expressed	  by	  
professional	   APCs	   such	   as	   DCs.	   Upon	   receptor	   triggering,	   signal	   transduction	  
cascades	  are	  initiated	  when	  signalling	  proteins	  associate	  with	  the	  cytoplasmic	  tail	  of	  
CD28.	   Within	   the	   cytoplasmic	   tail,	   the	   proximal	   YMNM	   motif	   binds	   to	   the	   p85	  
subunit	   of	   PI3K	   and	  Grb2	   or	   GADS.	   The	   distal	   proline-­‐rich	  motifs	   PRRP	   and	   PYAP	  
bind	  to	  the	  proteins	  Itk	  and	  Grb2/filamin	  A/Lck,	  respectively	  (figure	  1.3)	  [13].	  
	  
	  
Figure	  1.3:	  The	  CD28	  co-­‐stimulatory	  receptor	  	  
CD28	   lacks	   intrinsic	   catalytic	   activity	   and	   delivers	   signals	   via	   three	   potential	   protein-­‐protein	  
interaction	  motifs	  (shown	  in	  yellow)	  found	  within	  the	  cytoplasmic	  tail.	  	  	  
	  
The	  PI3K	  signal	  pathway	  ultimately	  leads	  to	  increased	  NF-­‐κB	  transcriptional	  activity	  
and	  increased	  survival.	  Binding	  of	  Grb2	  to	  the	  distal	  motif	  initiates	  the	  formation	  of	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two	  signalling	  complexes.	  The	  vav-­‐Sos	  complex	  leads	  to	  cytoskeletal	  rearrangement	  
and	  formation	  of	  the	  AP1	  transcriptional	  complex	  via	  JNK	  activation,	  while	  the	  SLP-­‐
76-­‐LAT	   complex	   leads	   to	   NF-­‐κB	   transcriptional	   activation	   and	   enhanced	  
transcription	  of	  NFAT-­‐dependent	  genes	  including	  IL-­‐2	  	  [13].	  	  
Under	   physiological	   conditions,	   T	   cell	   activation	   requires	   two	   stimulatory	   signals.	  
Signal	   1	  mediated	  by	   the	  engagement	  of	   the	   TCR	  with	   the	  peptide-­‐MHC	   complex	  
and	   signal	   2	   is	  mediated	  by	   the	  CD28	   receptor	   engaging	   its	   natural	   ligands,	   CD80	  
and	   CD86,	   expressed	   on	   mature	   DCs.	   Conventional	   CD28	   mAbs	   can	   mimic	   the	  
second	  signal	  and	  lead	  to	  a	  signal1-­‐dependent	  T	  cell	  activation.	  Superagonistic	  CD28	  
mAbs	  (CD28SA)	  however	  can	  provide	  both	  stimulatory	  signals	  and	  achieve	  full	  T	  cell	  
activation	  independent	  of	  TCR	  engagement	  [14].	  The	  signalling	  events	  generated	  by	  
CD28SA	  are	  strictly	  dependent	  on	  the	  expression	  of	  functional	  TCR,	  the	  downstream	  
syk	  family	  kinase	  ZAP-­‐70	  and	  the	  transmembrane	  adaptor	  LAT	  [15].	  The	  activation	  
of	   the	   SLP76	   signalosome	   (SLP76-­‐Vav-­‐Itk-­‐PLCγ)	   is	   also	   essential	   for	   inducing	   the	  
sustained	  transmembranous	  calcium	  flux	  required	  for	  CD28SA-­‐mediated	  production	  
of	   IL-­‐2	   and	   IFNγ[14].	   Furthermore,	   PI3K	   or	   its	   downstream	   effector	   AKT	   is	  
mandatory	  for	  CD28SA-­‐mediated	  IL-­‐2	  and	  IFNγ	  production	  [16].	  
1.3.2. 	  Co-­‐inhibitory	  receptors	  
TCR	  signaling	  can	  be	  controlled	  by	  various	  mechanisms	  that	  differ	   in	   their	   time	  of	  
action	  and/or	  target	  molecule.	  Negative	  regulatory	  mechanisms	  are	  in	  place	  to	  act	  
before	   T	   cell	   activation	   to	   maintain	   its	   quiescent	   state.	   These	   range	   from	   the	  
sequestration	  of	  ITAM	  motifs	  in	  the	  lipid	  bilayers	  [17]	  to	  the	  autoinhibitory	  domain	  
of	  phosphatase	  calcineurin,	  the	  action	  of	   IkB	  and	   its	  transcriptional	  activators	  Foxj	  
and	   Foxo3a	   [18].	   Rapidly	   after	   activation	   of	   the	   TCR	   signalosome,	   immediate	  
feedback	  is	  provided	  by	  the	  protein	  tyrosine	  phosphatase	  SHP-­‐1,	  miR-­‐181a	  and	  DOK	  
adaptor	   proteins.	   Delayed	   feedback	   is	   conducted	   by	   the	   HPK1-­‐SLP76-­‐14-­‐3-­‐3	  
pathway	  and	  STS	  proteins.	  Hours	  after	  T	  cell	  activation,	  modulation	  of	  TCR	  signaling	  
is	   conducted	   by	   additional	   inhibitory	   signals	   downstream	   of	   immune	   checkpoint	  
proteins	  impart	  a	  degree	  of	  control	  over	  the	  direction	  and	  magnitude	  of	  the	  primary	  
signal,	   keeping	   the	   immune	   response	   tuned	   and	   amenable	   to	   baseline	   tonic	  
signaling	   [19].	   Inhibitory	   receptors	   (figure	   1.4)	   attenuate	   and	   counterbalance	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activation	  signals	  initiated	  by	  stimulatory	  receptors.	  The	  subsequent	  outcomes	  on	  T	  
cell	   function	   can	   range	   from	   temporary	   inhibition	   to	   permanent	   inactivation	   and	  
cell	  death	  [20].	  	  
	  
	  
Figure	  1.4:	  Schematic	  structure	  of	  T	  cell	  co-­‐inhibitory	  receptors	  
The	  	  domain	  	  structures	  	  of	  	  the	  	  following	  	  co-­‐inhibitory	  	  receptors	  	  are	  	  schematically	  	  depicted:	  	  B-­‐	  	  
and	   T-­‐lymphocyte	   	   attenuator	   	   (BTLA),	   	   Cytotoxic	   T-­‐Lymphocyte	   Antigen	   4	   (CTLA-­‐4),	   Lymphocyte-­‐
activation	   gene	   3	   (LAG-­‐3),	   Leukocyte-­‐associated	   immunoglobulin-­‐like	   receptor	   1	   (LAIR-­‐1),	  
Programmed	  Death	  1	   (PD-­‐1)	   sialic	   acid	  binding	   Ig-­‐like	   lectins	   (Siglecs),	   T-­‐cell	   immunoreceptor	  with	  
immunoglobulin	   and	   ITIM	   domains	   (TIGIT),	   T	   cell	   immunoglobulin	   mucin-­‐3	   (TIM-­‐3).	   Extracellular	  
immunoglobulin	   domains	  of	   co-­‐inhibitory	   receptors	   include	   Ig-­‐like	   (Ig),	   V-­‐type,	   C2-­‐type	   and	   I-­‐type.	  
ITIM-­‐	  immunoreceptor	  tyrosine-­‐based	  inhibition	  motif,	  ITSM-­‐immunoreceptor	  tyrosine-­‐based	  switch	  
motif.	  (Table	  adapted	  from	  Thaventhiran	  et	  al.,	  2012	  [11])	  
	  
1.3.2.1.	  Mechanisms	  of	  co-­‐inhibitory	  receptors	  
The	   majority	   of	   T	   cell	   co-­‐inhibitory	   receptors	   belong	   to	   the	   immunoglobulin	   (Ig)	  
superfamily	  (table	  1)	  [21].	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Table	  1:	  T	  cell	  co-­‐inhibitory	  receptors	  	  
	  
Abbreviations:	   1-­‐3	   three	   general	   types	   of	   distinct	   mechanisms	   of	   action;	   B	   cell-­‐NHL:	   B	   cell	   non-­‐
Hodgkin’s	   Lymphomas;	   Bat3-­‐	   Human	   Leukocyte	   Antigen	   B	   (HLA-­‐B)-­‐associated	   Transcript	   3;	   BATF:	  
Basic	   Leucine	   Zipper	   Transcription	   Factor,	   ATF-­‐like;	   BTLA:	   B-­‐	   and	   T-­‐lymphocyte	   Attenuator;	   Csk:	  
COOH-­‐terminal;	   CTLA-­‐4:	   Cytotoxic	   T-­‐Lymphocyte	   Antigen	   4;	   DC:	   Dendritic	   Cells;	   Fyn:	   a	   Src	   family	  
tyrosine-­‐protein	   kinase;	   Grb2:	   Growth	   factor	   receptor-­‐bound	   protein	   2;	   GVDH:	   Graft	   Versus	   Host	  
Disease;	   HCV:	   Hepatitis	   C	   Virus;	   HIV:	   Human	   Immunodeficiency	   Virus;	   HVEM:	   Herpes	   Virus	   Entry	  
Mediator;	  ITIM-­‐	  Immunoreceptor	  Tyrosine-­‐based	  Inhibition	  n	  Motif;	  ITSM:	  Immunoreceptor	  Tyrosine	  
based	   Switch	   Motif;	   LAG-­‐3:	   Lymphocyte-­‐Activation	   Gene	   3;	   LAIR-­‐1:	   Leukocyte-­‐Associated	  
Immunoglobulin-­‐like	   Receptor	   1;	   Lck:	   Lymphocyte-­‐specific	   protein	   tyrosine	   kinase;	   LIGHT:	  
Lymphotoxin-­‐like,	   exhibits	   inducible	   expression,	   and	   competes	   with	   herpes	   simplex	   virus	  
glycoprotein	  D	  for	  HVEM,	  a	  receptor	  expressed	  by	  T	  lymphocytes;	  LN:	  Lupus	  Nephritis;	  MHC	  II:	  Major	  
Histocompatibility	   Complex	   II;	  Mo:	  Monocyte;	  MS:	  Multiple	   Sclerosis;	  MΦ:	  Macrophage;	  N/A:	  Not	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Applicable;	  NK:	  Natural	  Killer	  cells;	  NKT:	  Natural	  Killer	  T	  cells;	  PD-­‐1:	  Programmed	  cell	  death	  protein	  1;	  
pDC:	  plasmacytoid	  dendritic	  cell;	  PD-­‐L1:	  Programmed	  cell	  death	  1	  ligand	  1;	  PI3K:	  Phosphoinositide	  	  
3-­‐kinase;	   PS:	   Phosphatidyl	   Serine;	   RA:	   Rheumatoid	   Arthritis;	   RCC:	   Renal	   Cell	   Carcinoma;	   SHP-­‐1/2/:	  
Src	  homology	  2-­‐containing	  tyrosine	  phosphatase	  1/2/;	  Siglecs:	  Sialic	  acid	  binding	  Ig-­‐like	  lectins;	  SLE:	  
Systemic	   Lupus	   erythematous,	   Srk	   kinase;	   SKP2:	   S-­‐phase	   Kinase-­‐associated	   Protein	   2;	   TIGIT:	   T-­‐cell	  
immunoreceptor	  with	  immunoglobulin	  and	  ITIM	  domains;	  TIM-­‐3:	  T	  cell	  Immunoglobulin	  Mucin-­‐3	  
(Table	  adapted	  from	  Thaventhiran	  et	  al.,	  2012	  [11]).	  	  
	  
There	  are	  three	  major	  mechanisms	  that	  are	  utilized	  by	  membrane	  bound	  inhibitory	  
receptors	   in	  T	  cells	   (Figure	  1.5).	  The	  first	  mechanism	  involves	  the	  sequestration	  of	  
the	   ligands	   for	   costimulatory	   receptors,	   depriving	   the	   T	   cell	   from	   receiving	  
activation	   signals	   necessary	   for	   complete	   activation.	   The	   second	   mechanism	  
involves	   the	   recruitment	   of	   intracellular	   phosphatases	   by	   an	   immunoreceptor	  
tyrosine-­‐based	   inhibition	  motif	   (ITIM)	   and/or	   an	   immunoreceptor	   tyrosine-­‐based	  
switch	  motif	   (ITSM)	   that	   make	   up	   the	   cytoplasmic	   tail	   of	   certain	   inhibitory	  
receptors,	  which	  dephosphorylate	  signalling	  molecules	  downstream	  of	  the	  TCR	  and	  
costimulatory	   pathways,	   leading	   to	   a	   quantitative	   reduction	   in	   activation-­‐induced	  
gene	   expression.	   The	   third	   mechanism	   involves	   the	   upregulation	   (or	  
downregulation)	   of	   genes	   that	   code	   for	   proteins	   involved	   in	   the	   inhibition	   of	  
immune	   functions	   [21].	   A	   co-­‐inhibitory	   receptor	   could	   use	   a	   combination	   of	   the	  
above	   and	   possibly	   other	   yet	   to	   be	   discovered	   mechanisms	   to	   regulate	   T	   cell	  
signalling.	   A	   large	   number	   of	   co-­‐inhibitory	   receptors	   recruit	   intracellular	  
phosphatases	   to	   their	   cytoplasmic	   domains	   in	   order	   to	   dephosphorylate	   signaling	  





Figure	  1.5:	  Mechanisms	  through	  which	  co-­‐inhibitory	  receptors	  regulate	  T	  cell	  signaling	  
Upon	  ligand	  engagement	  the	  cytoplasmic	  signaling	  motifs	  of	  co-­‐inhibitory	  receptors	  such	  as	  ITIM	  or	  
ITSM	  are	  phosphorylated	  and	  bind	  intracellular	  mediators	  such	  as	  the	  phosphatases	  SHP-­‐1	  and	  SHP-­‐
2,	   which	   then	   dephosphorylate	   key	   signaling	   molecules	   downstream	   of	   the	   T	   cell	   receptor.	   The	  
suppression	   of	   transcription	   factors	   can	   also	   be	   classified	   under	   mechanism	   1.	   Co-­‐inhibitory	  
receptors	  that	  use	  this	  mechanism	  are	  CTLA-­‐4,	  PD-­‐1,	  BTLA,	  TIM-­‐3,	  LAIR-­‐1and	  Siglecs.	  Mechanism	  2	  is	  
used	   by	   co-­‐inhibitory	   receptors	   such	   as	   PD-­‐1	   and	   involves	   upregulating	   a	   program	   of	   genes	   that	  
inhibit	   T	   cell	   function.	   Mechanism	   3	   involves	   ectodomain	   competition.	   Here	   the	   co-­‐inhibitory	  
receptors	   (CTLA-­‐4,	  BTLA,	  LAG-­‐3,	  TIGIT	  and	  Siglecs)	  prevents	  optimal	  signal	   transduction	  at	   	   the	  cell	  
membrane	   by	   sequestering	   counter	   receptors/ligands	   and/or	   preventing	   the	   formation	   of	  
microclusters	   and	   lipid	   rafts	  which	   are	  necessary	   for	   immunological	   	   synapse	   formation	   and	  T	   cell	  
activation.	  (Figure	  adapted	  from	  Thaventhiran	  et	  al.,	  2012	  [11]).	  
	  
Most	   of	   these	   co-­‐inhibitory	   receptors	   contain	   one	   or	   several	   ITIMs	   within	   the	  
cytoplasmic	   domain	   (figure	   1.4)	   which	   recruit	   Src	   homology	   2	   (SH2)	   domain-­‐
containing	   phosphatases.	   ITIMs	   are	   structurally	   defined	   as	   a	   six-­‐amino	   acid	  
consensus	  sequence	  (I/V/L)xYxx(L/V),	  containing	  a	  single	  tyrosine	  (Y),	  a	  hydrophobic	  
residue	  (I,	  V	  or	  L)	  at	  the	  C-­‐terminal	  position	  Y+3	  and	  a	  less	  conserved	  hydrophobic	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residue	  at	  the	  N-­‐terminal	  position	  Y-­‐2	  [22,	  23].	  The	  motif	  is	  highly	  conserved	  except	  
for	   the	  amino	  acids	   surrounding	   the	   single	   tyrosine	   residue,	  where	   x	  denotes	  any	  
amino	  acid.	  	  
Despite	  the	  large	  number	  of	  different	  ITIM-­‐bearing	  receptors	  on	  a	  single	  cell	  type,	  
each	   co-­‐inhibitory	   receptor	   has	   a	   crucial	   and	   non-­‐redundant	   role	   in	  
immunoregulation.	  The	  ITIM-­‐bearing	  co-­‐inhibitory	  receptors	  vary	  in	  their	  expression	  
patterns,	  level	  of	  inhibition	  and	  the	  type	  of	  signal	  delivered.	  Upon	  T	  cell	  activation	  
ITIM-­‐bearing	   receptors	   translocate	   to	   the	   immunological	   synapse	   with	   activating	  
receptors	  that	  brings	  them	  in	  close	  proximity	  to	  a	  kinase,	  which	   in	  the	  majority	  of	  
cases	  is	  a	  Src	  family	  kinase	  (e.g.	  Lck).	  The	  kinase	  phosphorylates	  the	  tyrosine	  residue	  
within	   the	   ITIM	   motif	   and	   leads	   to	   the	   recruitment	   of	   SH2	   domain-­‐containing	  
phosphatases	   SHP-­‐1	   and/or	   SHP-­‐2,	   SHIP,	  which	   then	  dephosphorylate	   several	   key	  
molecules	   that	   are	   involved	   in	   the	   initial	   steps	   of	   the	   T	   cell	   signalling	   pathway	  
(figure	   1.6).	   SHIP1	   and	   SHIP2	   are	   lipid	   phosphatases	   while	   SHP-­‐1	   and	   SHP-­‐2	   are	  
tyrosine	   phosphatases	   [24].	   The	   way	   in	   which	   activating	   signals	   are	   modified	  
depends	  on	  the	  phosphatase	  recruited	  to	  the	  ITIM	  motif.	  	  
A	  variant	  of	  the	  ITIM	  termed	  immune	  receptor	  tyrosine-­‐based	  switch	  motif	  (ITSM)	  is	  
found	  in	  some	  co-­‐inhibitory	  receptors.	  Programmed	  cell	  death	  protein	  1	  (PD-­‐1),	  B-­‐	  
and	  T-­‐lymphocyte	  attenuator	  (BTLA)	  contain	  both	  an	  ITIM	  and	  an	  ITSM	  within	  their	  
cytoplasmic	   domain.	   The	   ITSM	  motif	   	   has	   a	   consensus	   sequence	   (T)xYxx(V/I)	   and	  
binds	   to	   an	   adaptor	   protein	   called	   SH2	   domain-­‐containing	   molecule	   1A,	   which	  
influences	  the	  activating	  signals	  by	  regulating	  the	  recruitment	  of	  SHP-­‐1	  and	  SHP-­‐2	  
[25].	  Inhibition	  can	  also	  be	  executed	  by	  a	  co-­‐inhibitory	  receptor	  in	  the	  absence	  of	  an	  
intracellular	  ITIM	  motif.	  For	  example,	  CTLA-­‐4	  does	  not	  have	  ITIMs	  but	  does	  contain	  







Figure	  1.6:	  Activation	  of	  protein	  tyrosine	  phosphatases	  (PTP)	  and	  regulation	  of	  TCR	  signalling	  	  
TCR	  triggering	  activates	  a	  number	  of	  signalling	  pathways	  that	  include	  calcium,	  MAPK	  and	  NFκB.	  Co-­‐
inhibitory	   receptors	   recruit	   SH2-­‐domain	   containing	   protein	   tyrosine	   phosphatases,	   SHP-­‐1	  &	   SHP-­‐2	  
through	   binding	   of	   the	   PTP	   SH2	   domains	   to	   phosphorylated	   ITIMs	   in	   their	   cytoplasmic	   domains.	  
Engagement	   of	   PTP	   SH2	   domains	   leads	   to	   activation	   of	   the	   PTPs	   which	   dephosphorylate	   key	  
substrates	   that	   lie	   within	   the	   TCR	   signalling	   pathways.	   CTLA-­‐4	   and	   PD-­‐1	   are	   shown	   as	   specific	  
examples	  with	  the	  PTPs	  that	  are	  recruited	  and	  the	  substrates	  that	  are	  dephosphorylated.	  In	  addition	  
to	   PTPs,	   CTLA	   has	   been	   shown	   to	   associate	   with	   the	   protein	   phosphatase	   PP2A	   and	   negatively	  
regulate	   PI3K.	   CTLA-­‐4-­‐Cytotoxic	   T-­‐Lymphocyte	   Antigen	   4,	   ITIM-­‐immunoreceptor	   tyrosine-­‐based	  
inhibition	  motif,	   ITSM-­‐immunoreceptor	   tyrosine-­‐based	   switch	  motif,	   PD-­‐1-­‐Programmed	   cell	   death	  
protein	  1	  SHP-­‐1/2-­‐Src	  homology	  2-­‐containing	  tyrosine	  phosphatase	  1/2,	  Siglecs-­‐sialic	  acid	  binding	  Ig-­‐






1.3.2.2.	  PD-­‐1	  and	  LAG-­‐3	  co-­‐inhibitory	  receptors	  
PD-­‐1	  belongs	  to	  the	  Ig	  superfamily	  (IgSF)	  of	  surface	  proteins	  (Table	  1).	  PD-­‐1	  is	  made	  
up	  of	  one	  Ig	  domain,	  a	  ~20	  amino	  acid	  stalk	  region,	  a	  transmembrane	  domain	  and	  
an	   intracellular	   domain	   containing	  both	   an	   ITIM	  and	   an	   ITSM	   (figure	   1.4).	   PD-­‐1	   is	  
inducibly	  expressed	  on	  the	  surface	  of	  T	  cells	  within	  24hours	  of	  activation,	  although	  
its	   functional	   effects	   on	   for	   e.g.	   IFN-­‐γ,	   TNF-­‐α	   and	   IL-­‐2	   production	   are	   observable	  
within	  a	  few	  hours	  [26].	  PD-­‐1	  normally	  exhibits	  a	  uniform	  cell	  surface	  expression	  but	  
redistributes	   itself	   close	   to	   the	   site	   of	   TCR	   engagement	   within	   microclusters	   for	  
successful	   interaction	  with	   its	   ligands	  PD-­‐L1	   (constitutively	  expressed	  on	  T	  cells,	  B	  
cells,	  DCs,	  macrophages,	  mesenchymal	   stem	  cells	   and	  bone	  marrow	  derived	  mast	  
cells)	   and	   PD-­‐L2	   (inducibly	   expressed	   on	   DCs,	   macrophages	   and	   bone	   marrow	  
derived	  mast	  cells)	  [27].	  
Upon	   PD-­‐1	   ligation,	   both	   of	   the	   cytoplasmic	   ITIM	   and	   ITSM	   tyrosine	   motifs	   are	  
phosphorylated	   possibly	   by	   Lck	   and/or	   C-­‐terminal	   Src	   kinase	   with	   a	   consequent	  
recruitment	   of	   SHP2.	   This	   reduces	   the	   TCR-­‐triggered	   phosphorylation	   of	   CD3ζ,	  
ZAP70	  and	  PKCθ,	  while	  also	  blocking	  the	  CD28-­‐mediated	  activation	  of	  PI3K	  and	  Akt	  
[28].	   TCR	   stimulation	   induces	   the	   activation	   and	   upregulation	   of	   casein	   kinase	   2	  
(CK2),	   which	   phosphorylates	   PTEN	   (phosphatase	   and	   tensin	   homolog	   deleted	   on	  
chromosome	   10)	   in	   the	   Ser380-­‐Thr382-­‐Thr383	   cluster	   within	   the	   C-­‐terminal	  
regulatory	   domain	   and	   inhibits	   its	   phosphatase	   activity,	   allowing	   sustained	  
activation	   of	   the	   PI3K/Akt	   pathway	   to	   support	   glucose	   uptake,	   survival	   and	  
expansion.	  PD-­‐1	  inhibits	  the	  TCR-­‐induced	  CK2-­‐mediated	  stabilizing	  phosphorylation	  
of	   PTEN,	   which	   results	   in	   ubiquitin-­‐dependent	   degradation	   and	   diminished	  
abundance	   of	   PTEN	   protein	   but	   increased	   PTEN	   phosphatase	   activity	   [29].	   	   PTEN	  
acts	   predominantly	   as	   a	   lipid	   phosphatase	   by	   dephosphorylating	   PI(3,4,5)P3	   to	  
generate	  PI(4,5)P2	  and	  thus	  directly	  opposes	  PI3K	  activation	  by	  limiting	  its	  substrate	  




Figure	  1.7:	  	  PD-­‐1-­‐mediated	  regulation	  of	  PTEN	  activity	  via	  CK2	  
TCR	   activation	   induces	   CK2	   activation	   and	   subsequent	   phosphorylation	   of	   the	   PTEN	   C-­‐terminal	  
serine-­‐threonine	   cluster	   S380-­‐T382-­‐T383,	  which	   inhibits	   the	   PTEN	  phosphatase	   activity	   and	   allows	  
activation	   of	   the	   PI3K/Akt	   pathway.	   PD-­‐1	   suppresses	   CK2	   and	   prevents	   the	   stabilizing	  
phosphorylation	   of	   the	   PTEN	   C-­‐terminal	   serine-­‐threonine	   cluster	   S380-­‐T382-­‐T383.	   This	   results	   in	  
increased	  PTEN	  phosphatase	  activity	  and	  inhibition	  of	  PI3K/Akt.	  	  
	  
The	   inhibitory	  signal	  mediated	  by	  PD-­‐1	  depends	  on	  the	  strength	  of	   the	  TCR	  signal	  
with	  much	  stronger	  phosphorylation	  of	  PD-­‐1	  and	  association	  with	  SHP2	  observed	  at	  
high	  levels	  of	  TCR	  stimulation.	  Even	  in	  the	  absence	  of	  TCR	  engagement,	  a	  basal	  level	  
of	  PD-­‐1	  phosphorylation	  and	  SHP2	  recruitment	  is	  detectable	  [30].	  	  
PD-­‐1	  ligation	  interferes	  with	  the	  induction	  of	  the	  cell	  survival	  factor	  Bcl-­‐xL	  [25]	  and	  
the	  expression	  of	  transcription	  factors	  associated	  with	  effector	  cell	  function	  such	  as	  
GATA-­‐3,	   T-­‐bet	   and	   Eomes	   [26].	   PD-­‐1	   ligation	   can	   also	   block	   cell	   cycle	   progression	  
and	  proliferation	  of	  T	  cells	  by	   interfering	  with	  multiple	   regulators	  of	   the	  cell	   cycle	  
via	   a	  mechanism	   that	   utilises	   the	   suppression	   of	   transcription	   factors	   in	   order	   to	  
downregulate	   genes	   that	   code	   for	   proteins	   involved	   in	   cell	   cycle	   control.	   The	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standard	  cell	  cycle	  is	  traditionally	  subdivided	  into	  the	  G1,	  S,	  G2	  and	  M	  phases	  with	  a	  
G0	   resting	   state.	   Cyclin-­‐dependent	   kinases	   (CDK)	   are	   key	   regulatory	   proteins	   that	  
are	  activated	  at	  specific	  checkpoints	  during	  the	  cell	  cycle	  to	  influence	  downstream	  
processes	   by	   phosphorylating	   specific	   proteins.	   There	   are	   five	   active	   CDKs	   during	  
the	  cell	  cycle;	  during	  G1	  (CDK4,	  CDK6	  and	  CDK2),	  S	  (CDK2),	  G2	  and	  M	  (CDK1),	  and	  
different	  cyclins	  are	  needed	  at	  different	  phases	  to	  provide	  enzymatic	  activity	  to	  the	  
cyclin-­‐Cdk	  holoenzyme	  complexes	  which	  can	  be	  inhibited	  by	  Cdk	  inhibitors	  (CKI)	  of	  
the	  Cip/Kip	   family	   such	  as	  p21	   (Waf1,	  Cip1),	  p27	   (kip1)	  and	  p57	   (Kip2).	  Cdc25	  are	  
dual-­‐specificity	   phosphatases	   that	   target	   CDKs	   and	   control	   the	   entry	   and	  
progression	  through	  the	  cell	  cycle	  phases	  [31].	  	  
A	   recent	   study	   demonstrated	   that	   PD-­‐1	   ligation	   blocks	   cell	   cycle	   progression	  
through	  the	  G1	  phase	  by	  suppressing	  the	  transcription	  of	  SKP2,	  a	  gene	  that	  encodes	  
components	   of	   a	   p27kip1degrading	   ubiquitin	   ligase	   called	   SCFSkp2,	   via	   inhibition	   of	  
PI3K–Akt	  and	  Ras–MEK-­‐ERK	  signalling	  pathway.	  These	  result	  in	  the	  accumulation	  of	  
p27kip1and	   suppression	   of	   cyclin	   E-­‐Cdk2	   activity.	   Consequent	   impairment	   in	  
phosphorylation	   of	   the	   transcription	   factor	   retinoblastoma	   (Rb)	   and	   the	   anti-­‐
proliferative	   signal	   transducer	   Smad3,	   increase	   Smad3	   transactivation	   due	   to	   the	  
inhibition	  of	  E2F-­‐regulated	  gene	  expression.	  This	   results	   in	   the	   suppression	  of	   the	  
gene	   encoding	   Cdc25A	   with	   concomitant	   increase	   in	   ubiquitin-­‐dependent	  
proteosomal	   degradation	   of	   the	   Cdc25A	   protein,	   increased	   p15	   abundance	   and	  
finally	  more	  suppression	  of	  SKP2	  expression	  [32].	  In	  addition	  to	  influencing	  cell	  cycle	  
genes,	   PD-­‐1	   can	   cause	   T	   cell	   exhaustion	   by	   upregulating	   a	   program	   of	   genes	  
including	   that	   of	   the	   basic	   leucine	   transcription	   factor,	   ATF-­‐like	   (BATF)	   which	  
functions	  as	  a	  negative	  regulator	  of	  AP-­‐1	  activity	  [33].	  
Continued	  interaction	  between	  PD-­‐1	  and	  its	  ligand	  PD-­‐L1	  suppress	  TCR-­‐driven	  stop	  
signals	   and	   prevent	   recruitment	   of	   key	   signalling	   molecules	   to	   initiate	   T	   cell	  
activation.	  The	  inability	  to	  form	  stable	  immunological	  synapses	  with	  allogeneic	  APCs	  
causes	  a	  long-­‐term	  maintenance	  of	  the	  anergic	  state	  that	  seems	  to	  depend	  on	  PD-­‐1-­‐
PD-­‐L1	   interaction	   [34].	   The	   expression	   of	   PD-­‐1	   also	   modulates	   the	   threshold	   of	  
antigen	  density	  required	  to	  activate	  cognate	  T	  cells	  which	  has	  an	  impact	  on	  antigen	  
recognition	  in	  peripheral	  tissues	  especially	  in	  the	  context	  of	  tolerance	  [35].	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Another	   co-­‐inhibitory	   molecule	   that	   plays	   an	   important	   role	   in	   regulating	   T	   cell	  
activation	   is	   the	   Lymphocyte	   activation	   gene-­‐3	   (LAG-­‐3;	   CD223),	   a	   CD4-­‐related	  
transmembrane	   protein.	   LAG-­‐3	   binds	   to	   MHC	   class	   II	   molecules	   found	   on	   the	  
surface	  of	  APCs	  but	  with	  a	  much	  higher	  affinity	  than	  CD4	  and	  at	  a	  different	  site	  from	  
CD4	   endowing	   it	  with	   a	   possible	   role	   as	   a	   negative	   competitor	   for	   CD4	   (Table	   1).	  
LAG-­‐3	   is	   mainly	   retained	   intracellularly	   near	   the	   microtubule-­‐organising	   centre	  
(MTOC)	   and	   is	   found	   co-­‐localised	   with	   Rab11b,	   a	   monomeric	   G-­‐protein	   that	  
regulates	   endosomal	   recycling	   of	   transferrin	   (Tfn)	   receptors	   to	   the	   plasma	  
membrane	  [36].	  Upon	  T	  cell	  activation	  LAG-­‐3	  is	  rapidly	  translocated	  to	  the	  plasma	  
membrane.	  LAG-­‐3	  is	  first	  detectable	  24hrs	  following	  activation	  and	  peak	  expression	  
is	  observed	  at	  around	  day	  2	   followed	  by	  a	  gradual	  decline	   in	  expression	  by	  day	  8	  
[37].	   LAG-­‐3	   expressed	   on	   the	   surface	   can	   be	   cleaved	   within	   the	   transmembrane	  
domain	   at	   the	   connecting	   peptide	   (CP)	   by	   two	  members	   of	   the	   TNFα	   converting	  
enzyme	  (TACE)	  family	  of	  metalloproteases	  known	  as	  ADAM	  10	  and	  ADAM	  17	  [38],	  
to	  release	  soluble	  LAG-­‐3	  (sLAG-­‐3)	  which	  may	  contribute	  to	  the	  regulatory	  function	  
of	   LAG-­‐3.	   Although	   the	   mechanism	   of	   how	   LAG-­‐3	   associates	   with	   the	   TCR-­‐CD3	  
complex	  and	  negatively	  regulates	  TCR-­‐induced	  signal	  transduction	  is	  not	  completely	  
understood,	   a	   single	   lysine	   residue	   468	   within	   a	   conserved	   KIEELE	   motif	   in	   the	  
cytoplasmic	  domain	  of	  LAG-­‐3	  has	  been	  shown	  to	  be	  indispensable	  in	  executing	  the	  
inhibitory	  effect	  on	  CD4-­‐dependent	  T	   cell	   function	   [39,	  40].	   Similar	   to	   the	  protein	  
kinase	  C	  binding	  site	  in	  the	  CD4	  molecule,	  the	  cytoplasmic	  tail	  of	  LAG-­‐3	  contains	  a	  
region	  with	   a	   potential	   serine	   phosphorylation	   site.	   Another	  motif	   that	   has	   been	  
identified	  in	  the	  intracytoplasmic	  region	  of	  LAG-­‐3	  is	  an	  unusual	  ‘EP’	  (glutamic	  acid-­‐
proline)	   repeat	   that	  binds	  a	  protein	   termed	  LAP	   (LAG-­‐3-­‐associated	  protein)	  and	   is	  
predicted	   to	  be	   important	   in	   the	  anchorage	  of	   the	   IS	   to	   the	  microtubule	  network	  
following	   TCR	   engagement	   [41].	   These	   properties	   suggest	   that	   the	   LAG-­‐3	  
cytoplasmic	   domain	   mediates	   intracellular	   signal	   transduction	   and/or	   molecular	  
aggregation	   [40].	   LAG-­‐3	   inhibits	   T	   cell	   expansion	   by	   blocking	   entry	   of	   activated	   T	  
cells	  into	  the	  growth	  phase	  of	  the	  cell	  cycle	  and	  results	  in	  the	  accumulation	  of	  cells	  
in	   the	  S-­‐phase.	  LAG-­‐3	   is	   involved	   in	   limiting	  the	  expansion	  of	  activated	  T	  cells	  and	  
controlling	  the	  size	  of	  the	  memory	  T	  cell	  pool	  [42].	  LAG-­‐3	  is	  also	  thought	  to	  play	  a	  
role	   in	  modulating	   DC	   function	   and	   also	   in	   enhancing	   the	   suppressive	   activity	   of	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CD4+CD25+	   regulatory	   T	   cells	   (Treg).	   LAG-­‐3	   can	   negatively	   regulate	   T	   cell	  
homeostasis	  by	  Treg-­‐dependent	  and	  independent	  mechanisms.	  	  
1.3.2.3.	  Other	  key	  co-­‐inhibitory	  receptors	  	  
In	  addition	   to	  PD-­‐1	  and	  LAG-­‐3	  other	  T	   cell	   co-­‐inhibitory	   receptors	   include	  CTLA-­‐4,	  
BTLA,	  TIM-­‐3,	  LAIR-­‐1,	  TIGIT	  and	  Siglecs	  (figure	  1.4	  and	  table	  1).	  	  
CTLA-­‐4	   has	   an	   essential	   role	   in	   negative	   regulation	   and	   maintenance	   of	   T	   cell	  
homeostasis.	  The	  expression	  of	  CTLA-­‐4	  on	  T	  cells	   controls	   the	   thresholds	  of	  T	   cell	  
activation	   following	   TCR	   ligation	   [43].	   CTLA-­‐4	   is	   a	   type	   I	   transmembrane	  
glycoprotein	  of	  the	  Ig	  superfamily	  found	  at	  low	  levels	  as	  a	  non-­‐functional	  covalent	  
homodimer	   on	   the	   surface	   of	   T	   cells	   24-­‐48	   hours	   following	   TCR	   stimulation	   and	  
binds	   to	   the	  homodimeric	   ligand	  CD80	   (B7-­‐1)	  and	  CD86	   (B7-­‐2)	  expressed	  by	  APCs	  
(Table	  1).	   These	   ligands	  also	  bind	   to	   the	  more	  abundant	  CD28	   receptor,	   although	  
with	  a	  lower	  affinity.	  Naive	  and	  memory	  T	  cells	  have	  a	  large	  pool	  of	  CTLA-­‐4	  localized	  
to	  intracellular	  vesicles	  (TGN,	  endosomes	  and	  lysosomes)	  which	  can	  be	  mobilised	  to	  
accumulate	  at	  the	  IS	  and	  partitioned	  to	  lipid	  rafts	  upon	  T	  cell	  activation.	  The	  amount	  
of	  CTLA-­‐4	  transported	  depends	  on	  the	  strength	  of	  the	  TCR	  signal	  and	  calcium	  influx,	  
and	   is	   facilitated	  by	   the	   chaperone	  adaptor	   TCR-­‐interacting	  molecule	   (TRIM)	   [44].	  
CTLA-­‐4	   uses	   a	   mechanism	   of	   signal	   initiation	   that	   does	   not	   fit	   with	   the	   current	  
paradigm	   for	   receptor-­‐medicated	   signalling	   where	   ligand-­‐induced	   conformational	  
changes	  or	   ligand-­‐induced	  dimerization	  take	  place	  [44].	  Several	  models	  have	  been	  
proposed	   to	   explain	   how	   CTLA-­‐4	   can	   influence	   TCR	   signalling.	   These	   include	  
competitive	   antagonism	   of	   CD28,	   direct	   engagement	   of	   negative	   signalling	  
molecules	  and	  the	   inhibition	  of	   lipid-­‐raft	  and	  microcluster	   formation	  (Figure	  1.5	  &	  
1.6).	  Studies	  have	  shown	  that	  CTLA-­‐4	  can	  bind	  negative	  signalling	  molecules	  such	  as	  
SHP2	  and	  PP2A	   (a	   serine/threonine	  phosphatase)	  which	   can	   then	  dissociate	  upon	  
CTLA-­‐4	   ligation	  and	  dephosphorylate	  certain	  proximal	  TCR	  signalling	  proteins	  such	  
as	  TCR-­‐ζ	  and	  LAT	  [45].	  	  
B	  and	  T	  lymphocyte	  associated	  (BTLA)	  belongs	  to	  the	  IgSF	  of	  co-­‐inhibitory	  receptors	  
and	   binds	   to	   the	   herpes	   virus	   entry	   mediator	   (HVEM)	   which	   belongs	   to	   the	   TNF	  
superfamily	  of	  costimulatory	  molecules	  (Table	  1).	  Surface	  expression	  levels	  of	  BTLA	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is	  low	  on	  naive	  CD4+	  T	  cells	  but	  is	  rapidly	  upregulated	  following	  TCR	  activation	  with	  
peak	  surface	  expression	  after	  48	  hours	  [46].	  
BTLA	  functions	  via	  the	  recruitment	  of	  tyrosine	  phosphatases	  (SHP-­‐1	  and	  SHP-­‐2)	  and	  
interaction	   with	   lipid	   raft	   components	   in	   order	   to	   attenuate	   TCR	   downstream	  
signalling	  pathways	  [47].	  
T	  cell	  immunoglobulin-­‐3	  (Tim-­‐3)	  is	  a	  type	  I	  glycoprotein	  receptor	  with	  a	  membrane	  
distal	   immunoglobulin	   variable	   (IgV)	   domain	   and	   a	   membrane	   proximal	   mucin	  
domain	  and	  is	  mainly	  expressed	  on	  IFN-­‐γ-­‐producing	  CD4+	  T	  helper	  1	  (Th1)	  and	  CD8+	  
CTLs.	  TIM-­‐3	  is	  recognized	  by	  galectin-­‐9,	  a	  member	  of	  carbohydrate-­‐binding	  proteins	  
that	  belong	  to	  a	  group	  of	  S-­‐type	  lectins	  (Table	  1)	  [48].	  
Unlike	  the	  inhibitory	  receptors	  which	  are	  expressed	  after	  T	  cell	  activation,	  LAIR-­‐1	  is	  
expressed	  in	  very	  high	  and	  relatively	  homogenous	  levels	  in	  naive	  T	  cells	  but	  in	  lower	  
and	  more	  heterogeneous	   levels	   in	  memory	  T	  cells	   [49].	  LAIR-­‐1	  has	  been	  shown	  to	  
exist	   in	   a	   basally	   tyrosine	   phosphorylated	   state	   that	   constitutively	   recruits	   and	  
activates	   SHP-­‐1,	   which	   can	   then	   dephosphorylate	   downstream	   TCR	   signalling	  
components	  and	   influence	   the	  basal	   threshold	  of	  T	   cell	   activation	   [50,	  51].	   LAIR-­‐1	  
expression	   levels	   might	   contribute	   to	   the	   higher	   threshold	   for	   TCR	   stimulation	  
observed	  in	  naive	  cells	  compared	  to	  effector	  and	  memory	  cells.	  
T	   cell	   Ig	   and	   ITIM	  domain	   (TIGIT)	   is	   a	  more	   recently	   identified	   inhibitory	   receptor	  
that	   is	   expressed	   on	   activated	   T	   cells.	   TIGIT	   is	   an	   immunoglobulin	   protein	   of	   the	  
CD28	   family	   [52].	  TIGIT	  binds	   to	  surface	  CD155	   (poliovirus	   receptor)	  molecules	  on	  
DCs	   (Table	   1).	   TIGIT-­‐CD155	   interaction	   can	   indirectly	   inhibit	   T	   cell	   responses	   by	  
driving	  DCs	  to	  a	  more	  IL-­‐10	  producing-­‐tolerogenic	  phenotype	  [53].	  
Sialic	  acid-­‐binding	  Ig-­‐like	  lectins	  (Siglecs)	  are	  type	  I	  transmembrane	  proteins	  of	  the	  
IgSF	  and	  have	  the	  unique	  ability	  to	  transmit	  signals	  into	  immune	  cells	  upon	  binding	  
to	  sialylated	  glycans	  [54].	  Several	  Siglecs	  contain	   inhibitory	  signalling	  motifs	  within	  
their	  cytoplasmic	  domains	  and	  are	  thought	  to	  be	  important	  contributors	  of	  negative	  
signals	  that	  dampen	  the	  immune	  response	  [55].	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1.3.3. 	  Cytokines	  regulate	  T	  cell	  function	  	  
Regulation	  of	  T	  cell	  activation	  can	  also	  be	  mediated	  by	  the	  binding	  of	  cytokines	  to	  
specific	   cell-­‐surface	   receptors.	   IL-­‐2	   is	   a	   potent	   T-­‐cell	   growth	   factor	   and	   plays	   a	  
central	   role	   in	   controlling	   the	  magnitude	  of	   clonal	  expansion,	   the	  development	  of	  
effector	   cells	   and	   the	   subsequent	   contraction	   of	   the	   antigen-­‐specific	   T	   cells	   [56].	  
The	  secretion	  of	  IL-­‐2	  as	  a	  consequence	  of	  signalling	  through	  the	  TCR	  is	  accompanied	  
by	   the	   expression	   of	   a	   high	   affinity	   receptor	   consisting	   of	   three	   subunits,	   IL-­‐2Rα	  
(CD25),	   IL-­‐2Rβ	   (CD122),	   and	   γc	   (CD132).	   IL-­‐2	   is	   directionally	   secreted	   within	   the	  
immunological	   synapse.	   IL-­‐2	   is	   first	   captured	   by	   CD25	   and	   the	   resulting	   binary	  
complex	  leads	  to	  conformational	  changes	  within	  IL-­‐2	  that	  promote	  interactions	  with	  
the	   other	   subunits,	   forming	   a	   stable	   quaternary	   high-­‐affinity	   IL-­‐2R,	   which	   then	  
drives	   clonal	   expansion	   [57].	   Upon	   signal	   transduction	   the	   IL-­‐2/IL-­‐2R	   complex	   is	  
rapidly	  internalized.	  IL-­‐2,	  CD122	  and	  CD132	  components	  of	  the	  complex	  are	  rapidly	  
degraded,	  while	  CD25	  is	  recycled	  to	  the	  cell	  surface.	  Thus,	  the	  clonal	  expansion	  of	  T	  
cells	   requires	   a	   continuous	   source	   of	   IL-­‐2	   to	   engage	   IL-­‐2R	   and	   form	  additional	   IL-­‐
2/IL-­‐2R	  complexes	  to	  sustain	  signalling	  [57].	  	  
IFN-­‐γ	   is	   a	   major	   pro-­‐inflammatory	   effector	   and	   regulatory	   cytokine	   produced	   by	  
activated	  T	  cells	  and	  NK	  cells.	   In	  addition	  to	  suppressing	  tumour	  development	  and	  
promoting	  tumour	  rejection,	   IFN-­‐γ	  orchestrates	  the	  trafficking	  of	  T	  cells	  to	  sites	  of	  
inflammation	  by	  up-­‐regulating	  the	  expression	  of	  adhesion	  molecules	  (ICAM-­‐1)	  and	  
chemokines	  (RANTES/	  CCL5)	  [58].	  	  
TGF-­‐β	  is	  a	  key	  immunosuppressive	  cytokine	  that	  enforces	  T	  cell	  tolerance	  by	  limiting	  
T-­‐cell	   activation	   signals.	   TGF-­‐β	   binds	   to	   type	   I	   and	   type	   II	   transmembrane	  
serine/threonine	  kinase	   receptors	  which	  signal	   to	   the	  nucleus	  via	  phosphorylation	  
and	   subsequent	   nuclear	   localization	  of	   intracellular	   Smad	  proteins,	   culminating	   in	  
the	   transcriptional	   regulation	   of	   target	   genes	   [59].	   TGF-­‐β	   is	   usually	   found	   at	   high	  
concentrations	   in	  the	  immediate	  tumour	  microenvironment,	  where	  it	  can	  regulate	  
tumour	   initiation,	   progression	   and	   metastasis.	   TGF-­‐β	   inhibits	   both	   the	   clonal	  
expansion	   and	   cytotoxicity	   of	   CD8+	   T	   cells	   via	   repression	   of	   the	   cytotoxic	   gene	  
program,	   which	   ultimately	   favours	   tumour	   progression	   [7].	   Furthermore,	   TGF-­‐β	  
triggers	  apoptosis	  as	  well	  as	  oxidative	  stress	  in	  immune	  cells	  [60].	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1.3.4. 	  Membrane	  lipids	  and	  Integrins	  in	  T	  cell	  activation	  	  
The	   efficiency	   of	   T	   cell	   signalling	   is	   increased	   by	   spatial	   organisation	   of	   receptors	  
and	   signalling	   mediators.	   In	   particular,	   the	   triggered	   receptors	   and	   their	  
downstream	   signalling	   proteins	   are	   spatially	   organised	   into	   cholesterol-­‐	   and	  
sphingolipid-­‐rich	   plasma	   membrane	   microdomains	   termed	   lipid	   rafts	   [61].	   In	  
addition	   apical	   sorting,	   lipid	   rafts	   facilitate	   cell	  migration,	   association	  of	   signalling	  
molecules	   and	   crosstalk	   between	   cell	   types.	   Upon	   T	   cell	   activation	   there	   is	   an	  
increase	  in	  the	  synthesis	  fatty	  acids	  for	  the	  biogenesis	  of	  new	  membrane	  domains	  
prior	  to	  cell	  division.	  In	  addition	  fatty	  acids	  are	  also	  a	  source	  of	  energy	  and	  functions	  
as	  signalling	  molecules.	  
Apart	   from	  influencing	  TCR	  stimulation,	  co-­‐stimulatory	  and	  co-­‐inhibitory	  receptors	  
play	  a	  role	  in	  trafficking	  of	  effector	  memory	  T	  cells	  by	  regulating	  their	  migration	  to	  
non-­‐lymphoid	   tissue.	   T	   cell	   migration	   involves	   four	   different	   adhesion	   steps;	  
tethering,	   rolling,	   activation	   and	   arrest.	   CD28	   enhances	   integrin-­‐mediated	   T	   cell	  
adhesion	   and	   cytoskeletal	   rearrangements	   via	   the	   Rho	   family	  GTPase	   Rac1,	  while	  
CTLA-­‐4	   enhances	   integrin-­‐mediated	   adhesion	   via	   a	   Rap1-­‐mediated	   pathway	   [62].	  
CD28	   and	   CTLA-­‐4	   enhance	   integrin-­‐mediated	   T	   cell	   adhesion	   in	   vitro	   but	   exert	  
opposite	  effects	  on	  T	  cell	  motility	  in	  vivo,	  through	  unknown	  mechanisms.	  	  
Sustained	  T	  cell	  signalling	  requires	  prolonged	  T	  cell-­‐APC	  interactions.	  Integrins	  such	  
as	   lymphocyte	  function-­‐associated	  antigen	  1	  (LFA1)	  constitute	  a	  family	  of	  proteins	  
that	   are	   capable	   of	   inside-­‐out	   signalling,	   mediate	   T	   cell-­‐APC	   adhesion	   and	   are	  
essential	   for	   IS	   formation	   [63].	   The	   principle	   ligand	   of	   LFA-­‐1	   is	   the	   intercellular	  
adhesion	   molecule-­‐1	   (ICAM-­‐1).	   LFA-­‐1	   integrates	   into	   TCR-­‐linked	   cytoskeletal-­‐
regulated	   signalling	  events,	   inducing	  T	   cell	  migration	   [64].	   LFA-­‐1	  engagement	  also	  
lowers	   TCR	   activation	   thresholds	   and	   increases	   sensitivity	   to	   CD28	   costimulation,	  
accelerating	   several	   aspects	   T	   cell	   maturation	   [65].	   In	   addition	   to	   integrins,	   the	  
expression	   of	   chemokines	   receptors	   by	   T	   cells	   enables	   migration	   in	   response	   to	  
chemoattractant	   gradients	   provided	   by	   chemokines.	   These	   directional	   cues	   are	  
critical	  for	  T	  cell	  trafficking	  and	  migration	  into	  inflammatory	  sites.	  CCR5	  and	  CXCR4	  
are	  structurally	  related	  chemokine	  receptors	  which	  bind	  to	  RANTES/CCL5	  and	  SDF-­‐
1/CXCL12,	  respectively	  [66].	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1.4. T	  cell	  metabolism	  underpins	  activation	  	  
Upon	  activation	  naïve	  T	  cells	  undergo	  a	  rapid	  burst	  in	  proliferation	  and	  differentiate	  
towards	   an	   effector	   phenotype	   depending	   on	   the	   stimulatory	   cues	   and	   cytokines	  
present	  during	   the	  priming	  event	   [67].	   The	  pro-­‐stimulatory	   immune	   cell	   response	  
involves	   epigenetic	   changes,	   elevated	   production	   of	   inflammatory	   cytokines,	  
transmigration	  through	  tissues	  and	  cellular	  division.	  Activated	  dynamic	  T	  cells	  need	  
to	  adopt	  a	  metabolic	  program	  that	  would	  satisfy	  the	  bioenergetic	  and	  biosynthetic	  
demands	   of	   sustaining	   rapid	   cell	   proliferation,	   adapting	   to	   changes	   in	  
microenvironment	  and	  performing	  the	  necessary	  effector	  functions	  [68].	  In	  addition	  
to	   being	   regulated	   by	   inhibitory	   receptors,	   the	   metabolic	   commitment	   of	   an	  
immune	  cell	  following	  activation	  enforces	  its	  fate	  and	  effector	  function	  [69].	  	  	  
Adenosine	   triphosphate	   (ATP)	   shuttles	   chemical	   energy	   within	   the	   cell	   to	   fuel	  
anabolic	   functions.	   ATP	   is	   produced	   in	   both	   quiescent	   and	   activated	   cells	   via	  
glycolysis	   and/or	   mitochondrial	   oxidative	   phosphorylation	   (OXPHOS).	   AMPK	  
functions	  as	  a	  sensor	  of	  cellular	  adenylates	  [ATP,	  adeonsine	  diphosphate	  (ADP),	  and	  
AMP],	  where	  an	  elevated	  AMP	  to	  ATP	  ratio	   leads	   to	   increased	  phosphorylation	  of	  
AMPK	  at	  Thr172	  on	  its	  activation	  loop	  by	  the	  kinases	  LKB1,	  TAK1,	  or	  CaMKKβ.	  AMP	  
binds	  and	  activates	  AMPK	  when	  ATP	  levels	  drop	  [70].	  This	  promotes	  ATP	  production	  
and	   blocks	   its	   consumption,	   until	   ATP	   homeostasis	   is	   re-­‐established	   whereupon	  
increased	   binding	   of	   ATP	   to	   AMPK	   inhibits	   its	   kinase	   activity.	   Activation	   of	   AMPK	  
leads	   to	   the	   inhibition	  of	  mRNA	   translation	   through	   inhibition	  of	  mTORC1	  activity	  
[70].	  	  
1.4.1. Glycolysis	  	  
TCR	   stimulation	   induces	   cell	   surface	   expression	   of	   glucose	   transporters-­‐1	   (Glut1)	  
which	   mediates	   the	   transport	   of	   glucose	   into	   T	   cells.	   Glycolysis	   refers	   to	   the	  
metabolic	  pathway	  that	  converts	  glucose	  into	  pyruvate	  through	  a	  sequence	  of	  ten	  
enzyme-­‐catalysed	   reactions.	  Glyceraldehyde-­‐3-­‐phosphate	  dehydrogenase	   (GAPDH)	  
is	  a	  bifunctional	  enzyme	  involved	  in	  both	  glucose	  metabolism	  and	  gene	  regulation.	  
The	  RNA	  binding	  function	  of	  the	  enzyme	  is	  influenced	  by	  the	  metabolic	  state	  of	  the	  
cell.	   GAPDH	   dampens	   the	   posttranscriptional	   production	   of	   proinflammatory	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cytokines	  such	  as	  IFNγ	  and	  IL-­‐2,	  by	  binding	  to	  AU-­‐rich	  regions	  in	  the	  3ʹ′	  untranslated	  
region	   (UTR)	   of	   the	   cytokine	   mRNAs	   [71].	   Upon	   T	   cell	   activation	   and	   a	   rise	   in	  
glycolysis,	  GAPDH	  switches	  from	  an	  RNA	  binding	  protein	  to	  function	  as	  a	  metabolic	  
enzyme.	   Thus	   supporting	   T	   cell	   proliferation	   and	   facilitating	   full	   effector	   cytokine	  
production.	  	  
TCR-­‐mediated	  glucose	  uptake	  requires	  CD28-­‐mediated	  Akt-­‐dependent	  regulation	  of	  
Glut1	   trafficking	   and	   glucose	   uptake	   and	   Akt-­‐independent	   regulation	   of	   Glut1	  
expression	   [72],	   to	   allow	   maximal	   glucose	   uptake	   for	   T	   cell	   activation	   and	  
proliferation.	  CD28-­‐mediated	  increase	  glycolytic	  flux	  is	  required	  for	  T	  cells	  to	  meet	  
the	   energetic	   and	   biosynthetic	   demands	   associated	  with	   a	   sustained	   proliferation	  
and	   effector	   functions	   [73].	   	   TCR-­‐mediated	   upregulation	   of	   Glut1	   facilitates	   the	  
uptake	   of	   glucose.	   Each	   glucose	   molecule	   is	   broken	   down	   in	   the	   cytosol	   by	  
anaerobic	   glycolysis	   into	   two	   molecules	   of	   pyruvate,	   two	   reduced	   nicotinamide	  
adenine	  dinucleotide	  (NADH)	  molecules	  and	  two	  net	  ATP	  molecules.	  Depending	  on	  
the	   state	   of	   T	   cell	   activation	   pyruvate	   has	   two	   alternate	   fates.	   Metabolically	  
quiescent	  naïve	   cells	   adopt	  a	  basal	   level	  of	  nutrient	  uptake	  and	  primarily	   channel	  
glucose-­‐derived	   pyruvate	   to	   be	   fully	   oxidized	   in	   the	   tricarboxylic	   acid	   (TCA)	   cycle	  
[69].	  This	  generates	  NADH	  and	  reduced	  flavin	  adenine	  dinucleotide	  (FADH2)	  to	  fuel	  
oxygen-­‐dependent	   OXPHOS,	   which	   will	   generate	   up	   to	   36	   molecules	   of	   ATP	   per	  
glucose.	  Metabolically	  active	  cells	  adopt	  an	   increased	   level	  of	  nutrient	  uptake	  and	  
preferentially	  use	  glycolysis	  over	  OXPHOS	  for	  ATP	  production.	  Here	  glucose-­‐derived	  
pyruvate	   is	   primarily	   transformed	   into	   lactate	   to	   regenerate	   NAD+	   for	   use	   in	  
glycolysis	  [69].	  The	  intermediates	  of	  the	  glycolytic	  pathway	  provide	  entry	  points	  for	  
glycolysis	   and	   also	   form	   building	   blocks	   for	   macromolecular	   synthesis.	   The	  
intermediates	  of	  the	  glycolytic	  pathway	  provide	  entry	  points	  for	  glycolysis	  and	  also	  
provide	   precursors	   for	   chemical	   constituents	   (e.g.	   nucleotides,	   amino	   acids	   and	  
lipids)	   required	   for	  macromolecular	   synthesis	   via	   anabolic	   pathways	   essential	   for	  




1.4.2. 	  Tricarboxylic	  acid	  cycle	  (TCA)	  and	  OXPHOS	  
In	  the	  TCA	  cycle,	  named	  after	  the	  three	  carboxyl	  groups	  of	  citric	  acid,	  citrate	  is	  both	  
the	   first	   product	   and	   the	   final	   reagent.	   During	   aerobic	   glycolysis	   pyruvate	   is	  
decarboxylated	  by	  pyruvate	  dehydrogenase	   to	  acetyl-­‐CoA	  with	   the	   release	  of	  CO2	  
and	  NADH.	  The	  high-­‐energy	  acetyl-­‐CoA	  molecule	  is	  combined	  with	  oxaloacetate	  to	  
form	   citrate,	   which	   undergoes	   further	   reactions	   catalysed	   by	   a	   series	   of	   seven	  
enzymes	  into	  two	  molecules	  of	  CO2,	  together	  with	  three	  equivalents	  of	  NADH	  from	  
NAD+	  and	  one	  equivalent	  of	  FADH2	  from	  FAD.	  The	  NADH	  and	  FADH2	  generated	  by	  
the	  citric	  acid	  cycle	  are	  in	  turn	  oxidized	  by	  the	  electron	  transport	  chain	  (ETC)	  in	  the	  
inner	   mitochondrial	   membrane	   [1].	   Here,	   electrons	   are	   transported	   from	   higher	  
energy	  NADH/FADH2	  to	  lower	  energy	  O2	  through	  a	  chain	  of	  four	  protein	  complexes	  
(I,	  II,	  III	  and	  IV),	  with	  a	  lipid	  soluble	  cofactor	  ubiquinone	  (coenzyme	  Q)	  and	  a	  water	  
soluble	  protein	  cytochrome	  c	  shuttling	  between	  the	  protein	  complexes	  (figure	  1.8).	  
During	  electron	  transport,	  the	  accompanying	  protons	  are	  released	  and	  pumped	  out	  
of	   the	   mitochondrial	   matrix.	   This	   creates	   a	   pH	   gradient	   across	   the	   inner	  
mitochondrial	  membrane	  due	  to	  the	  uneven	  distribution	  of	  protons	  and	  results	   in	  
electrochemical	  potential	  energy	  which	  returns	  the	  protons	  to	  mitochondrial	  matrix	  
through	  an	  integral	  membrane	  protein	  known	  as	  ATP	  synthase.	  The	  released	  energy	  
is	   used	   to	   phosphorylate	   ADP.	   The	   coupling	   of	   ATP	   synthesis	   to	   NADH/FADH2	  
oxidation	  is	  termed	  oxidative	  phosphorylation	  (OXPHOS)	  [1].	  The	  mitochondrial	  ETC	  
“leaks”	   electrons	   which	   react	   with	   oxygen	   to	   produce	   superoxide	   (O2−),	   which	   in	  
turn	   gets	   converted	   to	   hydrogen	   peroxide	   (H2O2)	   by	   Mn-­‐superoxide	   dismutase	  
(MnSOD).	   TCR-­‐induced	   calcium	   flux	   can	   permeate	   into	   the	   mitochondria	   and	  
stimulate	   the	  activity	  of	   the	  TCA	  cycle	  enzymes,	  and	   increase	   the	  electron	  “leak”.	  
Thus	  the	  greater	  the	  calcium	  flux,	  the	  greater	  the	  rise	   in	  mitochondrial	  respiration	  
to	  meet	  metabolic	   demands,	   and	   the	  more	  O2−	   is	   produced.	   These	  mitochondrial	  
reactive	  oxygen	  species	   (mitoROS)	  permeate	  membranes	  and	  represent	  the	  major	  
redox	  signal	  originating	  from	  the	  mitochondria.	  MitoROS	  can	  influence	  cell	  signaling	  
by	  redox	  modification	  of	  protein	  phosphatases	  which	  reduces	  their	  function	  and	  in	  




1.4.3. 	  Lipogenesis	  and	  glutaminolysis	  	  
Carbon	   enters	   the	   TCA	   cycle	   primarily	   at	   (i)	   the	   condensation	   of	   glucose-­‐derived	  
acetyl	  CoA	  with	  oxaloacetate	  (OAA)	  to	  generate	  citrate	  and	  at	  (ii)	  the	  conversion	  of	  
glutamine	   to	   alpha-­‐ketoglutarate	   (α-­‐KG)	   via	   glutaminolysis.	   Both	   entry	   points	  
contribute	   to	   the	   mitochondrial	   citrate	   pools.	   A	   key	   metabolic	   intermediate	   and	  
precursor	   for	   lipid	   biosynthesis	   is	   the	   cytosolic	   pool	   of	   acetyl-­‐CoA,	   formed	   from	  
glucose	  derived-­‐mitochondrial	  citrate	  via	  ATP	  citrate	   lyase	  (ACL).	  The	  acetyl-­‐CoA	  is	  
then	  converted	  to	  malonyl-­‐CoA	  [69].	  This	  irreversible	  reaction	  is	  the	  committed	  step	  
in	  fatty	  acid	  synthesis	  and	  is	  catalysed	  by	  the	  enzyme	  acetyl-­‐CoA	  carboxylase	  (ACC).	  	  
Acetyl-­‐CoA	   and	   malonyl-­‐CoA	   are	   then	   coupled	   to	   the	   substrate	   entry	   and	  
condensation	  domain	  of	  the	  multifunctional	  fatty	  acid	  synthase	  (FAS)	  enzyme	  [75].	  
Repeated	   condensations	   and	   reduction	   generate	   a	   palmitoyl	   (C16)	   chain	   on	   the	  
condensing	  domain,	  which	  is	  hydrolyzed	  to	  palmitate	  by	  the	  thioesterase	  on	  one	  of	  
the	   two	   other	   catalytic	   domains	  within	   the	   FAS	   enzyme.	   Newly	   synthesized	   fatty	  
acids	   (FA)	   can	   be	   converted	   into	   diacylglycerides	   (DAGs)	   and	   triacylglycerides	  
(TAGs).	  DAGs	  and	  TAGs	  are	   formed	  when	   fatty	  acids	  are	  esterified	   to	  a	  glycolysis-­‐
derived	  glycerol	  backbone.	  TAGs	  are	  mainly	  used	  for	  energy	  storage	  in	  the	  form	  of	  
lipid	   droplets.	   Intermediates	   of	   this	   pathway	   can	   also	   be	   converted	   into	   different	  
phosphoglycerides,	   including	   phosphatidylcholine	   (PC),	   phosphatidylethanolamine	  
(PE),	  phosphatidylglycerol	   (PG)	  and	  phosphatidylserine	  (PS),	  which	  build	  the	  major	  





Figure	  1.8:	  A	  schematic	  of	  glycolysis	  and	  de	  novo	  lipogenesis	  pathway	  	  
Glucose	  is	  transported	  into	  the	  cell	  via	  glucose	  transporter	  1	  (Glut1).	  Pyruvate	  is	  the	  end	  product	  of	  
glycolysis	   and	   is	   used	   either	   to	   produce	   lactate	   or	   is	   shuttled	   into	   the	   mitochondria.	   Inside	   the	  
mitochondria,	   pyruvate	   is	   either	   oxidized	   to	   AcCoA	   or	   converted	   to	   oxaloacetic	   acid	   (OAA)	  
(anaplerosis).	   AcCoA	   and	   OAA	   together	   give	   rise	   to	   citrate,	   which	   enters	   the	   Krebs	   cycle.	   Citrate	  
either	  continues	  with	  the	  next	  step	  in	  the	  Krebs	  cycle	  or	  leaves	  the	  mitochondria	  and	  is	  used	  by	  ATP-­‐
citrate	  lyase	  (ACL)	  in	  the	  cytosol	  to	  produce	  AcCoA	  and	  OAA.	  In	  the	  cytosol,	  AcCoA	  is	  carboxylated	  to	  
malonyl-­‐CoA	   by	   acetyl-­‐CoA	   carboxylase	   (ACC)	   which	   subsequently	   results	   in	   lipid	   synthesis.	   Fatty	  
acids	   can	   become	   available	   from	   the	   lipolysis	   of	   lipid	   droplets,	   converted	   to	   acyl-­‐carnitine	   for	  
transport	  into	  the	  mitochondria	  via	  the	  carnitine	  shuttle	  and	  used	  as	  fuel	  for	  β-­‐oxidation.	  The	  Krebs	  
cycle	   also	   generates	   NADH	   and	   FADH2,	   which	   donate	   electrons	   to	   the	   mitochondrial	   electron	  
transport	  chain,	  which	  produces	  ROS.	  Abbreviations	  for	  the	  components	  of	  the	  schematic	  are	  ATP-­‐
citrate	   lyase;	   ACL,	   acetyl-­‐CoA	   carboxylase;	   ACC,	   glucose	   transporter	   1;	   GLUT1,	   Glyceraldehyde	   3-­‐
phosphate	   dehydrogenase;	   GAPDH,	   Carnitine	   palmitoyltransferase	   I;	   CPT1,	   mitochondrial	   reactive	  
oxygen	  species;	  mitoROS.	  
	  
Glucose-­‐dependent	   fluctuations	   in	   the	   acetyl-­‐CoA	   pool	   availability	   for	   histone	  
acetylation	  reactions	  influences	  epigenetic	  regulation	  of	  T	  cell	  fate	  and	  function.	  To	  
prevent	   the	   depletion	   of	   the	   TCA	   cycle	   intermediates	   and	   disruption	   of	  
mitochondrial	  function,	  rapidly	  proliferating	  cells	  utilise	  anaplerosis	  (the	  process	  of	  
replenishing	   supplies	   of	   metabolic	   intermediates)	   to	   generate	   TCA	   cycle	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intermediates	  to	  replace	  the	  carboxylic	  acids	  withdrawn	  for	  other	  synthetic	  routes.	  
A	   key	   anaplerotic	   pathway	   is	   glutaminolysis;	   a	   metabolic	   shunt	   that	   converts	  
glutamine	   into	   α-­‐KG	   [76].	   In	   addition	   to	   being	   a	   precursor	   for	   amino	   acid	   and	  
nucleotide	  biosynthesis,	  glutamine	  is	  a	  key	  metabolite	  for	  supporting	  T	  cell	  function.	  
1.4.4. 	  T	  cell	  activation-­‐induced	  metabolic	  switch	  	  
TCR	  engagement	  induces	  a	  change	  in	  the	  expression	  of	  metabolic	  genes	  in	  order	  for	  
cellular	   metabolism	   to	   meet	   the	   bioenergetic	   and	   biosynthetic	   needs	   of	   T	   cell	  
activation.	   Cytokine	   receptors	   that	   are	   upregulated	   upon	   T	   cell	   activation	   further	  
fine-­‐tune	   the	   flux	   through	   the	   metabolic	   pathways	   that	   are	   integral	   for	   T	   cell	  
effector	  functions	  [68].	  	  	  
Quiescent	   cells	   catabolize	   nutrients	   to	   generate	   ATP	   for	   anabolic	   reactions	   that	  
maintain	  homeostasis	  and	  cell	  survival.	  Activated	  dynamic	  T	  cells	  uptake	  nutrients	  
such	   as	   glucose	   and	   glutamine	   for	   ATP	   production	   and	   convert	   glucose-­‐derived	  
pyruvate	   into	  metabolite	  precursors	   for	  macromolecular	  biosynthesis	   required	   for	  
cell	  division.	  In	  rapidly	  proliferating	  T	  cells	  the	  rates	  of	  glycolysis	  and	  mitochondrial	  
OXPHOS	  are	  increased	  to	  satisfy	  the	  high	  anabolic	  demands	  [77].	  	  
The	   bias	   towards	   glycolysis	   over	  OXPHOS	   depends	   on	   the	   differentiation	   state	   of	  
the	   T	   cell.	   Effector	   cells	   (Th1,	   Th2	   and	   Th17)	   rely	   more	   on	   glycolysis	   whereas	  
regulatory	   cells	   (Tregs)	   equally	   utilise	   glycolysis,	   fatty	   acid	   oxidation	   (FAO)	   and	  
OXPHOS.	  Although	  glycolysis	   is	   the	  major	  energy	   generating	  pathway	   in	   activated	  
effector	  T	  cells,	  mitochondrial	  OXPHOS	  is	  also	  required	  for	  de	  novo	  ATP	  production	  
and	  to	  generate	  mitochondrial-­‐derived	  reactive	  oxygen	  species	  (mitoROS).	  MitoROS	  
is	  thought	  to	  function	  as	  “bioenergetic”	  second	  messengers	  and	  essential	  for	  T	  cell	  
activation-­‐induced	  IL-­‐2	  production	  [78].	  
1.4.5. Role	  of	  autophagy	  in	  T	  cell	  metabolism	  	  
Autophagy	  has	  been	  shown	  to	  be	  vital	  for	  the	  maintenance	  of	  cellular	  bioenergetics	  
and	  sustained	  T	  cell	  viability	  following	  activation.	  Autophagy	  refers	  to	  the	  catabolic	  
process	   that	   recycles	   cytoplasmic	   components	   such	   as	   cytosolic	   proteins	   and	  
organelles,	   which	   get	   sequestered	   inside	   double-­‐membrane	   vesicles	   called	  
autophagosomes.	   These	   vesicles	   dock	   and	   fuse	   with	   lysosomes	   to	   generate	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metabolites	   that	   can	  be	  used	  either	  as	  an	  energy	   source	  or	  as	  building	  blocks	   for	  
macromolecular	  biosynthesis	  [79].	  	  
Autophagy	   initiation	   and	   progression	   requires	   the	   phosphorylation	   of	   Beclin-­‐1	   by	  
UNC51-­‐like	   kinase	  1	   (ULK1),	  which	   then	  activates	   the	   class	   III	   phosphoinositide	  3-­‐
kinase	   VPS34	   [80].	   Beclin-­‐1	   and	   VPS34	   together	   with	   p150,	   ATG14L,	   UVRAG	   and	  
Rubicon	  form	  the	  class	  III	  phosphatidylinositol	  3-­‐kinase	  (PI(3)KC3)	  complex	  [81].	  The	  
activity	  of	  the	  PI(3)KC3	  is	  vital	  for	  autophagy	  initiation	  and	  is	  tightly	  regulated.	  One	  
of	  the	  modulators	  of	  autophagy	  is	  mTOR	  complex	  1	  (mTORC1)	  [81].	  The	  activation	  
of	   mTOR1	   by	   anabolic	   inputs	   inhibits	   the	   activity	   of	   the	   ULK1	   complex	   through	  
direct	   phosphorylation,	   and	   autophagy	   is	   repressed.	   Conversely,	   ULK1	   is	   directly	  
phosphorylated	  by	  the	  AMP-­‐activated	  protein	  kinase	  (AMPK)	  in	  response	  to	  energy	  
restriction.	  Activated	  AMPK	  triggers	  autophagy	  by	  both	  inducing	  ULK1	  and	  inhibiting	  
mTOR	   [82].	   In	   tumour	   cells,	   Akt	   activity	   can	   inhibit	   autophagy	   via	   mTORC1	  
activation.	  Akt	  can	  also	  directly	  phosphorylate	  Beclin-­‐1	  and	  increase	  its	  interactions	  
with	   14-­‐3-­‐3	   regulatory	   proteins	   which	   then	   sequesters	   Beclin-­‐1	   from	   other	   core	  
autophagy	  proteins	  and	  suppress	  autophagy	  [83].	  
During	   autophagy,	   a	   protein	   called	   Microtubule-­‐associated	   protein	   1A/1B-­‐light	  
chain	   3	   (LC3)	   is	   conjugated	   to	   phosphatidylethanolamine	   (PE)	   through	   two	  
consecutive	  ubiquitylation-­‐like	  reactions	  catalyzed	  by	  the	  E1-­‐like	  enzyme	  Atg7	  and	  
the	  E2-­‐like	  enzyme	  Atg3	  to	  form	  	  LC3-­‐II,	  which	  is	  recruited	  to	  the	  autophagosomal	  
membrane.	   When	   the	   autophagosomes	   fuse	   with	   lysosomes,	   the	   intra-­‐
autophagosomal	  LC3-­‐II	  is	  also	  degraded	  by	  lysosomal	  proteases	  [84].	  Since	  changes	  
in	   cellular	   LC3-­‐II	   are	   proportional	   to	   the	   dynamic	   turnover	   of	   LC3-­‐II	   via	   the	  






1.5. Targeting	  T	  cells	  for	  therapy	  	  
T	   cells	   play	   an	   important	   role	   in	   disease	   initiation	   and	   propagation	   through	   the	  
secretion	   of	   a	   myriad	   of	   pro-­‐inflammatory	   cytokines.	   The	   targeting	   of	   T-­‐cell	   co-­‐
stimulatory/co-­‐inhibitory	   receptors	   in	   the	   treatment	   of	   immune	   disorders	   (e.g.	  
cancer,	   autoimmunity	   and	   infections)	   is	   a	   promising	   avenue.	   These	   therapies	   are	  
largely	  based	  on	  T	  cell	   Immunomodulatory	  monoclonal	  antibodies	  (mAbs)	  that	  are	  
either	   direct	   agonists	   or	   relieve	   T	   cell	   inhibitory	   signals	   [86].	   At	   the	   same	   time,	  
however,	  these	  mAbs	  can	  be	  associated	  with	  a	  risk	  of	  serious	  adverse	  effects,	  which	  
include	   systemic	   induction	   of	   proinflammatory	   cytokines	   (cytokine	   release	  
syndrome)	   and	   organ-­‐specific	   autoimmunity,	   which	   arise	   from	   dysregulated	  
activation	   of	   the	   T	   cells.	   These	   T-­‐cell	   engaging	   biologics	   potentially	   alter	   cellular	  
metabolism	   and	   the	   expression	   of	   stimulatory/inhibitory	   receptors.	   A	   detailed	  
understanding	  of	   these	  altered	  parameters	  would	  be	  highly	  beneficial	  and	  aid	  our	  
understanding	  of	  the	  safety	  profile	  of	  T	  cell	  modulatory	  mAbs	  in	  general.	  
1.5.1. 	  Immunomodulatory	  monoclonal	  antibodies	  	  
The	   exquisite	   specificity	   and	   high	   avidity	   towards	   a	   target	   antigen	   has	   made	  
antibody	   based	   therapeutic	   agents	   the	   most	   rapidly	   expanding	   class	   of	  
biotherapeutics	  undergoing	  clinical	  evaluation	  and	  development	  for	  the	  treatment	  
of	   cancers,	   autoimmune	   and	   inflammatory	   disorders.	   Antibodies,	   in	   addition	   to	  
inducing	  immune	  mechanisms	  can	  act	  through	  multiple	  mechanisms	  of	  action	  such	  
as	   inhibition	   of	   angiogenesis,	   blockage	   of	   receptors	   and	   signalling	   perturbations,	  
restricts	   tumour	   growth	   e.g.	   EGF-­‐R	   blocking	   antibodies,	   initiates	   G1	   arrest	   and	  
induces	   p27.	   Antibody	   therapy	   has	   revolutionized	   treatment	   for	   major	   disease	  
indications	  e.g.	  leukaemia,	  lymphoma,	  colorectal	  cancer,	  breast	  cancer,	  melanoma,	  
asthma,	  rheumatoid	  arthritis,	  psoriasis,	  multiple	  sclerosis,	  Crohn's	  disease,	  systemic	  
lupus	  erythematosus	  and	  several	  other	  autoimmune	  diseases	  [87].	  	  
Antibodies	   (immunoglobulins,	   Ig)	   are	   protein	   molecules	   secreted	   by	   mature	   B	  
lymphocytes	   which	   are	   vital	   mediators	   of	   the	   humoral	   immunity	   branch	   of	   the	  
adaptive	   immune	   system.	  Antibodies	   produced	   by	   a	   single	   B	   cell	   clone	   are	   called	  
monoclonal	   antibodies	   (mAbs)	   and	   have	   the	   ability	   to	   bind	   to	   a	   unique	   target	  
antigen	  with	  high	  specificity	  and	  affinity.	  Antibodies	  function	  as	  nature’s	  pro-­‐drugs,	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being	  inactive	   in	  the	  soluble	  form	  but	  become	  activators	  of	  effector	  systems	  upon	  
target	  antigen	  recognition.	  Antibodies	  are	  made	  up	  of	  different	  domains	  each	  with	  
a	   particular	   function.	   The	   Fab	   portion	   of	   antibodies	   determine	   target	   specificity	  
while	   the	  Fc	  portion	  binds	   to	  membrane	  Fc	   receptors	   (FcR)	  and	   is	   responsible	   for	  
effector	   function	  [88].	  Antibodies	  have	  key	  properties	  relevant	  to	  therapy	  and	  are	  
different	   from	   conventional	   small	   molecule	   drugs	   in	   their	   unique	   biological	  
activities,	   restricted	   tissues	   distribution	   and	   a	   common	   structural	   format.	   The	  
clinical	   efficacy	   of	   therapeutic	   mAbs	   is	   generally	   attributed	   to	   the	   target-­‐specific	  
mechanisms	   resulting	   from	   (1)	   binding	   to	   soluble	   ligands	   such	   as	   cytokines	   and	  
growth	   factors,	   (2)	   receptor	   antagonist	   activity	   by	   blocking	   dimerization,	   (3)	  
triggering	   downstream	   signalling	   to	   reduce	   proliferation	   and	   apoptosis,	   and	   (4)	  
target	  cell	  depletion	  through	  the	  induction	  of	  apoptosis	  or	  the	  activation	  of	  immune	  
mediated	  effector	  functions	  such	  as	  antibody-­‐dependent	  cell-­‐mediated	  cytotoxicity	  
(ADCC),	   antibody-­‐dependent	   cellular	   phagocytosis	   (ADCP)	   and	   complement-­‐
dependent	   cytotoxicity	   (CDC)	   via	   interactions	   involving	   the	   Fc	   domain.	   Some	  
therapeutic	  antibodies	  utilise	  a	  combination	  of	  several	  mechanisms	  of	  action	  [89].	  	  	  	  
1.5.2. Co-­‐inhibitory	  receptors	  as	  mAb	  targets:	  PD-­‐1	  and	  LAG-­‐3	  
T	   cell	   co-­‐inhibitory	   receptors	   are	   dysregulated	   by	   the	   tumour	   microenvironment	  
leading	   to	   a	   reduction	   in	   endogenous	   anti-­‐tumour	   immunity.	   Antagonists	   of	  
inhibitory	  signals	  can	  result	  in	  the	  amplification	  of	  antigen-­‐specific	  T	  cell	  responses	  
and	   increase	  anti-­‐tumour	   immune	  responses.	  PD-­‐1	   is	  being	  considered	  as	  a	  viable	  
target	  for	  therapeutic	  immunomodulation.	  CD8+	  T	  cell	  dysfunction	  brought	  about	  by	  
chronic	   antigen	   stimulation	   (e.g.	   during	   lymphocytic	   choriomeningitis	   virus	   LCMV	  
infection	  or	  tumours)	  has	  been	  shown	  in	  animal	  models	  to	  be	  partially	  reversed	  by	  
blockage	  of	  the	  PD-­‐1/PD-­‐L1	  pathway	  [90].	  LAG-­‐3	  is	  also	  overexpressed	  in	  CD8+	  T	  cell	  
exhaustion	  and	  the	  blockade	  of	  the	  LAG-­‐3/MHC	  II	  interactions	  using	  LAG-­‐3	  Ig	  fusion	  
protein	   enhances	   anti-­‐tumour	   immunity	   and	   is	   being	   evaluated	   in	   a	   number	   of	  
clinical	   trials.	   In	   addition	   to	   inducing	   T-­‐cell	   co-­‐inhibitory	   receptor	   expression,	  
tumour	   cells	   secrete	   TGF-­‐β	   into	   the	   microenvironment	   to	   render	   T	   cells	  
hyporesponsive	   by	   inhibiting	   their	   effector	   functions.	   TGF-­‐β	   antagonists	   can	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significantly	   suppress	   tumorigenesis	   and	   greatly	   improves	   the	   efficacy	   of	  
immunomodulatory	  chemotherapy	  in	  preclinical	  models	  [91].	  	  
1.5.3. Co-­‐stimulatory	  receptor	  as	  mAb	  targets:	  CD28	  
TGN1412	   was	   a	   humanised	   IgG4	   anti-­‐CD28	   superagonistic	   mAb	   (CD28SA)	  
withdrawn	  from	  development	  after	  a	  disastrous	  first-­‐in-­‐man	  trial	  in	  2006.	  CD28SA	  is	  
associated	  with	  a	  risk	  of	  serious	  adverse	  effects,	  which	  include	  systemic	  induction	  of	  
proinflammatory	   cytokines	   (cytokine	   release	   syndrome)	   and	   organ-­‐specific	  
autoimmunity,	   which	   arise	   from	   dysregulated	   activation	   of	   the	   T	   cells	   [92].	  
Significant	   focus	   in	   recent	   times	   has	   been	   on	   assessing	   the	   potential	   of	  
immunostimulatory	   mAbs	   to	   induce	   enhanced	   cytokine	   release,	   but	   much	   less	  
attention	   has	   been	   paid	   to	   other	   aspects	   of	   T	   cell	   biology	   including	   non-­‐
physiological	   activation	   phenotype/functions	   and	  migration	   characteristics.	   In	   this	  
thesis	  we	  study	  the	  activation	  parameters,	  migration	  capacity,	  degree	  of	  regulation,	  
and	  metabolic	  profiles	  of	  CD28SA-­‐activated	  T	  cells.	  	  
	  
1.6. Rationale,	  hypothesis,	  strategy	  and	  aims	  
Rationale	  	  
Physiological	  activation	  of	  T	  cells	   is	  associated	  with	  downregulation	  of	  cell	   surface	  
TCR,	   expression	   of	   adhesion	   molecules	   such	   as	   LFA-­‐1,	   expression	   of	   chemokine	  
receptors	   such	   as	   CCR5,	   synthesis	   of	   IL-­‐2,	   T	   cell	   proliferation	   and	   expression	   of	  
death	   receptors	   such	   as	   CD95,	   that	   help	   in	   contraction	   of	   the	   T	   cell	   immune	  
response.	  The	  activation	  of	  T	  cells	  is	  regulated	  by	  the	  expression	  and	  function	  of	  co-­‐
inhibitory	   receptors	   such	   PD-­‐1	   and	   LAG-­‐3,	   and	   by	   the	   presence	   of	   TGF-­‐β	   in	   the	  
microenvironment,	   which	   prevent	   excessive	   T	   cell	   activation	   by	   attenuating	   the	  
activation	   signals	   initiated	  by	  T	   cell	   stimulatory	   receptors.	  Dysregulation	   in	   any	  of	  
these	  parameters	  can	  result	  in	  substantial	  T	  cell	  proliferation	  and	  extravasation	  of	  T	  
cells,	   and	   highly	   elevated	   secretion	   of	   a	   number	   of	   pro-­‐inflammatory	   cytokines.	  
Since	   specific	   effector	   functions	   require	   specific	   metabolic	   pathways	   to	   provide	  
energy	   and	   biosynthetic	   precursors,	   dysregulated	   effector	   functions	   stem	   from	  




1. To	  elucidate	  the	  underlying	  cellular	  and	  molecular	  events	  that	  result	  in	  aberrant	  
activation	  of	  human	  T	  cells	  by	  CD28SA.	  
2. To	   determine	   the	   metabolic	   program	   of	   CD28SA-­‐activated	   and	   anti-­‐CD3-­‐
activated	  human	  T	  cells	  
3. To	   define	   the	   role	   of	   oxidative	   stress	   in	   TGF-­‐β-­‐associated	   functional	   and	  
metabolic	  alterations	  in	  TCR-­‐activated	  mouse	  T	  cells	  
Hypotheses	  tested	  in	  this	  study	  	  
1. Activation	   of	   T	   cells	   with	   TGN1412-­‐like	   CD28SA	   results	   in	   a	   hyperactive	  
phenotype	  with	  uninhibited	  effector	  functions.	  We	  hypothesised	  that	  CD28SA-­‐
activated	   T	   cells	   acquire	   a	   proactivatory	   phenotypic	   profile	   with	   increased	  
functional	  activities	  and	  deficiency	  in	  inhibitory	  inputs.	  	  
Experimental	   strategy:	   We	   used	   a	   humanized	   CD28-­‐specific	   superagonistic	  
(CD28SA)	  mAb	  called	  NIB1412	   to	   stimulate	  human	  CD4+	  T	   cells	   and	  compared	  
this	  to	  activation	  with	  conventional	  anti-­‐CD3	  mAbs.	  
2. CD28SA	  activation	   results	   in	  dramatic	  hyperactivation	  and	  proliferation,	  which	  
requires	   an	   altered	   metabolic	   program	   to	   satisfy	   the	   energy	   demands.	   We	  
postulated	   that	   the	   phenotypic	   and	   functional	   characteristics	   of	   T	   cells	  
activated	  with	  CD28SA	  are	  associated	  with	  a	  distinct	  metabolic	  profile.	  	  
Experimental	   strategy:	  We	   used	   NIB1412	   and	   conventional	   anti-­‐CD3	  mAbs	   to	  
stimulate	   human	   CD4+	   T	   cells,	   and	   compared	   their	   metabolic	   parameters	  
following	  activation.	  
3. Antigen-­‐specific	  activation	  of	  T	  cells	  in	  the	  presence	  of	  TGF-­‐β	  results	  in	  deficient	  
proliferation	  and	  reduced	  effector	  functions.	  Since	  studies	  have	  found	  that	  TGF-­‐
β	  triggers	  ROS,	  we	  hypothesised	  that	  antioxidant	  supplementation	  following	  T	  
cell	   activation	   restores	   the	   phenotypic	   and	   functional	   activities,	   and	   the	  
metabolic	  profile	  of	  T	  cells	  that	  are	  exposed	  to	  inhibitory	  inputs	  by	  TGF-­‐β.	  	  
Experimental	   strategy:	  We	  used	   an	   ex	   vivo	   antigen-­‐specific	   CD8+	   T	   cell	  mouse	  
model	  (transgenic	  F5-­‐TCR	  mouse	  model)	  to	  examine	  effector	  of	  TGF-­‐β-­‐exposed	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2. Methods	  and	  Materials	  	  
2.1. Reagents	  
All	  reagents	  were	  obtained	  from	  Sigma-­‐Aldrich	  unless	  otherwise	  stated.	  	  
2.2. Complete	  medium	  
Roswell	  Park	  Memorial	  Institute-­‐1640	  (RPMI-­‐1640)	  medium	  was	  supplemented	  with	  
10%	   FBS,	   50	   μM	   2-­‐ME,	   2	   mM	   HEPES	   buffer,	   1	   mM	   sodium	   pyruvate,	   2	   mM	   L-­‐
glutamine,	  100	  IU/	  ml	  streptomycin	  and	  100	  μg/	  ml	  penicillin	  
2.3. Human	  T	  cell	  isolation	  	  
Ethical	  approval	  for	  the	  use	  of	  human	  peripheral	  blood	  mononuclear	  cells	  (PBMCs)	  
from	  healthy	  donors	  was	  approved	  by	  the	  local	  ethical	  committee	  and	  all	  subjects	  
provided	  informed	  consent.	  PBMCs	  were	  isolated	  from	  heparinised	  venous	  blood	  by	  
density	   gradient	   separation	   using	   Lymphoprep	   as	   described	   by	   Böyum	   [93]	   (Axis-­‐
Shield,	   cat	  #	  О7811).	  The	  effector	  memory	  CD4+	  T	   cell	   (TEM)	   isolation	  kit	   (Miltenyi	  
Biotec,	   cat	   #	   130-­‐094-­‐125)	   was	   used	   to	   purify	   TEMs	   from	   PBMCs	   according	   to	  
manufacturer's	  instructions.	  	  
2.4. Mouse	  T	  cells	  and	  dendritic	  cells	  	  
C57BL/6	  mice	   homozygous	   for	   the	   H-­‐2Db-­‐restricted	   TCR-­‐αβ	   transgene,	   F5,	   which	  
recognises	   NP-­‐68	   [94],	   a	   nonameric	   peptide	   derived	   from	   influenza	   virus	  
A/NT/60/68	   nucleoprotein	   were	   a	   kind	   gift	   from	   Dr	   James	   Matthews	   [Cardiff;	  
Wales].	  Mice	  were	   housed	   under	   controlled	   conditions	   (temperature	   of	   between	  
19°C	  -­‐	  23°C	  under	  12	  h	  light/dark	  cycles,	  with	  free	  access	  to	  food	  and	  water)	  at	  the	  
Biomedical	   Services	   Unit,	   University	   of	   Liverpool.	   All	   animals	   were	   bred	   under	  
pathogen	   free	   conditions.	   Protocols	   described	   herein	   were	   undertaken	   in	  
accordance	  with	   criteria	  outlined	   in	   licenses	  granted	  under	   the	  Animals	   (Scientific	  
Procedures)	  Act	  1986	  (PPL	  40/2937	  and	  PPL	  40/2544)	  and	  approved	  by	  the	  Animal	  
Ethics	   Committee	   of	   the	   University	   of	   Liverpool.	   The	   NP68	   peptide	  
(366ASNENMDAM374)	   used	   to	   stimulate	   F5	   CD8	   T	   cells	  was	   synthesised	   by	   Peptide	  




For	  the	  generation	  of	  mature	  DCs,	  bone	  marrow	  cells	  were	  flushed	  from	  femora	  of	  
wild	   type	   mice.	   Cells	   were	   washed	   and	   cultured	   at	   a	   density	   of	   3x	   106	  
cells/microbiological	   petri	   dish	   in	   complete	   medium	   supplemented	   with	   20ng/ml	  
GM-­‐CSF	  and	  kept	  in	  a	  fully	  humidified	  incubator	  at	  37°C	  under	  5%	  CO2.	  Media	  was	  
then	  replenished	  on	  day	  3	  supplemented	  with	  20ng/ml	  GM-­‐CSF	  and	  differentiated	  
DCs	  were	  used	  between	  days	  6	  or	  7.	  Spleens	  were	  isolated	  from	  F5	  TCR	  transgenic	  
mice	   and	   homogenised	   using	   Jencons	   Uniform	   Grade	   B-­‐24	   Tissue	   Homogeniser	  
[Jencons	   Scientific	   Ltd.,	   Leighton	   Buzzard,	   UK]	   and	   then	   filtered	   through	   40	   μm	  
gauge	   Nylon	   Cell	   Strainers	   [Falcon,	   UK].	   Splenocytes	   were	   washed	   in	   HBSS	   and	  
centrifuged	  at	  300	  g	  for	  5	  minutes.	  Pelleted	  cells	  were	  treated	  with	  red	  blood	  cell	  
(RBC)	   lysis	   buffer	   (8.3	   g/L	   ammonium	   chloride	   in	   0.01	   M	   Tris-­‐HCl	   buffer)	   for	   6	  
minutes	   at	   room	   temperature	   to	   remove	   red	   blood	   cells.	   Following	   a	   final	  
















F5-­‐TCR	  T	  cells	  were	  activated	  according	  to	  the	  scheme	  below	  (figure	  2.1).	  
	  
Figure	  2.1:	  schematic	  outline	  of	  the	  experimental	  procedures	  used	  in	  Chapter	  5	  
Splenocytes	   derived	   from	  F5-­‐TCR	  mice	  were	   subjected	   to	   primary	   stimulation	  with	  NP68	   ±	   TGF-­‐β.	  
Tiron	   (Sigma,	   cat#	   89460)	   was	   added	   24hrs	   later	   as	   mitoROS	   produced	   upon	   TCR	   stimulation	   is	  
essential	   for	   T	   cell	   expansion.	   At	   72hrs	   cells	   were	   either	   re-­‐stimulated	   with	   1nM	  NP68	   (DCs	   pre-­‐
pulsed	  with	  NP68	  was	  used	  for	  IFN-­‐γ	  ELISpot)	  or	  harvested	  for	  the	  respective	  assays.	  Re-­‐stimulated	  
cells	   were	   used	   for	   three	   assays:	   staining	  with	   fluorochrome-­‐conjugated	   IL-­‐2/	   IFN-­‐γ	   after	   6	   hours	  
followed	   by	   flow	   cytometric	   analysis,	   IFN-­‐γ	   producing	   cells	   were	   measured	   by	   ELISpot	   after	   16h	  
stimulation	   with	   NP68-­‐pulsed	   DCs	   ±	   anti-­‐LAG-­‐3,	   and	   metabolic	   measurements	   after	   48hrs	   using	  
Seahorse	  XF	  analyzer.	  
2.5. Human	  endothelial	  cell	  culture	  	  
Human	   dermal	   microvascular	   endothelial	   cells	   (HDMEC)	   were	   purchased	   from	  
Promocell	   and	   were	   cultured	   in	   endothelial	   cell	   basal	   media	   (EBM)	  MV2	   growth	  
media	  (C-­‐22221;	  Promocell),	  supplemented	  with	  5%	  (v/v)	  fetal	  calf	  serum	  (FCS)	  and	  
EGF	  (5	  ng/ml),	  VEGF	  (0.5	  ng/ml),	  FGF-­‐2	  (10	  ng/ml),	   long	  R3	  insulin	  growth	  factor-­‐1	  
(20	   ng/ml),	   hydrocortisone	   (0.2	   µg/ml)	   and	   ascorbic	   acid	   (1	   µg/ml)	   (supplement	  
pack	  C-­‐39221;	  Promocell).	  
2.6. Stimulating	  antibodies	  and	  recombinant	  proteins	  
	  Humanized	  superagonistic	  anti-­‐CD28	  antibody	  NIB1412,	  a	  human	  IgG4	  sharing	  the	  
H	   chain	   V	   region	   and	   L	   chain	   sequences	   of	   TGN1412	   [95],	   was	   generated	   at	   the	  
39	  
	  
National	  Institute	  for	  Biological	  Standards	  and	  Control	  (NIBSC).	  Murine	  anti-­‐human	  
CD3	   (clone:	  UCHT1,	   cat	   #	   16-­‐0038-­‐85)	   antibody	  was	   purchased	   from	  eBioscience.	  
The	  cross-­‐linking	  goat	  anti-­‐human	  IgG	  (Fc)	  secondary	  antibody	  was	  purchased	  from	  
AbD	   Serotec	   (cat	   #	   5211-­‐8004).	   Recombinant	   PD-­‐L1	   was	   purchased	   from	   R&D	  
Systems	  (cat	  #	  156-­‐B7-­‐100).	  For	  mouse	  F5-­‐TCR	  work,	  anti-­‐LAG-­‐3	  blocking	  antibody	  
(C9B7W,	   cat#	  16-­‐2231-­‐85)	  was	  purchased	   from	  eBioscience	   Ltd,	   and	   recombinant	  
TGF-­‐β	   (HEK293	   derived,	   cat#	   100-­‐21)	   and	   IL-­‐2	   (E.coli	   derived,	   cat#	   200-­‐02)	   were	  
purchased	  from	  Peprotech	  EC	  Ltd.	  	  
2.7. T	  cell	  proliferation	  assays	  	  
96-­‐well	   round-­‐bottom	   non-­‐tissue	   culture	   treated	   plates	   were	   coated	   with	  
stimulating	   antibodies	   at	   37°C	   for	   2	   hours.	   Plates	   were	   washed	   twice	   to	   remove	  
unbound	  antibody	  before	  addition	  of	   T	   cells.	  Where	  NIB1412	  was	  used,	   the	  wells	  
were	   pre-­‐coated	   with	   cross-­‐linking	   goat	   anti-­‐human	   IgG	   (Fc)	   mAb	   anti-­‐IgG	   mAb	  
(20µg/ml).	  For	   the	  F5	  CD8	  T	  cell	  proliferation	  assay,	   isolated	  splenocytes	   from	  F5-­‐
TCR	  mice	  were	  plated	  out	  in	  quadruplicate	  at	  a	  density	  of	  1	  x	  105	  cells/	  well	  in	  96-­‐
well	   round-­‐bottom	   microtitre	   plates	   and	   activated	   with	   NP68	   or	   DCs	   pre-­‐pulsed	  
with	  NP68	  (In	  a	  20:1,	  T-­‐cell	  to	  DC	  ratio).	  	  
T	  cells	  were	  cultured	  in	  complete	  media	  (RPMI	  1640	  supplemented	  with	  15%	  foetal	  
calf	  serum	  (Life	  Technologies),	  2	  mM	  L-­‐glutamine,	  50	  U	  ml–1	  penicillin	  and	  0.05	  mg	  
ml–1	  streptomycin)	  for	  72	  h	  (at	  37	  °C)	  in	  either	  normoxic	  (20%	  O2)	  or	  hypoxic	  (5%	  O2)	  
conditions,	   and	  18	  hours	   before	   the	   end	  of	   the	   time	  point,	   the	   cells	  were	  pulsed	  
with	  tritiated	  thymidine	  ([3H]-­‐TdR,	  0.5	  µCi/well).	  Incorporation	  of	  [3H]-­‐TdR	  in	  T	  cells	  
was	   determined	   using	   a	   β-­‐scintillation	   counter	   (MicroBetaTrilux;	   PerkinElmer	   Life	  
Sciences,).	  Data	  obtained	  are	  presented	  as	  mean	  counts	  per	  minute	  (cpm).	  
2.8. Cell	  viability	  assay	  	  
Briefly,	  CD4+	  TEM	  were	  plated	  in	  base	  media	  with	  L-­‐glutamine	  ±	  glucose	  at	  a	  density	  
of	  5	  ×	  104	  cells/well	  in	  96-­‐well	  plates	  pre-­‐coated	  with	  anti-­‐CD3	  mAbs	  or	  NIB1412.	  	  
For	   the	  mouse	  F5-­‐TCR	  CD8	  T	   cell	   viability	  assay,	   cells	  were	  activated	  with	  NP68	  ±	  
TGF-­‐β	   at	   a	   density	   of	   5	   ×	   104	   cells/well	   in	   96-­‐well	   plates.	   Following	   overnight	  
incubation	   at	   37°C,	   each	   sample	  was	   collected	   and	   assayed	   for	   cell	   viability	   using	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trypan	   blue	   exclusion.	   Percentage	   viability	   was	   determined	   by	   the	   Countess™	  
automated	  cell	  counter.	  	  
2.9. Flow	  cytometric	  analysis	  	  	  
T	  cells	  were	  stained	  for	  20	  minutes	  at	  4°C.	  The	  following	  fluorochrome	  conjugated	  
antibodies	   (eBioscience	   Ltd,)	   diluted	   to	   the	   optimal	   concentration	   were	   used	   for	  
human	  work:	  anti–CD4	  PerCP-­‐Cyanine5.5	  (RPA-­‐T4,	  cat	  #	  45-­‐0049-­‐42),	  anti–PD-­‐1-­‐PE	  
(J105,	  cat	  #	  12-­‐2799-­‐42),	  anti–CD11a-­‐FITC	   (HI111,	  cat	  #	  11-­‐0119-­‐42),	  anti-­‐CCR5-­‐PE	  
(NP-­‐6G4,	  cat	  #	  12-­‐1956-­‐42),	  anti–TCR-­‐APC	  (IP26,	  cat	  #	  17-­‐9986-­‐42),	  anti-­‐CD28-­‐APC	  
(CD28.2,	   cat#	   17-­‐0289-­‐41),	   anti-­‐CXCR4-­‐APC	   (12G5,	   cat#	   17-­‐9999-­‐41),	   anti-­‐CD137-­‐
FITC	   (4B4,	   cat#	   11-­‐1379-­‐42),	   anti-­‐GITR-­‐PE	   (eBioAITR,	   cat#	   12-­‐5875-­‐41),	   anti-­‐CD27-­‐
FITC	  (O323,	  cat#	  11-­‐0279-­‐41),	  anti-­‐CD80-­‐FITC	  (2D10.4,	  cat#	  11-­‐0809-­‐41),	  anti-­‐HLA-­‐
DR-­‐FITC	   (LN3,	   cat#	   11-­‐9956-­‐42)	   and	   anti–IFNγ-­‐APC	   (4S.B3,	   cat	   #	   17-­‐7319-­‐82).	   For	  
mouse	   T	   cells	   cell	   surface	   staining	   was	   done	   with	   the	   following	   fluorochrome	  
conjugated	   antibodies:	   	   TRI-­‐COLOUR®	   conjugated	   anti-­‐mouse	   CD8	   (5H10,	   cat#	  
MCD0806)	   and	   Alexa	   Fluor®	   488	   conjugated	   anti-­‐mouse	   CD25	   (PC61	   5.3,	   cat#	  
RM6020)	  were	  purchased	  from	  Invitrogen	  [Paisley,	  UK],	  PE-­‐conjugated	  anti-­‐mouse	  
I-­‐A/I-­‐E	  (M5/114.15.2,	  cat#	  562010),	  FITC-­‐conjugated	  anti-­‐mouse	  IL-­‐2	  (JES6-­‐5H4,	  cat#	  
554427)	   and	   FITC-­‐conjugated	   anti-­‐mouse	   IFN-­‐γ	   (XMG1.2,	   cat#	   554411)	   were	  
purchased	   from	   BD	   Bioscience	   Ltd,	   and	   anti-­‐LAG-­‐3-­‐PE	   (C9B7W,	   cat#	   12-­‐2231-­‐83)	  
was	   purchased	   from	   eBioscience	   Ltd.	   For	   intracellular	   staining,	   surface	   markers	  
were	   stained	   first,	   followed	   by	   permeabilization	   using	   Cytofix/Cytoperm	   (BD	  
Pharmingen,	   cat	   #	   555028)	   and	   stained	   with	   anti–IFNγ-­‐APC	   or	   anti–PD-­‐1-­‐PE	   for	  
human	  cells,	  and	  for	  mouse	  cells	  with	  anti-­‐IL-­‐2	  FITC	  or	  anti-­‐	  IFN-­‐γ-­‐FITC.	  To	  quantify	  
mitochondrial	   superoxide	   production,	   cells	   were	   incubated	   with	   MitoSOX	   Red	  
(Invitrogen,	   cat#	   M36008)	   at	   37°C	   for	   10	   minutes,	   washed	   and	   fixed	   in	   2%	  
paraformaldehyde.	  	  MitoSOX	  Red	  was	  excited	  at	  488	  nm	  and	  fluorescence	  emission	  
at	  575	  nm	  was	  measured.	  Fluorescent	  signals	  from	  cells	  were	  acquired	  on	  BD	  FACS	  
Canto	  II	  flow	  cytometer	  and	  data	  were	  analysed	  using	  Cyflogic	  software	  v.	  1.2.1.	  	  
2.10. IFNγ	  ELISpot	  assay	  
Mouse	   IFN-­‐γ	   ELISpot	   kit	   (MABTECH,	   cat#	   3321-­‐2A)	  was	  used	   to	   enumerate	   IFN-­‐γ-­‐
secreting	  cells	  according	  to	  manufacturer’s	  instructions.	  Briefly,	  ELISpot	  plates	  were	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washed	  and	  coated	  overnight at 4˚C 	  with 	  IFN-­‐γ 	  capture 	  antibody 	  (15µg/ml).	  
The	  following	  day,	  wells	  were	  washed	  five	  times	  with	  200µl	  sterile	  PBS	  and	  blocked	  
with 	   complete	  medium	   for	  30mins	   at	   room	   temperature.	  Medium	  was	   removed	  
and	   F5-­‐TCR	  mouse	   T	   cells	   (2x104,	   100μl)	   were	   added	   to	   the	   wells	   with	   DCs	   pre-­‐
pulsed	  with	  1nM	  NP68	  as	  APCs	   (1x103,	  50μl)	   in	   the	  presence	  or	  absence	  of	  LAG-­‐3	  
blocking	   antibody	   (5μg/ml,	   50μl).	   Plates were incubated at 37˚C in 5% CO2	   for	  
48hours,	   after	  which	   cells were 	   discarded and wells washed 	   five 	   times with	 
200µl PBS. Biotin-­‐labelled detection antibody was diluted	   to 1µg/ml in PBS 
containing	   0.5% 	   FBS 	   and 	   added 	   to 	   the 	   wells 	   (100µl),	   and	   incubated 	   at	  
room	  temperature 	  for 	  2 	  hours.	  Wells	  were	  then	  washed 	  five 	  times 	  with 	  PBS	  
and	  100µl	  of	  Streptavidin-­‐ALP	  (diluted 1:1000 in PBS containing 0.5% FBS)	  was	  
added	   and	   incubated	   at	   room	   temperature	   for	   1hour.	  Wells	 were washed	 five 	  
times with PBS	   (200µl)	 and spots were	   visualised by the addition of	 100µl	  
BCIP/NBT substrate.	   Dried	   plates were counted on an AID ELISpot reader 	  
(Cadama	  Medical,	  Stourbridge,UK).	  
2.11. Re-­‐stimulation	  assay	  using	  rPD-­‐L1	  	  
Isolated	  T	  cells	  were	  stimulated	  and	  cultured	  as	  described	  above	  for	  48	  hours	  and	  
re-­‐stimulated	   in	   a	   96-­‐well	   round-­‐bottom	   non-­‐tissue	   culture	   treated	   plate	   pre-­‐
coated	  with	   1	   µg/ml	   anti-­‐CD3,	   10	   µg/ml	   rPD-­‐L1	   and	   the	   combination	   of	   1	   µg/ml	  
anti-­‐CD3	  +	  10	  µg/ml	  rPD-­‐L1.	  Cells	  were	  incubated	  at	  37°C	  for	  one	  hour	  after	  which	  
Golgi	  plug	  was	  added	  and	   incubated	   for	  another	  5	  hours	   (figure	  2.2).	   Intracellular	  





Figure	  2.2:	  Schematic	  of	  the	  protocol	  used	  to	  investigate	  the	  functional	  significance	  of	  PD-­‐1	  
pathway	  on	  NIB1412-­‐activated	  CD4+	  T	  cells.	  	  
2.12. Cell	  cycle	  analysis	  	  
Cells	  stimulated	  and	  cultured	  as	  described	  above	  were	  collected	  at	  the	  end	  of	  each	  
time	  point,	   fixed	   in	   ice-­‐cold	  70%	  ethanol	  and	  kept	  at	  4°C	  until	  analysis.	  Fixed	  cells	  
were	   washed	   and	   treated	   with	   RNase	   for	   20	  minutes.	   Subsequently,	   5	  µg/mL	   of	  
propidium	  iodide	  and	  0.1%	  Triton-­‐X	  were	  added	  for	  15	  mins	  and	  analysed	  by	  flow	  
cytometry.	  	  
2.13. Measurement	  of	  IL-­‐2	  	  
IL-­‐2	   levels	   in	   culture	   supernatants	   were	   determined	   by	   enzyme-­‐linked	  
immunosorbent	   assay	   (ELISA)	   using	   the	   Human	   Ready-­‐SET-­‐Go!	   ELISA	   kit	   from	  
eBioscience	  Ltd	  (cat	  #	  88-­‐7025-­‐22)	  following	  manufacturer’s	  instructions.	  	  	  
2.14. Gel	  Electrophoresis	  and	  Western	  Immunoblotting	  
Cells	   were	   lysed	   with	   RIPA	   buffer	   (150	   mM	   NaCl,	   1.0%	   IGEPAL®	   CA-­‐630,	   0.5%	  
sodium	   deoxycholate,	   0.1%	   SDS,	   and	   50	  mM	   Tris,	   pH	   8.0)	   with	   1	  mM	   PMSF	   and	  
protease	  inhibitor	  cocktail.	  10-­‐20	  μg	  of	  protein	  lysate	  were	  mixed	  with	  5	  μL	  loading	  
buffer	  (70%	  (v/v)	  NuPAGE	  sample	  loading	  buffer,	  30%	  (v/v)	  NuPAGE	  reducing	  agent)	  
and	  denatured	  by	  incubating	  at	  90°C	  for	  5mins.	  Samples	  and	  PrecisionPlus	  protein	  
Kaleidoscope	   standards	   were	   loaded	   onto	   NuPAGE	   Novex	   bis-­‐tris	   polyacrylamide	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gels	  and	  resolved	  by	  electrophoresis	  in	  a	  XCell	  Surelock	  mini-­‐cell	  (Invitrogen),	  using	  
a	   3-­‐(N-­‐morpholino)	   propanesulphonic	   acid	   (MOPS)	   running	  buffer	   (50	  mM	  MOPS,	  
50	   mM	   Tris	   base,	   3.5	   mM	   sodium	   dodecyl	   sulphate,	   1mM	   EDTA,	   0.25%	   (v/v)	  
NuPAGE	   antioxidant),	   at	   90	   Volts	   for	   10	  minutes,	   followed	   by	   60	  minutes	   at	   170	  
Volts.	   The	   resolved	   proteins	   were	   transferred	   to	   polyvinylidene	   difluoride	   (PVDF)	  
membranes	   (BioRad)	   at	   at	   200	  mA	   for	   90	  minutes.	   PVDF	  membranes	   were	   then	  
blocked	   with	   tris-­‐buffered	   saline	   (TBS;	   150	   mM	   NaCl,	   50	   mM	   Tris	   base,	   pH	   7.6)	  
containing	  0.1%	  (v/v)	  Tween-­‐20	  and	  10%	  (weight/volume;	  w/v)	  non-­‐fat	  dry	  milk	  at	  
room	   temperature	   for	   1hour.	   Washing	   steps	   between	   were	   done	   with	   TBS-­‐0.1%	  
Tween-­‐20.	  Membranes	  were	   probed	   overnight	   at	   4°C	  with	   the	   following	   primary	  
antibodies	   (at	   1:1000):	   anti-­‐pPTEN	   (phospho	   S380+	   T382+T383)	   antibody	   (Abcam,	  
cat	  #	  ab131107)	  and	  anti-­‐casein	  kinase	  IIα	  (1AD9)	  (Santa	  Cruz	  Biotechnology,	  cat	  #	  
sc-­‐12738),	   or	   anti-­‐LC3	   (MBL,	   cat#	   M152-­‐3),	   anti-­‐CREB	   (phospho	   Ser133)	   (CST,	  
#9198),	   anti-­‐ATP-­‐Citrate	   Lyase	   (phospho	   S455)	   (CST;	   #4331)	   and	   anti-­‐Acetyl	  
Coenzyme	   A	   Carboxylase	   (phospho	   S79)	   (Abcam;	   ab68191),	   diluted	   at	   optimal	  
concentrations	   in	   TBS-­‐0.1%	   Tween-­‐20	   containing	   2%	   (w/v)	   BSA,	   and	   followed	   by	  
appropriate	   horseradish	   peroxidase-­‐conjugated	   secondary	   antibodies	   (1:20000)	  
(CST,	   UK).	   Immunoblots	   were	   visualized	   using	   the	   ECL	   system	   (PerkinElmer	   Life	  
Sciences,	  UK).	  	  
Densitometry	   was	   performed	   using	   a	   GS-­‐710	   calibrated	   imaging	   densitometer	  
(BioRad)	  and	  quantification	  of	  immunoreactive	  bands	  using	  TotalLab	  100	  software,	  
normalised	  to	  total	  protein.	  	  
2.15. Real-­‐time	  RT-­‐PCR	  
Total	  RNA	  was	  extracted	  from	  cells	  and	  purified	  using	  RNeasy	  Mini	  Kit	  from	  QIAGEN	  
kit,	   according	   to	   the	   manufacturer’s	   instructions.	   cDNA	   was	   synthesized	   using	  
ImProm-­‐IITm	   Reverse	   Transcription	   System	   Promega	   kit	   according	   to	   the	  
manufacturer’s	   instructions.	   Primers	   were	   designed	   to	   amplify	   the	   entire	   coding	  
sequence	   of	   CTLA-­‐4:	   5’-­‐ATGGCTTGCCTTGGATTTCAGCGGCACAAGG-­‐3’	   and	   5’-­‐
TCAATTGATGGGAATAAAATAAGGCTGAAATTGC-­‐3’,	   and	   PD-­‐1:	   5’-­‐
CTCAGGGTGACAGAGAGAAG-­‐3’	   and	   5’-­‐GACACCAACCACCAGGGTTT-­‐3’.	   Real-­‐time	  
quantitative	   PCR	   (qRT-­‐PCR)	   analysis	   of	   PD1,	   CTLA-­‐4	   and	   GAPDH	   genes	   were	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performed	   on	   an	   ABI	   PRISM	   7000	   real-­‐time	   PCR	   instrument	   using	   Applied	  
Biosystems	   (UK)	   SYBR	   green	   PCR	   master	   mix.	   The	   GAPDH	   level	   was	   used	   as	   a	  
normalization	  control.	  	  
2.16. Static	  adhesion	  and	  transendothelial	  migration	  of	  TEMs	  	  
Isolated	   TEMs	   were	   stimulated	   with	   5	   µg/ml	   anti-­‐CD3,	   10µg/ml	   NIB1412	   and	   the	  
CD3+NIB1412	   as	   described	   above	   and	   harvested	   after	   48hours.	   Cells	   were	   then	  
centrifuged	  and	  after	   the	  supernatant	  was	  discarded,	  cells	  were	   treated	  with	  pre-­‐
warmed	  CellTracker™	  Green	   CMFDA	   (Molecular	   Probes)	  working	   solution	   (1	   µM).	  
Following	  an	   incubation	  period	  at	  37°C	  for	  30mins,	  cells	  were	  centrifuged	  and	  the	  
CellTracker™	  working	   solution	  was	  discarded.	   Labelled	   cells	  were	   re-­‐suspended	   in	  
complete	  media	  and	  added	  to	  the	  HDMEC	  layer	  as	  described	  below.	  
	  For	   the	   adhesion	   assay	   HDMECs	   were	   seeded	   on	   gelatin-­‐coated	   96-­‐well	   tissue	  
culture	   plates	   (Nunc)	   in	   endothelial	   cell	   media	   for	   48	   hours,	   while	   for	   the	  
transendothelial	  migration	  assay	  HDMECs	  were	  seeded	  on	  gelatin-­‐coated	  Transwell	  
inserts	  [6.5mm	  diameter,	  3.0μm	  polyester	  membrane;	  Corning	  Costar;	  Pittston,	  PA,	  
USA].	  Media	  was	  then	  changed	  to	  1%	  (v/v)	  FCS	  containing	  media	  for	  24	  hours.	  For	  
the	  adhesion	  assay	  the	  CMFDA-­‐labelled	  TEMs	  (0.2	  mL,	  5×105	  cells/mL)	  were	  added	  to	  
the	   confluent	   HDMECs	   and	   incubated	   for	   30	  minutes.	   After	   washing	   three	   times	  
with	  PBS	  (0.2	  mL),	  adherent	  cells	  in	  three	  randomly	  selected	  optical	  fields	  per	  well	  
were	  visualized	  and	  counted.	  For	  immunofluorescence	  imaging,	  samples	  were	  fixed	  
in	   4%	   formaldehyde	   for	   30	   min	   and	   following	   a	   washing	   step	   stained	   with	  
rhodamine	   phalloidin	   and	   DAPI	   (Molecular	   Probes)	   overnight	   at	   4°C	   and	  
subsequently	   washed	   three	   times	   with	   PBS.	   Images	   were	   acquired	   using	   a	   Axio	  
Observer	  Zeiss	  microscope	  with	  objective	  LD	  "Plan-­‐Neofluar"	  20x/0.4	  Corr	  Ph2	  M27,	  
and	  analysed	  with	  ZEN	  Pro	  2012	  software.	  	  	  
For	   the	   transendothelial	   cell	   migration	   assay,	   CMFDA-­‐labelled	   TEms	  
(1×105	  cells/insert)	   were	   added	   to	   the	   confluent	   HDMECs	   and	   incubated	   for	   12	  
hours.	   Cells	   in	   the	   lower	   compartment	   were	   collected	   and	   fluorescence	   was	  
quantified	   using	   a	   Varioskan™	   Flash	   Multimode	   Plate	   Reader	   (Thermo	   Scientific,	  
Waltham,	  MA).	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2.17. Bioenergetics	  of	  T	  cells	  
CD4+	  TEM	  were	   stimulated	  with	  plate-­‐bound	  anti-­‐CD3	  mAb	  or	  NIB1412	   for	  48	  h	   in	  
complete	  media,	  while	  mouse	  F5-­‐TCR	  CD8	  T	  cells	  were	  activated	  with	  NP68	  for	  72h.	  
Cells	   were	   then	   re-­‐suspended	   in	   serum-­‐free	   base	   media	   (Seahorse	   Bioscience;	  
102353-­‐100)	  with	   2	  mM	   L-­‐glutamine	   ±	   1mM	   sodium	   pyruvate	   ±	   25	  mM	   glucose.	  
Subsequently	  cells	  were	  seeded	   in	  pre-­‐coated	  Poly-­‐D	  Lysine	   (50	  μg/ml)	  XF	  96-­‐well	  
microplates	   (Seahorse	   Bioscience)	   at	   3×105	   cells	   per	   well,	   spun	   down,	   and	  
inoculated	   at	   37°C	   for	   30mins.	   Bioenergetics	   of	   CD4+	   TEM	   and	   F5-­‐TCR	  CD8+	   T	   cells	  
were	   determined	   using	   the	   XF	   Cell	   Mito	   Stress	   Test	   Kit	   (Seahorse	   Bioscience;	  
103015-­‐100)	  (figure	  2.3),	  XF	  Glycolysis	  Stress	  Test	  Kit	  (Seahorse	  Bioscience;	  102194-­‐
100)	   (figure	  2.4)	   and	  a	  XFe96	  Analyzer	   (Seahorse	  Bioscience).	   For	   the	  XF	  Cell	  Mito	  
Stress	   Test	   Kit	   the	   drug	   injections	   ports	   of	   the	   XF96	  Assay	   Cartridge	  were	   loaded	  
with	   1	   µM	   Oligomycin	   in	   port	   A,	   160	   μM	   2,4-­‐DNP	   in	   port	   B,	   and	   1	   µM	   of	   both	  
Antimycin	  A	  and	  Rotenone	  in	  port	  C.	  For	  the	  XF	  Glycolysis	  Stress	  Test	  Kit,	  the	  culture	  
media	  was	  replaced	  with	  glucose-­‐free	  media	  and	  all	  ports	  were	  loaded	  with	  10mM	  
of	  glucose	   in	  port	  A,	  1	  µM	  Oligomycin	   in	  port	  B	  and	  100mM	  of	  2-­‐deoxy-­‐D-­‐glucose	  
(2-­‐DG)	   in	   port	   C.	   Seahorse	   experiments	   were	   done	   using	   the	   following	   assay	  







Figure	  2.3:	  Changes	  in	  oxygen	  consumption	  rates	  (OCR)	  during	  the	  sequential	  delivery	  of	  drugs	  
Following	  the	  measurement	  of	  basal	  respiration,	  Oligomycin	  was	  injected	  to	  inhibit	  ATP-­‐synthase	  in	  
order	   to	   measure	   the	   oxygen	   consumed	   for	   ATP	   production	   during	   mitochondrial	   respiration-­‐
coupled	  oxidative	  phosphorylation	  of	  ADP.	  The	  addition	  of	   the	  uncoupling	  agent	  2,	  4-­‐DNP	  enabled	  
measurement	  of	   the	  maximal	   respiratory	   capacity	  of	   the	   cells.	   The	   final	   injection	  of	   rotenone	  and	  






Figure	  2.4:	  Changes	  in	  extracellular	  acidification	  rate	  (ECAR)	  during	  the	  sequential	  delivery	  of	  drugs	  
Glycolysis	  and	   the	  glycolytic	   reserve	  of	   cells	  were	  measured	  by	   the	  sequential	  addition	  of	  glucose,	  
Oligomycin	  and	  2-­‐D-­‐glucose	   (2-­‐DG).	  The	  ECAR	  after	  glucose	   injection	   is	   the	  basal	   rate	  of	  glycolysis,	  
while	  the	  addition	  of	  Oligomycin	  inhibits	  mitochondrial	  ATP	  production	  and	  shifts	  energy	  production	  
predominantly	  to	  the	  glycolytic	  pathway,	  revealing	  the	  maximum	  glycolytic	  capacity	  of	  the	  cells.	  The	  
difference	  between	  the	  glycolytic	  capacity	  and	  the	  glycolytic	  rate	  revealed	  the	  glycolytic	  reserve.	  
2.18. Acetyl-­‐CoA	  measurement	  
Concentration	   of	   acetyl-­‐CoA	   in	  whole-­‐cell	   lysates	   (lysed	   in	   RIPA	   buffer)	   from	  pre-­‐
activated	   CD4+	   TEM	   was	   measured	   by	   fluorescence	   assay	   using	   a	   commercial	   kit	  
according	   to	   the	  manufacturer’s	   instructions	   (Abcam;	  PicoProbe	  Acetyl	  CoA	  Assay	  
kit:	   ab87546).	   Fluorescence	   was	   quantified	   using	   a	   Varioskan™	   Flash	   Multimode	  
Plate	  Reader	  (Thermo	  Scientific,	  UK).	  
2.19. Citrate	  and	  alpha-­‐ketoglutarate	  measurement	  
Concentration	   of	   Citrate	   and	   α-­‐ketoglutarate	   in	   whole-­‐cell	   lysates	   (lysed	   in	   RIPA	  
buffer)	   from	  pre-­‐activated	   CD4+	   TEM	  was	  measured	   by	   fluorescence	   assay	   using	   a	  
commercial	  kit	  according	   to	   the	  manufacturer’s	   instructions	   (Abcam;	  Citrate	  assay	  
kit:	   ab83396,	   Alpha	   Ketoglutarate	   (alpha	   KG)	   Assay	   Kit:	   ab83431).	   Relative	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fluorescence	  units	  /	  intenstiy	  were	  quantified	  using	  a	  Varioskan™	  Flash	  Multimode	  
Plate	  Reader	  (Thermo	  Scientific,	  UK).	  
2.20. Statistical	  analysis	  	  
Unpaired	   t-­‐test	   was	   used	   to	   analyse	   proliferation,	   adhesion,	   transendothelial	  
migration,	   phospho-­‐PTEN	   and	   Ck2	   densitometric	   data	   and	   results	   presented	   as	  
mean	  ±	  SD/SEM.	  Two-­‐way	  ANOVA	  followed	  by	  Bonferroni	  test	  was	  used	  to	  analyse	  
IL-­‐2	  ELISA	  data	  using	  GraphPad	  Prism	  5	  (GraphPad	  Software	  Inc,	  San	  Diego,	  CA).	  p	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3. Failure	   to	   upregulate	   cell	   surface	   PD-­‐1	   is	  
associated	  with	  dysregulated	  stimulation	  of	  T	  cells	  
by	  TGN1412-­‐like	  CD28	  superagonist	  	  
	  
3.1. Abstract	  	  
The	   CD28	   superagonist	   (CD28SA),	   TGN1412	   was	   administered	   to	   humans	   as	   an	  
agent	   that	   can	   selectively	   activate	   and	   expand	   regulatory	   T	   cells	   but	   resulted	   in	  
uncontrolled	   T	   cell	   activation	   accompanied	   by	   cytokine	   storm.	   The	   molecular	  
mechanisms	   that	   underlie	   this	   uncontrolled	   T	   cell	   activation	   are	   unclear.	  
Physiological	   activation	   of	   T	   cells	   leads	   to	   upregulation	   of	   not	   only	   activation	  
molecules	  but	  also	  inhibitory	  receptors	  such	  as	  PD-­‐1.	  The	  uncontrolled	  activation	  of	  
CD28SA-­‐stimulated	   T	   cells	   was	   hypothesised	   to	   be	   caused	   by	   both	   the	   enhanced	  
expression	  of	  activation	  molecules	  and	  the	  lack	  of	  or	  reduced	  inhibitory	  signals.	   In	  
this	   study,	   anti-­‐CD3	   antibody-­‐stimulated	   human	   T	   cells	   were	   shown	   to	   undergo	  
time-­‐limited	   controlled	   DNA	   synthesis,	   proliferation	   and	   interleukin-­‐2	   secretion,	  
accompanied	  by	  PD-­‐1	  expression.	  In	  contrast,	  CD28SA	  activated	  T	  cells	  demonstrate	  
uncontrolled	   activation	   parameters	   including	   enhanced	   expression	   of	   LFA-­‐1	   and	  
CCR5	   but	   fail	   to	   express	   PD-­‐1.	  	  The	   functional	   relevance	   of	   the	   lack	   of	   PD-­‐1	  
mediated	   regulatory	  mechanism	   in	   CD28SA-­‐stimulated	   T	   cells	  was	   demonstrated.	  
The	   findings	   provide	   a	   molecular	   explanation	   for	   the	   dysregulated	   activation	   of	  
CD28SA-­‐stimulated	  T	  cells	  and	  also	  highlight	  the	  potential	  for	  the	  use	  of	  differential	  
expression	  of	  PD-­‐1	  as	  a	  biomarker	  of	  safety	  for	  T	  cell	  immunostimulatory	  biologics.	  
3.2. Introduction	  
Immunostimulatory	  antibodies	  are	   in	  clinical	  trials	  for	  a	  variety	  of	   indications,	   [86]	  
particularly	   in	  eliciting	  anti-­‐tumour	  responses	  but	  they	  come	  with	  a	  risk	  of	  serious	  
adverse	  effects	  such	  as	  systemic	  induction	  of	  pro-­‐inflammatory	  cytokines	  (cytokine	  
storm)	  and	  organ-­‐specific	  autoimmunity	  [96].	   In	  2006,	  a	  phase	  I	   first-­‐in-­‐man	  dose-­‐
escalation	   trial	   of	   TGN1412,	   a	   humanized	   CD28-­‐specific	   superagonistic	   mAb	  
originally	   intended	   for	   the	   treatment	  of	  B	   cell	   chronic	   lymphocytic	   leukaemia	  and	  
rheumatoid	   arthritis,	   caused	   severe	   immune-­‐mediated	   toxicity	   in	   a	   cohort	   of	  
healthy	   volunteers	   [92].	   The	   unforeseen	   biological	   action	   in	   humans	   included	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substantial	  proliferation	  and	  extravasation	  of	  T	  cells,	  and	  a	  life-­‐threatening	  cytokine	  
storm	  with	  highly	  elevated	  levels	  of	  various	  pro-­‐inflammatory	  cytokines	  [97].	  	  	  	  
Physiological	  T	  cell	  activation	  occurs	  when	  the	  T	  cell	  receptor	  (TCR)	  is	  engaged	  by	  an	  
antigen-­‐bearing	  MHC	  molecule	  on	  the	  surface	  of	  antigen	  presenting	  cells	  (APCs)	  and	  
this	  represents	  the	  first	  signal	  for	  T	  cell	  activation.	  Co-­‐stimulatory	  receptors	  such	  as	  
CD28	   can	   act	   as	   secondary	   signals	   to	   amplify	   this	   first	   signal.	   In	   general,	   CD28	  
ligation	   in	   the	   absence	   of	   TCR	   engagement	   has	   no	   functional	   effect	   on	   T	   cells;	  
however,	   CD28SA	   antibodies	   can	   activate	   T	   cells	   without	   concomitant	   TCR	  
engagement	  [16].	  
Activation	   of	   T	   cells	   through	   TCR	   triggering	   and	   CD28	   engagement	   leads	   to	  
downregulation	   of	   cell	   surface	   TCR,	   expression	   of	   molecules	   such	   as	   lymphocyte	  
function-­‐associated	   antigen-­‐1	   (LFA-­‐1)	   and	   C-­‐C	   chemokine	   receptor	   type	   5	   (CCR5),	  
synthesis	  of	  interleukin	  (IL)-­‐2	  and	  T	  cell	  proliferation.	  Importantly,	  the	  activation	  of	  
T	  cells	  is	  regulated	  by	  the	  expression	  and	  function	  of	  co-­‐inhibitory	  receptors	  such	  as	  
PD-­‐1,	   TIM-­‐3,	   LAG-­‐3	   and	   CTLA-­‐4	   [11].	   These	   co-­‐inhibitory	   receptors	   prevent	  
excessive	   T	   cell	   activation	   by	   attenuating	   the	   activation	   signals	   initiated	   by	   T	   cell	  
stimulatory	  receptors	  [98].	  The	  PD-­‐1	  co-­‐inhibitory	  receptor	  has	  been	  shown	  to	  be	  a	  
powerful	   negative	   regulator	   of	   activated	   T	   cells	   [26].	   In	   the	   absence	   of	   PD-­‐1-­‐
mediated	   signals,	   there	   is	   an	   increased	   propensity	   for	   T	   cells	   to	   expand	   with	  
stronger	   accompanying	   inflammatory	   cascades	   [99].	   It	   remains	   unknown	  whether	  
the	  excessive	  T	  cell	  activation	  observed	  with	  CD28SA-­‐stimulated	  T	  cells	  is	  a	  result	  of	  
dysregulated	   inhibitory	   inputs	   to	   these	   T	   cells.	   We	   hypothesized	   that	   a	   lack	   of	  
inhibitory	   inputs	   from	   the	   PD-­‐1	   pathway	   could	   contribute	   to	   the	   uncontrolled	  
proliferation	   and	   cytokine	   release	   of	   CD28SA-­‐activated	   T	   cells.	   In	   this	   study,	   we	  





3.3. Results	  	  
3.3.1. Dysregulated	  T	  cell	  function	  induced	  by	  CD28SA	  
stimulation	  	  
Ligation	  of	  the	  TCR/CD3	  complex	  activates	  T	  cells	  and	  co-­‐engagement	  of	  CD28	  with	  
TCR/CD3	  enhances	  this	  response,	  while	  in	  general,	  ligation	  of	  CD28	  in	  isolation	  with	  
conventional	  monoclonal	  antibodies	  does	  not	  stimulate	  T	  cells.	  To	  assess	  the	  effects	  
of	   CD28SA-­‐mediated	   T	   cell	   stimulation,	   we	   activated	   human	   T	   cells	   with	   either	  
NIB1412	  (CD28SA),	  or	  anti-­‐CD3.	  	  
	  
Previous	  studies	  have	  identified	  CD4+	  effector	  memory	  T	  cells	  (TEMs)	  as	  the	  primary	  
responders	  to	  CD28SA	  stimulation,	  [100]	  [101]	  and	  therefore	  we	  mainly	  focussed	  on	  
TEMs	  for	   phenotypic	   and	   functional	   assessments.	   Phosphorylation	  of	   the	   TCR/CD3	  
complex	  upon	   T	   cell	   activation	   results	   in	   a	   rapid	   downregulation	   of	   the	   complex,	  
[102]	   to	   allow	   for	   the	  desensitization	  of	   the	   stimulated	   cell.	  We	  have	   shown	   that	  
NIB1412-­‐activated	   TEMs	   maintain	   elevated	   TCR	   expression	   levels	   of	   up	   to	   80%,	  
similar	  to	  that	  of	  unstimulated	  cells,	  while	  anti-­‐CD3	  stimulated	  TEMs	  rapidly	  reduce	  
TCR	   expression	   upon	   activation	   and	   maintain	   negligible	   surface	   expression	  






Figure	  3.1:	  Elevated	  TCR	  expression	  in	  NIB1412-­‐activared	  TEMS	  
Human	  CD4+	   TEM	  were	   stimulated	   for	   1	   to	   4	  days	  with	  plate-­‐bound	  anti-­‐CD3	  mAb	   (CD3,	   5	  μg/ml);	  
NIB1412	   (NIB1412,	   10	   μg/ml);	   anti-­‐CD3	   mAb	   and	   NIB1412	   (CD3	   &	   NIB1412);	   control	   category	  
included	   cells	  without	   any	   treatment	   (Control).	   Cells	  were	   harvested	   at	   indicated	   time	   points	   and	  
stained	  with	  fluorochrome-­‐conjugated	  anti-­‐CD4	  and	  anti-­‐TCR	  antibodies	  followed	  by	  flow	  cytometric	  
analysis.	  Populations	  of	  CD4+TCR+	  cells	  are	  shown	  in	  the	  upper	  right	  quadrant	  as	  percentages	  of	  total	  
T	  cells.	  Results	  are	  representative	  of	  four	  independent	  experiments.	  
	  
Our	   results	   also	   show	   that	   NIB1412-­‐stimulated	   TEM	   cells	   showed	   greater	  
proliferation	   at	   antibody	   concentrations	   of	   2.5.	   5	   and	   10	   μg/ml	   and	   displayed	   a	  
higher	   maximum	   proliferative	   capacity	   compared	   to	   anti-­‐CD3-­‐stimulated	   T	   cells	  
(figure	   3.2),	   and	   also	   express	   lower	   levels	   of	   the	   prototypical	   death	   receptor	   Fas	  





Figure	  3.2:	  Higher	  proliferative	  capacity	  of	  NIB1412-­‐stimulated	  TEMS	  
Human	  CD4+	  TEM	  cells	  were	  stimulated	  with	  the	  indicated	  concentrations	  of	  plate-­‐bound	  antibodies	  
and	  proliferation	  was	  measured	  three	  days	  post-­‐activation	  by	  3H-­‐labeled	  thymidine	  incorporation.	  
The	  vertical	  axis	  represents	  mean	  cpm	  ±	  SD	  from	  triplicate	  wells.	  The	  data	  are	  representative	  of	  four	  
independent	  experiments,	  (*p	  <	  0.05,	  ***p	  <	  0.001;	  unpaired	  t-­‐test).	  
	  
	  
Figure	  3.3:	  Reduced	  CD95	  receptor	  expression	  on	  NIB1412-­‐stimulated	  TEMS	  
Cell	   surface	  staining	  of	  human	  CD4+	  TEM	  stimulated	   for	  4days	  with	  5μg/ml	  of	  plate-­‐bound	  anti-­‐CD3	  
mAb	  and/or	  10μg/ml	  of	  NIB1412.	  The	  percentages	  of	  the	  CD4+	  CD95+	  cells	  are	  shown	  in	  the	  upper	  
right	  quadrant.	  Results	  are	  representative	  of	  three	  independent	  experiments	  
	  
To	   better	   understand	   the	   proliferative	   activity	   of	   stimulated	   TEMs,	  we	   determined	  




Figure	  3.4:	  	  A	  higher	  percentage	  of	  NIB1412-­‐stimulated	  TEMS	  remain	  in	  S-­‐phase	  	  
Human	   CD4+	   TEM	   were	   stimulated	   for	   1	   to	   6	   days,	   fixed	   with	   ice	   cold	   70%	   ethanol,	   stained	   with	  
propidium	  iodide	  and	  cells	  in	  S-­‐phase	  were	  quantified	  by	  flow	  cytometry.	  Results	  are	  representative	  
of	  at	  least	  four	  independent	  experiments.	  
	  
A	   higher	   percentage	   of	   NIB1412-­‐stimulated	   TEMs	   were	   in	   S-­‐phase	   throughout	   the	  
measured	   six	   days.	   The	   proportion	   of	   anti-­‐CD3-­‐stimulated	   TEMs	   in	   S-­‐phase	   was	  
highest	  on	  day	  4	  with	  percentages	  of	  up	   to	  12%,	  which	   then	   reduced	   in	  numbers	  
while	   the	   proportion	   of	   NIB1412-­‐stimulated	   TEMs	   in	   S-­‐phase	   remained	   high	   at	  
around	  30%.	  Following	  day	  4,	  the	  percentage	  of	  cells	  in	  S-­‐phase	  remained	  stable	  in	  
NIB1412-­‐stimulated	  TEMs	  (Figure	  3.4).	  When	  NIB1412	  was	  combined	  with	  anti-­‐CD3,	  
the	   percentage	   of	   cells	   in	   S-­‐phase	   peaked	   earlier	   (at	   day	   2)	   and	  was	   significantly	  
higher	   than	   the	   cells	   stimulated	  with	   either	   of	   the	   antibodies	   on	   their	   own.	   This	  
result	   shows	   that	   NIB1412-­‐stimulated	   TEMs	   remain	   in	   S-­‐phase	   for	   a	   much	   longer	  
period	  of	  time	  than	  anti-­‐CD3-­‐stimulated	  T	  cells.	  	  
	  
IL-­‐2	   is	   a	  prerequisite	   growth	   factor	   for	   the	   long	   term	  proliferation	  and	   survival	   of	  
activated	  T	  cells	   [103].	   In	  vitro	   studies	  of	  TGN1412	  have	  shown	  high	   levels	  of	   IL-­‐2	  
cytokine	   release	   [104].	   In	   the	   current	   study,	   NIB1412-­‐stimulated	   TEMs	   displayed	  
prolonged	   and	   higher	   IL-­‐2	   secretion	   of	   up	   to	   25,000pg/ml,	   compared	   to	   ~	   5,000	  
pg/ml	   of	   IL-­‐2	   secretion	   for	   anti-­‐CD3-­‐stimuated	   TEMs.	   The	   anti-­‐CD3	   and	   NIB1412	  





Figure	  3.5:	  NIB1412-­‐stimulated	  TEMS	  secrete	  more	  IL-­‐2	  
IL-­‐2	  concentrations	  in	  the	  supernatants	  from	  human	  CD4+	  TEM	  stimulated	  for	  24,	  48	  and	  72hrs	  were	  
determined	   by	   two-­‐site	   enzyme-­‐linked	   immunosorbent	   assay	   (ELISA).	   The	   IL-­‐2	   titres	   from	   four	  
independent	  experiments	  (mean	  ±	  SD	  of	  replicate	  samples)	  are	  expressed	  as	  picograms	  per	  mL	  on	  a	  
log10	  scale.	  	  (*p	  <	  0.05,	  **p	  <	  0.01,	  ***p	  <	  0.001;	  two-­‐way	  ANOVA)	  
	  
Our	  results	  show	  elevated	  IL-­‐2	  release	  by	  TEMs	  when	  stimulated	  with	  NIB1412,	  which	  
may	   contribute	   to	   the	   prolonged	   S-­‐phase	   observed	   in	   the	   NIB1412-­‐stimulated	  
conditions.	  
3.3.2. Dysregulated	  expression	  of	  co-­‐stimulatory	  receptors	  on	  
CD28SA-­‐activated	  CD4+	  effector	  memory	  T	  cells	  	  
Studies	   have	   shown	   that	   CD28	   superagonists	   induce	   a	   sustained	   activation	   of	  
downstream	  signalling	  events	   [16].	   Flow	  cytometric	  analysis	  of	   the	  CD28	   receptor	  
revealed	  that	  anti-­‐CD3	  mAb	  stimulated	  TEMs	  have	  no	  CD28	  expression	  at	  24hrs	  after	  
TCR	   activation	   but	   re-­‐express	   the	   receptor	   back	   to	   levels	   similar	   of	   unstimulated	  
control	  cells	  from	  day	  2	  onwards.	  In	  contrast,	  NIB1412-­‐activated	  TEMs	  do	  not	  reduce	  
CD28	  expression	  at	  24hrs	  post-­‐activation.	   Instead	   the	  CD28	   receptor	   fluctuates	   in	  






Figure	  3.6:	  CD28	  receptor	  expression	  levels	  fluctuate	  in	  NIB1412-­‐stimulated	  TEMS	  
Human	  CD4+	   TEM	  were	   stimulated	   for	   1	   to	   4	   days	  with	   plate-­‐bound	   anti-­‐CD3	  mAb	   (CD3,	   5	   μg/ml);	  
NIB1412	   (NIB1412,	   10	   μg/ml);	   anti-­‐CD3	   mAb	   and	   NIB1412	   (CD3	   &	   NIB1412);	   control	   category	  
included	   cells	  without	   any	   treatment	   (Control).	   Cells	  were	   harvested	   at	   indicated	   time	   points	   and	  
stained	   with	   fluorochrome-­‐conjugated	   anti-­‐CD4	   and	   anti-­‐CD28	   antibodies	   followed	   by	   flow	  
cytometric	   analysis.	   Populations	   of	   CD4+CD28+	   cells	   are	   shown	   in	   the	   upper	   right	   quadrant	   as	  
percentages	  of	  total	  T	  cells.	  Results	  are	  representative	  of	  four	  independent	  experiments.	  
	  
We	   also	   examined	   the	   expression	  of	   other	   co-­‐stimulatory	   receptors:	   CD137,	  GITR	  
and	  CD27	  (figure	  3.7).	  Both	  CD137	  and	  GITR	  were	  found	  to	  be	  expressed	  at	  a	  much	  
higher	  percentage	  on	  NIB1412-­‐activated	  TEMs	  compared	  to	  TEMs	  that	  were	  activated	  
with	  anti-­‐CD3	  mAb.	   Interestingly,	   the	  CD27	  receptor	  was	  only	   induced	   in	  anti-­‐CD3	  
mAbs-­‐stimulated	   TEMs	   and	   was	   absent	   in	   both	   unstimulated	   and	   on	   NIB1412-­‐






Figure	  3.7:	  NIB1412-­‐stimulated	  TEMS	  express	  high	  levels	  of	  GITR	  and	  CD137	  but	  not	  CD27	  
Human	  CD4+	  TEM	  were	  stimulated	  for	  3	  days	  with	  plate-­‐bound	  anti-­‐CD3	  mAb	  (CD3,	  5	  μg/ml);	  NIB1412	  
(NIB1412,	   10	   μg/ml);	   control	   category	   included	   cells	   without	   any	   treatment	   (Control).	   Cells	   were	  
harvested	   and	   stained	  with	   fluorochrome-­‐conjugated	   anti-­‐CD4	   and	   anti-­‐GITR,	   anti-­‐CD137,	   or	   anti-­‐
CD27	  antibodies	  followed	  by	  flow	  cytometric	  analysis.	  Populations	  of	  double	  positive	  cells	  are	  shown	  
in	   the	   upper	   right	   quadrant	   as	   percentages	   of	   total	   T	   cells.	   Results	   are	   representative	   of	   four	  
independent	  experiments.	  
3.3.3. CD28SA-­‐activated	  CD4+	  effector	  memory	  T	  cells	  express	  
markers	  associated	  with	  antigen	  presentation	  	  
In	   addition	   to	   the	   co-­‐stimulatory	   receptors	   CD137	   and	   GITR,	   we	   also	   found	   that	  
HLA-­‐DR	   and	   CD80	   were	   expressed	   at	   a	   much	   higher	   percentage	   on	   NIB1412-­‐
activated	   TEMs	   compared	   to	   anti-­‐CD3	  mAb-­‐activated	   TEMs	   (figure	   3.8).	   HLA-­‐DR	   and	  





Figure	  3.8:	  NIB1412-­‐stimulated	  TEMS	  express	  high	  levels	  of	  HLA-­‐DR	  and	  CD80	  
Human	  CD4+	  TEM	  were	  stimulated	  for	  3	  days	  with	  plate-­‐bound	  anti-­‐CD3	  mAb	  (CD3,	  5	  μg/ml);	  NIB1412	  
(NIB1412,	   10	   μg/ml);	   control	   category	   included	   cells	   without	   any	   treatment	   (Control).	   Cells	   were	  
harvested	   and	   stained	   with	   fluorochrome-­‐conjugated	   anti-­‐CD4	   and	   anti-­‐HLA-­‐DR,	   or	   anti-­‐CD80	  
antibodies	  followed	  by	  flow	  cytometric	  analysis.	  Populations	  of	  double	  positive	  cells	  are	  shown	  in	  the	  
upper	  right	  quadrant	  as	  percentages	  of	  total	  T	  cells.	  Results	  are	  representative	  of	  four	  independent	  
experiments.	  
	  
3.3.4. Enhanced	  expression	  of	  LFA-­‐1	  and	  CCR5	  on	  CD28SA-­‐
activated	  CD4+	  effector	  memory	  T	  cells	  	  
Following	  the	  TGN1412	  clinical	  study,	   it	  was	  found	  that	  the	   lymphocytes	  migrated	  
from	  the	  blood	  stream	  into	  organs	  causing	  significant	  tissue	  damage	  [92,	  106].	  The	  
capability	   of	   superagonists	   to	   upregulate	   chemokine	   and	   adhesion	   receptors	   has	  
not	   been	   investigated.	   In	   this	   study,	   flow	   cytometric	   analysis	   of	   the	   cell	   surface	  
expression	  of	  LFA-­‐1	  and	  CCR5	  revealed	  that	  a	  much	  higher	  percentage	  of	  NIB1412-­‐
activated	   TEMs	   express	   LFA-­‐1	   (up	   to	   3-­‐fold	   higher)	   and	   CCR5	   (up	   to	   8-­‐fold	   higher)	  





Figure	  3.9:	  NIB1412-­‐stimulated	  TEMS	  express	  high	  levels	  of	  LFA-­‐1	  
Human	  CD4+	   TEM	  were	   stimulated	   for	   1	   to	   4	   days	  with	   plate-­‐bound	   anti-­‐CD3	  mAb	   (CD3,	   5	   μg/ml);	  
NIB1412	   (NIB1412,	   10	   μg/ml);	   anti-­‐CD3	   mAb	   and	   NIB1412	   (CD3	   &	   NIB1412);	   control	   category	  
included	   cells	  without	   any	   treatment	   (Control).	   Cells	  were	   harvested	   at	   indicated	   time	   points	   and	  
stained	   with	   fluorochrome-­‐conjugated	   anti-­‐CD4	   and	   anti-­‐LFA-­‐1	   antibodies	   followed	   by	   flow	  
cytometric	   analysis.	   Populations	   of	   CD4+LFA-­‐1+	   cells	   are	   shown	   in	   the	   upper	   right	   quadrant	   as	  






Figure	  3.10:	  NIB1412-­‐stimulated	  TEMS	  express	  high	  levels	  of	  CCR5	  
Human	  CD4+	   TEM	  were	   stimulated	   for	   1	   to	   4	   days	  with	   plate-­‐bound	   anti-­‐CD3	  mAb	   (CD3,	   5	   μg/ml);	  
NIB1412	   (NIB1412,	   10	   μg/ml);	   anti-­‐CD3	   mAb	   and	   NIB1412	   (CD3	   &	   NIB1412);	   control	   category	  
included	   cells	  without	   any	   treatment	   (Control).	   Cells	  were	   harvested	   at	   indicated	   time	   points	   and	  
stained	   with	   fluorochrome-­‐conjugated	   anti-­‐CD4	   and	   anti-­‐CCR5	   antibodies	   followed	   by	   flow	  
cytometric	   analysis.	   Populations	   of	   CD4+CCR5+	   cells	   are	   shown	   in	   the	   upper	   right	   quadrant	   as	  
percentages	  of	  total	  T	  cells.	  Results	  are	  representative	  of	  four	  independent	  experiments.	  
	  
Combined	   anti-­‐CD3	   and	   NIB1412-­‐stimulated	   TEMs	   displayed	   an	   LFA-­‐1	   expression	  
level	  intermediate	  to	  that	  of	  either	  agonist	  alone,	  while	  CCR5	  expression	  was	  similar	  
to	   that	   of	   NIB1412-­‐stimulated	   TEMs.	   In	   addition	   to	   elevated	   CCR5	   expression,	  
NIB1412-­‐stimulated	   TEMs	   also	   expressed	   CXCR4	   at	   low	   albeit	   detectable	   levels	  





Figure	  3.11:	  NIB1412-­‐stimulated	  TEMS	  express	  CXCR4	  
Human	  CD4+	  TEM	  were	  stimulated	  for	  3	  days	  with	  plate-­‐bound	  anti-­‐CD3	  mAb	  (CD3,	  5	  μg/ml);	  NIB1412	  
(NIB1412,	   10	   μg/ml);	   control	   category	   included	   cells	   without	   any	   treatment	   (Control).	   Cells	   were	  
harvested	  and	  stained	  with	   fluorochrome-­‐conjugated	  anti-­‐CD4	  and	  anti-­‐CXCR4	  antibodies	   followed	  
by	  flow	  cytometric	  analysis.	  Populations	  of	  CD4+CXCR4+	  cells	  are	  shown	  in	  the	  upper	  right	  quadrant	  
as	  percentages	  of	  total	  T	  cells.	  Results	  are	  representative	  of	  four	  independent	  experiments.	  
	  
3.3.5. Enhanced	  adhesion	  and	  migration	  of	  CD28SA-­‐activated	  
CD4+	  effector	  memory	  T	  cells	  
The	  ability	  of	  T	  cells	  to	  adhere	  and	  migrate	  along	  endothelial	  surfaces	  is	  dependent	  
on	  the	  binding	  of	  LFA-­‐1	  on	  T	  cells	  to	  the	  intercellular	  adhesion	  molecule-­‐1	  (ICAM-­‐1)	  
expressed	   on	   endothelial	   cells	   [107].	   Since	   our	   data	   showed	   elevated	   LFA-­‐1	  
expression	   on	   NIB1412-­‐stimulated	   TEMs,	   we	   investigated	   their	   attachment	   and	  
migratory	   capabilities.	   We	   show	   that	   NIB1412-­‐stimulated	   TEMs	   adhere	   to	   (Figure	  
3.12	  and	  3.13)	  and	  migrate	  (Figure	  3.14)	  across	  endothelial	  cell	  layers	  in	  significantly	  





Figure	  3.12:	  Enhanced	  adhesion	  of	  NIB1412-­‐stimulated	  TEMS	  
Immunofluorescent	  microscopy	   of	   HDMEC	  monolayer	   with	   adherent	   CMFDA-­‐labelled	   TEMs	   initially	  
stimulated	  with	  the	  indicated	  antibodies	  and	  stained	  for	  F-­‐actin	  and	  DNA	  using	  fluorescently	  labeled	  
phalloidin	  (red)	  and	  DAPI	  (blue),	  respectively.	  (Scale	  bar	  =	  20	  microns).	  Phase	  optics	  was	  adjusted	  to	  






Figure	  3.13:	  Enhanced	  adhesion	  of	  NIB1412-­‐stimulated	  TEMS	  
CMFDA-­‐labelled	   TEMs	   initially	   stimulated	   with	   the	   indicated	   antibodies	   were	   added	   to	   confluent	  
HDMECs	   and	   incubated	   for	   30	   minutes.	  Cells	   were	   washed	   and	   the	   remaining	   adherent	   cells	  
visualized	  under	  fluorescence	  microscopy.	  Vertical	  axis	  represents	  the	  number	  of	  adherent	  TEMs	  per	  
field	  (**p<0.01;	  ***p<0.001,	  unpaired	  t-­‐test).	  Results	  from	  four	  independent	  donors	  are	  represented	  








Figure	  3.14:	  Enhanced	  transendothelial	  migration	  of	  NIB1412-­‐stimulated	  TEMS	  
Transmigration	  of	  stimulated	  CD4+	  TEMs	  across	  HDMEC	  layer	  on	  transwell	  inserts.	  Transmigrated	  cells	  
were	   quantified	   by	   fluorescence	   and	   the	   results	   are	   presented	   as	   the	   mean	   (±	   SD)	   number	   of	  
transmigrated	   cells	   from	   3	   replicate	   wells	   per	   condition.	   Results	   are	   representative	   of	   three	  
independent	  experiments	  (***p<0.001unpaired	  t-­‐test).	  
3.3.6. Failure	  to	  upregulate	  cell	  surface	  PD-­‐1	  and	  CTLA-­‐4	  by	  
CD28SA-­‐activated	  CD4+	  effector	  memory	  T	  cells	  	  
Activation	  of	  T	  cells	  via	  the	  TCR/CD3	  complex	  leads	  to	  upregulation	  of	  surface	  PD-­‐1.	  
Up	  to	  18%	  of	  NIB1412-­‐stimulated	  TEMs	  expressed	  PD-­‐1,	  which	  declined	  to	  ~	  3	  to	  6%	  
from	  48	  hrs	  onwards	  (Figure	  3.15).	  	  
Anti-­‐CD3	  stimulated	  TEMs	  expressed	  high	  PD-­‐1,	  which	  peaked	  around	  day	  3	  to	  about	  
60%	  and	  remained	  relatively	  constant	  up	  to	  4	  days	  post-­‐activation.	  The	  proportion	  
of	  PD-­‐1+	  TEMs	  on	  day	  2	  post-­‐activation	  was	  up	  to	  17-­‐fold	  higher	  in	  the	  anti-­‐CD3	  mAb	  
condition	  compared	   to	   the	  NIB1412	  condition	   (Figure	  3.15).	   From	  day	  2	  onwards,	  
the	  proportion	  of	  anti-­‐CD3-­‐activated	  CD4+	  TEMs	  expressing	  PD-­‐1	  was	  11-­‐	  to	  12-­‐fold	  
higher	  compared	  to	  when	  they	  were	  stimulated	  with	  NIB1412.	  The	  combination	  of	  
NIB1412	  and	  anti-­‐CD3	  generally	  resulted	  in	  PD-­‐1	  expression	  intermediate	  to	  that	  of	  




Figure	  3.15:	  Failure	  of	  NIB1412-­‐stimulated	  TEMS	  to	  upregulate	  cell	  surface	  PD-­‐1	  
Human	  CD4+	   TEM	  were	   stimulated	   for	   1	   to	   4	   days	  with	   plate-­‐bound	   anti-­‐CD3	  mAb	   (CD3,	   5	   μg/ml);	  
NIB1412	   (NIB1412,	   10	   μg/ml);	   anti-­‐CD3	   mAb	   and	   NIB1412	   (CD3	   &	   NIB1412);	   control	   category	  
included	   cells	  without	   any	   treatment	   (Control).	   Cells	  were	   harvested	   at	   indicated	   time	   points	   and	  
stained	   with	   fluorochrome-­‐conjugated	   anti-­‐CD4	   and	   anti-­‐PD-­‐1	   antibodies	   followed	   by	   flow	  
cytometric	   analysis.	   Populations	   of	   CD4+PD-­‐1+	   cells	   are	   shown	   in	   the	   upper	   right	   quadrant	   as	  
percentages	  of	  total	  T	  cells.	  Results	  are	  representative	  of	  four	  independent	  experiments.	  
	  
Although	   surface	   staining	   of	   NIB1412-­‐activated	   CD4+	   T	   cells	   showed	   a	   negligible	  
surface	  PD-­‐1	  expression,	   intracellular	  staining	  of	   these	  cells	   revealed	  the	  presence	  





Figure	  3.16:	  NIB1412-­‐stimulated	  TEMS	  express	  intracellular	  PD-­‐1	  
Human	  CD4+	  TEM	  were	  stimulated	  for	  3	  days	  with	  plate-­‐bound	  anti-­‐CD3	  mAb	  (CD3,	  5	  μg/ml);	  NIB1412	  
(NIB1412,	  10	  μg/ml);	  anti-­‐CD3	  mAb	  and	  NIB1412	   (CD3	  &	  NIB1412);	   control	  category	   included	  cells	  
without	   any	   treatment	   (Control).	   Cells	  were	  harvested	   and	   stained	   for	   intracellular	   PD-­‐1	   following	  
fixation/permeabilization	   treatment.	   Population	   of	   CD4+	   PD-­‐1+	   cells	   are	   shown	   in	   the	   upper	   right	  
quadrant	  as	  percentages	  of	  total	  T	  cells.	  Results	  are	  representative	  of	  four	  independent	  experiments.	  
	  
However,	  the	  PD-­‐1	  mRNA	  levels	  in	  NIB1412-­‐activated	  CD4+	  T	  cells	  were	  significantly	  
lower	   than	   anti-­‐CD3	  mAbs-­‐activated	   cells	   (figure	   3.17i).	  Moreover,	   CTLA-­‐4	  mRNA	  
levels	  were	  also	   significantly	   lower	   in	  NIB1412-­‐activated	  CD4+	  T	   cells	   than	   in	  anti-­‐
CD3	  mAbs-­‐activated	  cells	  (figure	  3.17ii).	  	  
	  
	  
Figure	  3.17:	  NIB1412-­‐stimulated	  TEMS	  have	  significantly	  lower	  PD-­‐1	  and	  CTLA-­‐4	  mRNA	  levels	  
Human	  CD4+	  T	  cells	  were	  stimulated	  with	  plate-­‐bound	  anti-­‐CD3	  or	  NIB1412	  for	  1-­‐3	  Days.	  The	  mRNA	  
levels	   of	   (i)	   PD-­‐1	   and	   (ii)	   CTLA-­‐4	   were	   determined	   by	   real-­‐time	   RT-­‐PCR.	   The	   mRNA	   levels	   were	  
normalized	  to	   the	   loading	  control,	  GAPDH,	  and	  expressed	  as	  a	   fold	   increase	  of	   the	  PD-­‐1	  or	  CTLA-­‐4	  
mRNA	  levels	   in	  unstimulated	  cells.	  Data	  represented	  as	  mean	  +	  S.D	  of	  triplicates.	  n=2	   independent	  
experiments.	  (*P	  <	  0.05,	  **P	  <	  0.01;	  t-­‐test)	  
68	  
	  
Our	   results	   show	   that	   NIB1412	   stimulation	   of	   TEMs	   results	   in	   a	   dysregulated	  
phenotype	   in	   terms	   of	   minimal	   PD-­‐1	   and	   CTLA-­‐4	   expression,	   which	   prevents	   the	  
input	  of	  normal	  negative	  regulatory	  signals	  to	  control	  T	  cell	  activation.	  
3.3.7. Absence	  of	  PD-­‐1	  mediated	  regulation	  of	  T	  cell	  function	  in	  
CD28SA-­‐	  stimulated	  T	  cells.	  	  
	  To	   determine	   whether	   the	   absence	   of	   PD-­‐1	   expression	   has	   a	   functional	  
consequence	   on	  NIB1412-­‐activated	   CD4+	   T	   cells,	   recombinant	   PD-­‐L1	   (rPD-­‐L1)	  was	  
used	   to	   engage	   the	   PD-­‐1	   expressed	   on	   activated	   T	   cells.	   The	   proportion	   of	   cells	  
expressing	  IFNγ	  was	  decreased	  to	  half	   in	  CD4+	  T	  cells	  that	  were	  initially	  stimulated	  
with	   anti-­‐CD3	   and	   then	   re-­‐stimulated	  with	   anti-­‐CD3+rPD-­‐L1	   (Figure	   3.18).	   CD4+	   T	  
cells	   that	   were	   initially	   stimulated	   with	   the	   CD3	   and	   NIB1412	   combination	   were	  
unaffected	   in	   their	   IFNγ	   secretion	   upon	   re-­‐stimulation	   with	   anti-­‐CD3	   and	   rPD-­‐L1	  
(Figure	   3.18).	   These	   results	   suggest	   that	   the	   presence	   of	   surface	   PD-­‐1	   enables	   a	  
negative	  feedback	  response	  when	  bound	  to	  its	  ligand,	  which	  is	  absent	  in	  NIB1412-­‐






Figure	  3.18:	  Absence	  of	  PD-­‐1	  mediated	  regulation	  in	  NIB1412-­‐	  stimulated	  T	  cells	  
Human	   PBMCs	  were	   stimulated	   for	   48h	  with	   plate-­‐bound	   anti-­‐CD3	  mAb	   (CD3,	   5	   μg/ml);	   NIB1412	  
(NIB1412,	  10	  μg/ml);	  anti-­‐CD3	  mAb	  and	  NIB1412	   (CD3	  &	  NIB1412);	   control	  category	   included	  cells	  
without	  any	  treatment	  (Control).	  Cells	  were	  then	  re-­‐stimulated	  with	  anti-­‐CD3	  only	  (CD3,	  1	  μg/ml)	  or	  
with	   anti-­‐CD3	   and	   10	   μg/ml	   of	   rPD-­‐L1	   (CD3	   &	   rPD-­‐L1).	   	   Cells	   were	   harvested	   and	   stained	   with	  
fluorochrome-­‐conjugated	   anti-­‐CD4	   antibody,	   fixed,	   permeabilized,	   stained	   with	   fluorochrome-­‐
conjugated	  anti-­‐IFNγ	  antibody	  and	  analyzed	  by	  flow	  cytometry.	  The	  CD4+	  population	  is	  shown	  in	  light	  
grey	  and	  the	  CD4-­‐	  population	  in	  dark	  grey.	  The	  percentages	  of	  the	  CD4+	  IFNγ+	  cells	  are	  shown	  in	  the	  





3.3.8. PD-­‐1	  engagement	  reduces	  phospho	  PTEN	  levels	  in	  TEMs	  
stimulated	  by	  anti-­‐CD3	  but	  not	  CD28SA	  
The	   engagement	   of	   CD28	   on	   T	   cells	   leads	   to	   the	   activation	   of	   the	  
phosphatidylinositol	   3-­‐kinase	   (PI3K)/	   protein	   kinase	   B	   (Akt)	   pathway	   which	   is	  
important	   for	   cell	   survival	   and	   growth	   [108].	   Phosphatase	   and	   tensin	   homolog	  
(PTEN),	   a	   lipid	   phosphatase,	   negatively	   regulates	   the	   PI3K/Akt	   pathway	   [109].	   A	  
recent	   study	   has	   shown	   that	   the	   engagement	   of	   the	   PD-­‐1	   pathway	   suppresses	  
casein	  kinase	  2	  (CK2)	  and	  results	  in	  the	  inhibition	  of	  the	  stabilizing-­‐phosphorylation	  
of	   the	   Ser380-­‐Thr382-­‐Thr383	   residue	   cluster	   of	   PTEN.	   This	   increases	   PTEN	  
phosphatase	  activity	  which	  subsequently	   inhibits	   the	  phosphatidylinositol	  3-­‐kinase	  
(PI3K)/Akt	  pathway	  (figure	  1.7)	  [29].	  	  
Our	  results	  show	  that	  TEMs	  stimulated	  with	  NIB1412	  have	  significantly	  higher	  pPTEN	  
levels	  compared	  to	  when	  stimulated	  with	  anti-­‐CD3	  mAb.	  TEMS	  stimulated	  with	  anti-­‐
CD3	  in	  the	  presence	  of	  rPD-­‐L1	  result	  in	  significantly	  diminished	  pPTEN	  compared	  to	  
the	  anti-­‐CD3	  alone	  condition	  (Figure	  3.19).	  The	  rPD-­‐L1+NIB1412	  condition	  showed	  
similarly	  high	  pPTEN	  levels	  compared	  to	  the	  NIB1412	  alone	  condition	  (Figure	  3.19).	  
Consistent	  with	   the	   previous	   result,	   CK2	   expression	  was	   found	   to	   be	   significantly	  
higher	   in	   TEMs	   activated	   with	   NIB1412	   than	   when	   stimulated	   with	   anti-­‐CD3	   mAb	  
(Figure	   3.20).	   The	   CK2	   levels,	   although	   not	   significant,	   were	   reduced	   in	   TEM	  
stimulated	  with	  anti-­‐CD3	  in	  the	  presence	  of	  rPD-­‐L1,	  but	  no	  reduction	  was	  observed	  
in	  the	  rPD-­‐L1+NIB1412	  condition.	  These	  results	  point	  to	  the	  lack	  of	  engagement	  of	  
the	   PD-­‐1	   mediated	   regulation	   of	   the	   PI3K-­‐PTEN-­‐CK2	   signalling	   axis	   in	   CD28SA	  






Figure	  3.19:	  Effects	  of	  PD-­‐1	  engagement	  on	  phospho	  PTEN	  	  
Human	  CD4+	  TEMs	  were	  stimulated	  with	  anti-­‐CD3	  mAb	  (CD3,	  5	  μg/ml);	  NIB1412	  (NIB1412,	  10	  μg/ml);	  
rPD-­‐L1	  (rPD-­‐L1,	  10μg/ml);	  with	  anti-­‐CD3	  mAb	  and	  rPD-­‐L1	  (CD3	  +	  rPD-­‐L1)	  or	  with	  NIB1412	  and	  rPD-­‐L1	  
(NIB1412	  +	   rPD-­‐L1).	  At	   the	  end	  of	  72	  hrs,	   the	  cells	  were	   lysed	  and	  extracted	  protein	   separated	  by	  
SDS-­‐PAGE.	   pPTEN	   –	   S380/T382/383	   (47kDa)	   protein	   levels	   were	   assessed	   by	   immunoblotting	   and	  
actin	   (45kDa)	  was	  used	  as	   loading	  control.	  Blot	   is	   representative	  of	   four	   independent	  experiments.	  
pPTEN	  levels	  were	  quantified	  by	  densitometry,	  normalized	  to	  β-­‐actin	  and	  expressed	  as	  a	  percentage	  
of	   pPTEN	   levels	   in	   untreated	   cells.	   Data	   are	   represented	   as	   mean	   ±	   SEM	   of	   four	   independent	  
experiments.	  Statistical	  analysis	  was	  performed	  using	  unpaired	  t-­‐test	  (*	  p<0.05,	  **p<0.01).	  Phospho	  





Figure	  3.20:	  Effects	  of	  PD-­‐1	  engagement	  on	  CK2	  levels	  
Human	  CD4+	  TEMs	  were	  stimulated	  with	  anti-­‐CD3	  mAb	  (CD3,	  5	  μg/ml);	  NIB1412	  (NIB1412,	  10	  μg/ml);	  
rPD-­‐L1	  (rPD-­‐L1,	  10μg/ml);	  with	  anti-­‐CD3	  mAb	  and	  rPD-­‐L1	  (CD3	  +	  rPD-­‐L1)	  or	  with	  NIB1412	  and	  rPD-­‐L1	  
(NIB1412	  +	   rPD-­‐L1).	  At	   the	  end	  of	  72	  hrs,	   the	  cells	  were	   lysed	  and	  extracted	  protein	   separated	  by	  
SDS-­‐PAGE.	   CK2α	   (42kDa)	   protein	   levels	   were	   assessed	   by	   immunoblotting	   and	   actin	   (45kDa)	   was	  
used	   as	   loading	   control.	   All	   blots	   are	   representative	   of	   four	   independent	   experiments.	   CK2	   levels	  
were	  quantified	  by	  densitometry,	  normalized	  to	  β-­‐actin	  and	  expressed	  as	  a	  percentage	  CK2	  levels	  in	  
untreated	  cells.	  Data	  are	   represented	  as	  mean	  ±	  SEM	  of	   four	   independent	  experiments.	   Statistical	  









3.4. Discussion	  	  
TGN1412	   is	   a	   CD28SA	   that	   caused	   an	   uncontrolled	   expansion	   of	   T	   cells	   with	   an	  
accompanying	   cascade	   of	   proinflammatory	   cytokine	   release	   and	   infiltration	   of	   T	  
cells	   into	   tissues,	   in	   all	   six	   healthy	   volunteers	   enrolled	   in	   a	   Phase	   I	   clinical	   study	  
[92],[97].	   Despite	   initial	   recovery,	   their	   conditions	   deteriorated	   and	   this	   may	   be	  
linked	   to	   a	   prolonged	   adverse	   response	   due	   to	   the	   dysregulation	   of	   the	   immune	  
system	  by	  TGN1412.	  	  
We	  show	  that	  prolonged	  stimulatory	  signals,	  upregulation	  of	  the	  CCR5	  receptor	  and	  
the	  LFA-­‐1	  integrin	  on	  the	  cell	  surface,	  and	  lack	  of	  inhibitory	  receptors	  such	  as	  PD-­‐1	  
in	  CD28SA-­‐treated	  T	  cells	  are	  responsible	  for	  the	  hyperactive	  phenotype	  observed.	  
We	   also	   showed	   the	   prolonged	   unrestricted	   proliferation	   in	   CD28SA-­‐activated	  
effector	  memory	  CD4+	  T	  cells.	  These	  results	  indicate	  the	  unrestricted	  expansion	  of	  a	  
CD28SA-­‐induced	   immune	   response,	  while	   the	  anti-­‐CD3-­‐induced	   immune	   response	  
contracts	  post-­‐activation.	  When	  T	  cells	  are	  activated	  with	  CD28SA	  and	  anti-­‐CD3	   in	  
combination,	  the	  resulting	  phenotype	  expresses	  intermediate	  levels	  of	  PD-­‐1,	  LFA-­‐1	  
and	  CCR5,	  compared	  to	  when	  activated	  with	  either	  agonist	  on	   its	  own.	  This	  might	  
suggest	  that	  anti-­‐CD3	  activation	  induces	  regulatory	  signals.	  	  
Enhanced	  and	  prolonged	  secretion	  of	  IL-­‐2	  and	  autocrine	  triggering	  of	  IL-­‐2	  receptors	  
(IL-­‐2Rs)	   could	   contribute	   to	   sustained	   proliferation	   of	   CD28SA-­‐stimulated	   T	   cells.	  
Data	  from	  our	  lab	  indicate	  that	  NIB1412-­‐simulated	  T	  cell	  proliferation	  requires	  IL-­‐2-­‐
IL-­‐2R	  interaction	  (data	  from	  collaborator	  Stebbings	  et	  al.).	  Activation	  with	  anti-­‐CD3	  
reduces	   levels	   of	   CD28	   post-­‐activation	   but	   these	   are	   reset	   and	   maintained	   at	  
physiologically	   high	   levels	   from	   day	   2.	   For	   CD28SA-­‐activated	   T	   cells	   the	   CD28	  
receptor	  re-­‐emerges	  within	  a	  short	  time	  frame	  following	  activation	  which	  makes	  it	  
available	  for	  re-­‐engagement	  by	  unbound	  CD28SA,	  leading	  to	  repeated	  upregulation	  
and	  downregulation	  of	  the	  CD28	  receptor	  and	  continuous	  induction	  of	  input	  signals.	  
This	   may	   reflect	   the	   sustained	   signalling	   observed	   in	   previous	   studies	   [16].	  
Activation	   of	   T	   cells	   in	   combination	   with	   CD28SA	   and	   anti-­‐CD3	   shows	   a	   delay	   in	  
CD28	   receptor	   re-­‐emergence	   until	   day	   3,	   which	   reduces	   again	   at	   day	   4.	   The	  
presence	   of	   anti-­‐CD3-­‐mediated	   signals	   may	   influence	   CD28	   receptor	   expression,	  
and	  in	  turn	  reduce	  repeated	  stimulation	  by	  unbound	  CD28SA.	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The	  contraction	  phase	  of	  T	  cell	  activation	  is	  mainly	  brought	  about	  through	  apoptosis	  
induced	  via	  the	  Fas-­‐FasL	  system,	  [110]	  and	  we	  have	  shown	  a	  diminished	  capacity	  of	  
CD28SA	  stimulated	  T	  cells	  to	  upregulate	  Fas	  (CD95),	  which	  might	  explain	  the	  failure	  
of	  these	  T	  cells	  to	  undergo	  normal	  contraction.	  	  
CD28SA-­‐stimulated	  T	  cells	  also	  upregulate	  significant	  levels	  of	  HLA-­‐DR	  and	  CD80,	  co-­‐
stimulatory	  molecules	  typically	  expressed	  by	  antigen	  presenting	  cells.	  Circulating	  T	  
cells	  in	  HIV-­‐1-­‐infected	  individuals	  undergo	  a	  transition	  from	  a	  reactive	  to	  an	  antigen	  
presenting	   phenotype	   by	   expressing	   both	   HLA-­‐DR	   and	   CD80	   molecules.	   The	  
expression	  of	  these	  co-­‐stimulatory	  receptors	   is	  thought	  to	  reflect	  the	  chronicity	  of	  
the	   T	   cell	   activation	   [111].	   Studies	   have	   shown	   that	   T	   cells	   acquire	   markers	   of	  
antigen	  presentation	   from	  APCs	   [112].	   Since	  we	   isolated	   the	   TEM	  population	   from	  
PBMCs	  prior	   to	   stimulation	  with	  NIB1412,	   it	   suggests	   that	   superagonist	   activation	  
may	  lead	  to	  the	  endogenous	  upregulation	  of	  HLA-­‐DR	  and	  CD80.	  This	  could	  enable	  T	  
cell	   to	   T	   cell	   antigen	   presentation.	   In	   a	   heterogeneous	   mixture	   of	   cells	   CD28SA-­‐
activated	  T	  cells	  would	  be	  capable	  of	  activating	  a	  variety	  of	  T	  cells	  by	  acting	  as	  APCs.	  
Furthermore,	   histological	   studies	   have	   revealed	   that	   CD80	   expression	   can	   be	  
detected	  on	  tissue-­‐infiltrating	  T	  cells	  [113].	  Taken	  together,	  the	  expression	  of	  LFA-­‐1	  
and	  markers	  of	  antigen	  presentation	  suggests	  that	  CD28SA-­‐activated	  T	  cells	  have	  a	  
high	  tissue	  infiltration	  capability.	  	  
Effector	   memory	   cells	   respond	   to	   the	   inflammatory	   chemokines	   CCL3,	   CCL4	   and	  
CCL5,	  and	  upon	  re-­‐stimulation	  up-­‐regulate	  CCR5	  and	  become	  tissue	  invasive	  [114].	  	  
TGN1412	   can	   induce	   monocytes	   to	   secrete	   high	   levels	   of	   CCL5	   within	   2hrs	   of	  
stimulation	   [115].	   It	   is	   likely	   that	   CD28SA-­‐induced	   upregulation	   of	   CCR5	   was	   a	  
contributing	   factor	   to	   the	   lymphocyte	   tissue	   invasion	   observed	   in	   the	   volunteers	  
during	   the	  TGN1412	  clinical	   trial.	  A	  prominent	   feature	  of	   the	  pathologic	  events	   in	  
the	   trial	   patients	  was	  prolonged	   lymphocyte	  depletion	   from	   the	   circulation	  which	  
was	  suggested	  to	  be	  related	  to	  unregulated	  T	  cell	  extravasation	  [92,	  106].	  LFA-­‐1	  is	  
the	  predominant	  adhesion	  molecule	  on	  T	  cells	   [63]	  and	  plays	  an	   important	  role	   in	  
extravasation	   of	   lymphocytes	   into	   inflamed	   tissue.	   Since	   NIB1412-­‐stimulated	   TEMs	  
expressed	  high	  levels	  of	  LFA-­‐1,	  it	  is	  possible	  that	  these	  cells	  might	  be	  more	  likely	  to	  
undergo	   extravasation.	   We	   show	   enhanced	   adhesion	   and	   transendothelial	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migration	   of	   NIB1412-­‐stimulated	   TEMs	   compared	   to	   anti-­‐CD3-­‐stimulated	   TEMS.	   A	  
variety	   of	   negative	   regulators	   are	   known	   to	   play	  roles	  in	   the	   resolution	   of	  T	  
cell	  response	  with	  PD-­‐1	  being	  a	  key	  inhibitory	  receptor	  [11].	  The	  PD-­‐1	  pathway	  has	  
been	  shown	  to	  play	  crucial	  roles	  in	  the	  regulation	  of	  autoimmunity,	  transplantation	  
immunity,	   infectious	   immunity,	   and	   tumour	   immunity	   [98].	   The	   PD-­‐1-­‐PD-­‐L1	  
interaction	   plays	   an	   important	   role	   during	   the	   contraction	   phase	   of	   the	   immune	  
response	   [98].	  PD-­‐1	  deficient	  experimental	  mouse	  models	  display	  a	  breakdown	  of	  
tolerance	   and	   a	   higher	   susceptibility	   to	   proliferate	   with	   higher	   amounts	   of	   IFN-­‐γ	  
production	  [116],	  which	  leads	  to	  the	  development	  of	  spontaneous	  strain-­‐dependent	  
autoimmune	   diseases.	   The	   recognition	   that	   the	   PD-­‐1	   pathway	   provides	   strong	  
negative	  signalling	  and	  is	  a	  dominant	  regulator	  of	  activated	  T	  cells	  has	  led	  to	  focus	  
on	   development	   of	   therapeutic	   strategies	   aimed	   at	   manipulating	   this	   PD-­‐1	   [98].	  
Thus,	   PD-­‐1	   was	   chosen	   as	   a	   candidate	   receptor	   to	   see	   its	   potential	   lack	   of	  
contribution	   in	   CD28SA-­‐activated	   T	   cells.	   In	   our	   study,	   we	   show	   that	   CD28SA-­‐
activated	  T	  cells	  fail	  to	  upregulate	  PD-­‐1	  and	  the	  negative	  feedback	  conferred	  by	  the	  
PD-­‐1-­‐PD-­‐L1	   interaction	   was	   found	   to	   be	   absent	   in	   these	   T	   cells.	   Further	  
investigations	   are	   required	   in	   order	   to	   gain	   an	   understanding	   of	   the	  mechanisms	  
that	  regulate	  PD-­‐1	  expression	  and	  function	  in	  this	  context.	  	  	  
Although,	   PD-­‐1	  was	   absent	   on	   the	   surface	   of	   CD28SA-­‐activated	   CD4+	   T	   cells,	   it	   is	  
present	  within	  the	  cytoplasm	  of	  these	  cells.	  PD-­‐1	  has	  been	  shown	  to	  be	  present	  in	  
vesicles	  near	  the	  Golgi	  and	  in	  the	  trans-­‐Golgi	  network	  [117].	  Since	  PD-­‐1	  is	  known	  to	  
be	  upregulated	  on	  the	  cell	  surface	  upon	  TCR	  triggering,	  it	  suggests	  that	  the	  fusion	  of	  
PD-­‐1-­‐containing	   vesicles	   within	   the	   cytoplasm	   to	   the	   plasma	   membrane	   is	  
dependent	  on	  signalling	  pathways	  that	  emanate	  from	  the	  TCR	  that	  are	  not	  engaged	  
by	   CD28SA.	   The	   exact	   molecular	   signals	   that	   connect	   TCR	   to	   PD-­‐1	   upregulation	  
require	  further	  definition.	  
We	   have	   shown	   that	   engagement	   of	   the	   PD-­‐1	   receptor	   by	   PD-­‐L1	   reduces	   PTEN	  
phosphorylation	  in	  anti-­‐CD3-­‐stimulated	  TEMs	  but	  not	  in	  CD28A-­‐stimulated	  TEMs.	  The	  
presence	  of	  phosphorylated	  PTEN	  in	  CD28SA-­‐stimulated	  TEMs	  suggests	  that	  there	  is	  
an	  absence	  of	  PTEN	  lipid	  phosphatase	  activity	  to	  inhibit	  the	  PI3K/AKT	  signaling	  axis,	  
leaving	   the	  T	  cells	   in	  a	  hyper-­‐proliferative	  state.	  Since	   the	  PI3K	  pathway	   regulates	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diverse	   cellular	   activities	   such	   as	   growth,	   migration,	   survival,	   vesicular	   trafficking	  
and	   glucose	   metabolism	   [118],	   it	   would	   be	   worth	   investigating	   key	   signalling	  
proteins	  that	  branch	  from	  the	  PI3K	  nexus	  that	  may	  be	  dysregulated	  during	  CD28SA	  
activation.	   The	   lack	   of	   a	   reliable	   biomarker	   predictive	   of	   uncontrolled	   T	   cell	  
stimulation	  by	  TGN1412	  was	  a	  key	  factor	  in	  the	  failure	  of	  preclinical	  safety	  testing	  of	  
this	  immunostimulatory	  mAb.	  Detailed	  understanding	  of	  the	  target	  biology	  followed	  
by	   identification	  and	  screening	  of	   target	  specific	  biomarkers	   for	   risk	  assessment	   is	  
essential	   to	   improve	   the	   safety	   profile	   of	   biologics	   [87].	   Our	   study	   demonstrates	  
that	   CD28SA-­‐stimulated	   T	   cells	   display	   a	   phenotype	   that	   is	   reflective	   of	   a	  
predisposition	   to	   excessive	   activation	   and	   lack	   of	   regulation	   by	   PD-­‐1	   mediated	  
inhibitory	  signals,	  which	  can	  potentially	  be	  used	  as	  biomarkers	  to	  predict	  the	  effects	  
a	  T	  cell	  stimulatory	  biologic.	  However,	  the	  utility	  of	  testing	  for	  functionality	  of	  the	  
PD-­‐1	  pathway	  as	  a	  biomarker	  of	  hazard	  needs	  further	  investigation	  and	  validation.	  
The	  metabolic	  program	  underlying	   the	  excessive	  activation	  of	  CD28SA-­‐activated	  T	  
cells	   is	   unknown.	   Since,	   both	   the	   activity	   and	   fate	  of	   T	   cells	   are	  directly	   linked	   to	  
their	  metabolic	   profile;	  we	  decided	   to	   investigate	   the	  metabolic	   characteristics	   of	  
CD28SA-­‐stimulated	   T	   cells	   and	   compared	   them	   to	   T	   cells	   activated	   via	   the	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4. CD28	   superagonist	   activation	   of	   T	   cells	   induces	   a	  
cancer	  cell-­‐like	  metabolic	  program	  	  
	  
4.1. Abstract	  	  
CD28	   superagonist	   (CD28SA),	   a	   therapeutic	   immunomodulatory	   monoclonal	  
antibody	  triggered	  rapid	  and	  exaggerated	  activation	  of	  CD4+	  effector	  memory	  T	  cells	  
(TEM)	   in	   humans	   with	   unwanted	   serious	   adverse	   effects.	   Distinct	   metabolic	  
programs	  have	  been	  shown	  to	  determine	  the	  fate	  and	  responses	  of	   immune	  cells.	  
Here,	  we	   show	   that	   human	   CD4+	   TEM	   stimulated	  with	   CD28SA	   adopt	   a	  metabolic	  
program	   similar	   to	   those	   of	   cancer	   cells	   with	   enhanced	   glucose	   utilization,	   lipid	  
biosynthesis	   and	   proliferation	   in	   hypoxic	   conditions.	   Identification	   of	   metabolic	  
profiles	  underlying	  hyperactive	  T	  cell	  activation	  provides	  a	  platform	  to	  test	  safety	  of	  
immunostimulatory	  antibodies.	  
4.2. Introduction	  	  
CD28	   Superagonists	   (CD28SAs)	   are	   monoclonal	   antibodies	   (mAbs)	   that	   crosslink	  
CD28	  co-­‐stimulatory	   receptors	   resulting	   in	  potent	  T	  cell	  activation	   independent	  of	  
concomitant	   T	   cell	   receptor	   (TCR)	   engagement	   [119].	   The	   CD28SA,	   TGN1412,	  
triggered	   an	   excessive	   and	   adverse	   cytokine	   release	   (cytokine	   storm)	   when	  
administered	   to	   volunteers	   in	   a	   human	   Phase	   1	   clinical	   trial	   [92].	  We	   and	   others	  
have	  shown	  that	  CD28SA	  induces	  exaggerated	  activation,	  polyclonal	  expansion	  and	  
migration	  of	   CD4+	   effector	  memory	   T	   cells	   (TEM)	   [92,	   120,	   121].	   The	  basis	   for	   this	  
hyperactive	  dysregulated	  phenotype	  is	  the	  subject	  of	  much	  research	  and	  the	  lack	  of	  
inhibitory	   inputs	   [121]	   has	   been	   suggested	   as	   one	   potential	   mechanism	   (see	  
previous	   chapter).	   T	   cells	   need	   to	   undergo	  metabolic	   reprogramming	   in	   order	   to	  
adapt	   to	   their	   changing	  metabolic	   needs	   as	   they	   progress	   from	   resting	   T	   cells	   to	  
fully	   differentiated	   effectors	   and	   memory	   cells	   [69].	   T	   cells	   use	   glucose	   as	   the	  
primary	   nutrient	   source	   for	   energy	   generation	   and	   biomass	   production,	   although	  
amino	  acids	  such	  as	  glutamine	  are	  also	  utilised	  [69].	  Prior	  to	  activation,	  naive	  T	  cells	  
have	  low	  metabolic	  requirements	  and	  rely	  on	  mitochondrial	  oxidative	  pathways	  for	  
basal	  energy	  generation.	  Upon	  activation,	  T	  cells	  adopt	  a	  metabolic	  profile	  typified	  
by	  aerobic	  glycolysis	  and	  basal	  oxidative	  phosphorylation	  (OXPHOS)	  [69].	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Rapidly	   proliferating	   T	   cells	   require	   lipids	   to	   support	   membrane	   biogenesis	   and	  
depending	  on	  the	  T	  cell	  subset,	  lipids	  may	  be	  acquired	  or	  synthesised	  (lipogenesis)	  
[122].	  T	  cells	  use	  distinct	  metabolic	  programs	  according	  to	  their	  differentiation	  state	  
and	   immunological	   role.	   Studies	   have	   shown	   that	   CD4+	   T	   helper	   (Th)	   1,	   Th2	   and	  
Th17	   cells	   are	   highly	   glycolytic,	   while	   CD4+	   regulatory	   T	   cells	   have	   high	   lipid	  
oxidation	   rates	   [123].	   The	  metabolic	   phenotype	   of	   the	   TGN1412-­‐target	   cell,	   CD4+	  
TEM,	   has	   not	   been	   studied.	   Importantly,	   the	  metabolic	   program	   that	   supports	   the	  
dramatic	   hyperactivation	   and	   proliferation	   induced	   by	   CD28SA	   is	   currently	  
unknown.	  We	  hypothesised	  that	  that	  superagonistic	  activation	  programs	  CD4+	  TEM	  
metabolism	   to	   favour	   enhanced	   glycolysis	   and	   lipogenesis.	   In	   order	   to	   establish	  
whether	   CD28SA-­‐stimulated	   T	   cells	   have	   a	   lipogenic	   phenotype,	   we	   defined	   the	  
activity	  of	  key	  enzymes,	  ATP-­‐citrate	   lyase	   (ACL)	  and	  acetyl-­‐CoA	  carboxylase	   (ACC),	  
involved	  in	  the	  net	  conversion	  of	  glucose	  to	  lipid.	  	  	  
4.3. Results	  	  
4.3.1. CD28SA-­‐activated	  T	  cells	  display	  a	  hyperactive	  phenotype	  	  
We	   and	   others	   have	   previously	   shown	   that	   CD28SA-­‐activation	   results	   in	   a	  
hyperactive	   T	   cell	   phenotype	   [121,	   124].	   T	   cell	   activation	   triggers	   metabolic	  
programs	  that	  promote	  biomass	  generation	  which	  is	  evident	  by	  an	  increase	  in	  cell	  
size,	   termed	   blasting.	  We	   used	   a	   TGN1412-­‐like	   CD28SA	  mAb,	   termed	  NIB1412	   to	  
stimulate	  CD4+	  TEM	  and	  demonstrate	   that	   the	  percentage	  of	  blasting	  T	  cells	   in	   the	  
CD28SA-­‐stimulated	   condition	   is	   about	   45%	   greater	   than	   in	   the	   CD3-­‐activated	  





Figure	  4.1:	  CD28SA	  activation	  results	  in	  greater	  blasting	  of	  CD4+	  TEM	  	  
(a) Size	   (forward	   scatter	   [FSC])	   and	   granularity	   (side	   scatter	   [SSC])	   were	   quantified	   by	   flow	  
cytometry.	  FSC	  and	  SSC	  were	  measured	  on	  purified	  human	  CD4+	  TEM	  stimulated	  with	  anti-­‐CD3	  or	  
CD28SA	   for	   48	   h.	   Percentages	   ±	   SD	   indicate	   T	   cell	   blasts.	   The	   data	   are	   representative	   of	   four	  
independent	  experiments.	  NIB1412	  –	  CD28SA.	  
	  
4.3.2. CD28SA	  stimulation	  maximises	  OXPHOS	  potential	  	  
Activated	  immune	  cells	  prefer	  glycolysis	  over	  OXPHOS	  as	  it	  is	  around	  two	  orders	  of	  
magnitude	   faster	   for	   biomass	   accumulation	   and	   proliferation	   [125].	  Nevertheless,	  
OXPHOS	  is	  necessary	  for	  cell-­‐surface	  expression	  of	  the	  IL-­‐2	  receptor	  and	  thus	  vital	  
for	   lymphocyte	  proliferation	  [126]. To	  assess	  the	  contribution	  of	  OXPHOS	  to	  meet	  
the	   energy	   requirements	   during	   hyperactivation	   of	   CD4+	   TEM	   upon	   CD28SA	  
stimulation,	   we	   used	   extracellular	   flux	   analysis	   to	   measure	   oxygen	   consumption	  
rates	   (OCR)	   and	  basal	   respiration,	  ATP	  production,	  maximal	   respiration	   and	   spare	  
respiratory	  capacity	  (SRC)	  (see	  methods	  for	  details).	  CD28SA-­‐stimulated	  T	  cells	  had	  
higher	  basal	  respiration	  and	  ATP	  production	  when	  compared	  to	  CD3-­‐activated	  CD4+	  
TEM	  (Figure	  4.2	  (a)).	  The	  high	  oxygen	  consumption	  and	  ATP	  production	  is	  indicative	  
of	  enhanced	  rates	  of	  OXPHOS	  which	  occurs	  primarily	  in	  the	  mitochondria	  [127].	  To	  
determine	  whether	  CD28SA-­‐stimulated	  T	  cells	  had	  more	  active	  mitochondrial	  mass,	  
we	  stained	  CD4+	  TEM	  with	  Mitotracker	  deep	  red	  and	  found	  that	  CD28SA-­‐stimulation	  
led	  to	  a	  higher	  quantity	  of	  actively	  respiring	  mitochondria	  than	  when	  activated	  with	  
anti-­‐CD3	   mAbs	   (Figure	   4.2	   (b)	   and	   (c)).	   CD28SA-­‐stimulated	   T	   cells	   also	   produced	  
more	  mitochondrial	  reactive	  oxygen	  species	  (mitoROS)	  than	  CD3-­‐activated	  CD4+	  TEM	  
(Figure	   4.2	   (d))	   which	   is	   reflective	   of	   enhanced	   mitochondrial	   electron	   transport	  
activity	   [128].	   Collectively,	   these	   results	   indicate	   that	   CD28SA-­‐activated	   cells	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maximise	   their	   OXPHOS	   potential	   which	   is	   supported	   by	   their	   greater	   active	  
mitochondrial	  mass.	   
To	   test	   whether,	   CD28SA-­‐stimulated	   cells	   are	   reliant	   on	   OXPHOS	   for	   their	  
hyperproliferation,	   we	   cultured	   activated	   CD4+	   TEM	   under	   hypoxic	   or	   normoxic	  
conditions.	   While,	   CD3-­‐stimulated	   cells	   proliferated	   more	   in	   normoxic	   than	   in	  
hypoxic	  condition	  (Figure	  4.2	  (e)),	  CD28SA-­‐stimulated	  cells	  proliferated	  in	  both	  the	  
conditions	  with	  higher	  rate	  of	  proliferation	  in	  hypoxic	  condition.	  This	  suggests	  that	  
CD28SA	   activated	   T	   cells	   have	   a	   flexible	   metabolic	   program	   that	   reduces	   the	  


















Figure	  4.2:	  CD28SA	  stimulation	  maximizes	  OXPHOS	  potential	  
(a) Oxygen	  consumption	  rates	  (OCR;	  pMoles/min)	  of	  pre-­‐activated	  human	  CD4+	  TEMs	  were	  
measured	  using	  the	  seahorse	  XF96	  extracellular	  flux	  analyser	  in	  real	  time,	  under	  basal	  
conditions	  and	   in	  response	  to	  sequential	  addition	  of	  Oligomycin	  (1	  µM),	  2,4-­‐DNP	  (160	  
μM)	   and	   Antimycin	   A	   &	   Rotenone	   (1	   µM).	   Mean	   OCR	   values	   representing	   basal	  
respiration	   and	   ATP	   production	   are	   presented	   as	   bar	   charts.	   The	   bars	   represent	   the	  
mean	  ±	  SD.	  The	  data	  are	  representative	  of	  three	  independent	  experiments,	  (*P	  <	  0.05,	  
**P	  <	  0.01;	  unpaired,	  two-­‐tailed	  Student’s	  t-­‐test).	  	  
(b) Immunofluorescent	   (IF)	   images	   of	   mitochondria.	   IF	   images	   show	   CD3-­‐	   and	   CD28SA-­‐
stimulated	  human	  CD4+	  TEM	  stained	  with	  Mitotracker	  (red)	  and	  Hoechst	  (blue);	  Far	  right	  
quadrant	  represents	  merged	  image	  of	  the	  two	  stains;	  scale	  bars	  represent	  10	  μM.	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(c) Mitochondria	   were	   stained	   with	   MitoTracker	   Deep	   Red	   or	   (d)	   MitoSOX™	   Red	  
Mitochondrial	   Superoxide	   Indicator,	   and	   the	   staining	   intensities	   were	   quantified	   by	  
flow	  cytometry.	  Data	  represent	   the	  mean	  percent	  of	  cells	  ±	  SD	  (n=3)	  staining	  positive	  
for	  mitochondria,	  or	  mitochondrial	  ROS	  (mitoROS),	  with	  the	  mean	  percent	  of	  mitoROS	  
presented	  in	  a	  bar	  graph.	  The	  bars	  represent	  the	  mean	  ±	  SD	  (n=3).	  **	  denotes	  P-­‐value	  <	  
0.01	  as	  calculated	  by	  an	  unpaired,	  two-­‐tailed	  Student’s	  t-­‐test	  
(e) Human	   CD4+	   TEM	   were	   stimulated	   with	   the	   indicated	   concentrations	   of	   plate-­‐bound	  
antibodies	   and	   incubated	   in	   normoxic	   (20%	   O2)	   or	   hypoxic	   (5%	   O2)	   conditions.	  
Proliferation	   was	   measured	   three	   days	   post-­‐activation	   by	   3H-­‐labeled	   thymidine	  
incorporation.	   The	   vertical	   axis	   represents	  mean	   cpm	   ±	   SD	   from	   triplicate	  wells.	   The	  
data	   are	   representative	   of	   three	   independent	   experiments,	   (*P<	   0.05,	   **P<	   0.01;	  
unpaired	  two-­‐tailed	  t-­‐test).	  NIB1412	  –	  CD28SA.	  
4.3.3. CD28SA	  stimulation	  maximises	  glucose	  utilization	  	  
We	  next	  measured	   extracellular	   acidification	   rates	   (ECAR),	   a	  marker	   of	   glycolysis,	  
and	  found	  that	  CD28SA-­‐stimulated	  CD4+	  TEM	  displayed	  significantly	  higher	  glycolysis	  
and	  lacked	  glycolytic	  reserve	  compared	  to	  CD3-­‐stimulated	  cells	  (Figure	  4.3	  (a)).	  This	  
result	   indicates	   that	   CD28SA-­‐activated	   cells	   adopt	   a	   metabolic	   program	   that	  
maximises	   basal	   glycolytic	   rate.	   We	   tested	   whether	   the	   high	   glycolytic	   rate	   was	  
associated	   with	   altered	   glycolytic	   machinery	   in	   CD4+	   TEM.	   The	   enzyme	   GAPDH	   is	  
critical	  component	  of	  the	  glycolytic	  pathway	  that	  generates	  pyruvate	  from	  glucose	  
(figure	   1.8).	   	   Studies	   have	   shown	   that	   GAPDH	   shuttles	   between	   nuclear	   and	  
cytoplasmic	  compartments,	  with	  cytoplasmic	  GAPDH	  being	  active	  in	  glycolysis	  [129]	  
while	   nuclear	   GAPDH	   is	   thought	   to	   be	   involved	   in	   the	   initiation	   of	   apoptotic	  
cascades	   [130]	  and	  promoting	  gene	   transcription	   [131].	  We	  examined	   the	  cellular	  
distribution	  of	  GAPDH	  by	  immunofluorescence	  and	  observed	  that	  the	  distribution	  of	  
GAPDH	  staining	  was	   coincident	  with	   the	  nuclear	   contours	   in	  CD3-­‐stimulated	  CD4+	  
TEM.	   In	   contrast,	   CD28SA-­‐stimulated	   CD4+	   TEM	   had	   more	   dispersed	   cytosolic	  
distribution	  of	  GAPDH	  (Figure	  4.3	  (b)).	  Increased	  glycolytic	  rates	  need	  to	  be	  fuelled	  
by	   a	   commensurate	   increase	   in	   the	   uptake	   of	   glucose	   which	   is	   predominantly	  
mediated	   by	   the	   glucose	   transporter,	   GLUT1	   in	   T	   cells	   [132].	   In	   addition	   to	   TCR	  
activation,	  CD28	  costimulation	  acting	  through	  the	  PI3K/Akt	  pathway	  is	  an	  important	  
component	   in	   increasing	   glycolytic	   flux	   essential	   for	   cell	   proliferation	   [73].	   The	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uptake	   of	   the	   fluorescent	   glucose	   analog	   2-­‐NBDG	   (Fig	   4.3	   (c)	   (i))	   and	   cell	   surface	  
expression	   of	   GLUT1	   (Figure	   4.3	   (c)	   (ii))	   were	   both	   higher	   in	   CD28SA-­‐stimulated	  
CD4+	  TEM	  than	  in	  CD3-­‐stimulated	  cells.	  	  
The	   ratio	  of	   the	  basal	  ECAR	   to	  OCR	   indicates	   the	  cellular	  preference	   for	  glycolysis	  
versus	  OXPHOS	  [133].	  Figure	  4.3	  (d)	  (i)	  shows	  the	  ECAR/OCR	  ratio	  of	  CD28SA-­‐	  and	  
CD3-­‐stimulated	  T	  cells	  cultured	  (in	  base	  media	  with	  glutamine	  only)	  in	  the	  absence	  
of	   glucose	   (-­‐Glu)	   or	   in	   the	   presence	   of	   glucose	   (+Glu).	   In	   the	   -­‐Glu	   condition	   the	  
ECAR/OCR	   ratio	   was	   significantly	   lower	   in	   CD28SA-­‐stimulated	   cells	   than	   CD3-­‐
stimulated	   cells.	   In	   the	   +Glu	   condition	  CD28SA-­‐stimulated	   cells	   had	   a	   significantly	  
higher	  ECAR/OCR	  ratio	  than	  CD3-­‐stimulated	  cells.	  These	  plots	  demonstrate	  that	   in	  
the	   presence	   of	   glucose	   CD28SA-­‐stimulated	   cells	   preferentially	   drive	   glycolysis,	  
while	  CD3-­‐stimulated	  cells	  also	  drive	  OXPHOS.	  Collectively	  these	  results	  show	  that	  
CD28SA	  stimulation	  drives	  an	  adaptable	  metabolic	  program	  that	  maximises	  glucose	  
utilisation	   to	   drive	   both	  OXPHOS	   and	   glycolysis	   depending	   on	   glucose	   availability.	  
This	   was	   demonstrated	   by	   the	   cell	   viability	   in	   glucose	   deficient	   conditions.	   The	  
viability	   of	   CD28SA-­‐stimulated	   cells	   was	   unaffected	   after	   24hrs	   while	   more	   than	  















Figure	  4.3:	  CD28SA	  stimulation	  maximises	  glucose	  utilization	  
(a) Extracellular	   acidification	   rates	   (ECAR;	   mpH/min)	   of	   pre-­‐activated	   human	   CD4+	   TEMs	   were	  
measured	  using	  the	  seahorse	  XF96	  extracellular	  flux	  analyzer	  in	  real	  time,	  under	  basal	  conditions	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and	   in	  response	  to	  sequential	  addition	  of	  glucose	  (10	  mM),	  Oligomycin	  (1	  µM)	  and	  2-­‐deoxy-­‐D-­‐
glucose	   (2-­‐DG)	   (100	  mM).	  Mean	  ECAR	  values	  representing	  glycolysis	  and	  glycolytic	   reserve	  are	  
presented	  as	  bar	  charts.	  The	  bars	  represent	  the	  mean	  ±	  SD.	  The	  data	  are	  representative	  of	  three	  
independent	  experiments,	  (*P	  <	  0.05,	  **P	  <	  0.01;	  unpaired	  two-­‐tailed	  t-­‐test).	  
(b) Immunofluorescence	   images	   show	  CD3-­‐and	  CD28SA-­‐stimulated	  human	  CD4+	  TEM	  at	  48	  h	  post-­‐
activation	   stained	  with	   anti-­‐GAPDH	   (green)	   and	   DAPI	   (blue);	   scale	   bars	   represent	   10	   μm.	   Far	  
right	  quadrant	  represents	  merged	  image	  of	  the	  two	  stains.	  	  
(c) Human	  CD4+	  TEM	  were	  stimulated	  with	  anti-­‐CD3	  or	  CD28SA	  for	  48	  h.	  Cells	  were	  then	  incubated	  
with	  2-­‐NBDG	  for	  30mins	  and	  the	  amount	  of	  (i)	  2NBDG	  uptake	  was	  measured	  by	  flow	  cytometry,	  
with	   the	   mean	   percent	   of	   2-­‐NBDG	   positive	   CD4+	   TEM	   presented	   in	   a	   bar	   graph.	   The	   bars	  
represent	   the	  mean	  ±	  SD	   (n=3).	  **	  denotes	  P-­‐value	  <	  0.01	  as	   calculated	  by	  an	  unpaired,	   two-­‐
tailed	  Student’s	  t-­‐test.	  Cells	  were	  also	  stained	  for	  (ii)	  Glut1	  expression.	  	  	  
(d) Basal	  ECAR	  and	  OCR	  of	  pre-­‐activated	  human	  CD4+	  TEMs	  were	  measured	  using	  the	  seahorse	  XF96	  
extracellular	  flux	  analyzer	  in	  real	  time,	  with	  the	  (i)	  ECAR/OCR	  ratio	  presented	  as	  bar	  charts.	  The	  
bars	  represent	  the	  mean	  ±	  SD.	  	  The	  data	  are	  representative	  of	  three	  independent	  experiments,	  
(*P<	   0.05,	   **P<	   0.01;	   two-­‐tailed	   unpaired	   t-­‐test).	   (ii)	   Cell	   viability	   of	   CD3-­‐	   and	   CD28SA-­‐
stimulated	  human	  CD4+	  TEM	  cultured	  for	  24	  h	  in	  the	  presence	  or	  absence	  of	  glucose.	  Percentage	  
of	   viable	   cells	   was	   determined	   by	   using	   trypan	   blue.	   The	   data	   are	   representative	   of	   three	  
independent	  experiments.	   **	  denotes	  P-­‐value	  <	  0.01	  as	   calculated	  by	  an	  unpaired,	   two-­‐tailed	  
Student’s	  t-­‐test.	  	  	  
	  	  	  	  	  	  	  	  	  	  NIB1412	  –	  CD28SA.	  	  
	  
4.3.4. CD28SA-­‐activated	  T	  cells	  are	  metabolically	  programmed	  to	  
favour	  lipogenesis	  	  
Mitochondrial	  fatty	  acid	  oxidation	  (FAO;	  β-­‐oxidation)	  is	  a	  source	  of	  acetyl	  CoA	  that	  
is	   used	   in	   the	   TCA	   cycle	   for	   energy	   generation	   through	   OXPHOS	   [134].	   Carnitine	  
palmitoyl	  transferase	  (CPT1a)	  is	  a	  metabolic	  enzyme	  that	  controls	  the	  rate-­‐limiting	  
step	   in	   mitochondrial	   FAO	   [135].	   To	   determine	   whether	   mitochondrial	   FAO	  
contributes	  to	  OXPHOS,	  we	  measured	  changes	  in	  SRC	  in	  the	  presence	  of	  the	  CPT1a	  
inhibitor,	   etomoxir.	   	   In	   both	   +Glu	   and	   -­‐Glu	   conditions,	   around	   80%	   of	   FAO	  
contributed	  to	  the	  SRC	  of	  CD3-­‐stimulated	  CD4+	  TEM.	  In	  contrast,	  only	  about	  30%	  of	  
FAO	  contributed	  to	  the	  SRC	  of	  CD28SA-­‐stimulated	  cells	   in	  -­‐Glu	  while	  there	  was	  no	  
contribution	  of	  FAO	  to	  the	  SRC	  in	  the	  +Glu	  conditions	  (Figure	  4.4	  (a)).	  	  
IL-­‐2-­‐secreting	  CD8+	  effector	  memory	  T	  cells	  store	  exogenous	   long-­‐chain	  fatty	  acids	  
in	  lipid	  droplets	  which	  are	  then	  mobilized	  for	  mitochondrial	  FAO	  [122].	  In	  contrast,	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CD8+	  memory	   T	   cells	  were	   shown	   to	   use	   extracellular	   glucose	   to	   synthesise	   fatty	  
acids	  for	  neutral	  lipid	  stores	  [122],	  which	  then	  undergo	  lipolysis	  to	  supply	  fatty	  acids	  
for	   FAO	   as	  well	   as	   for	   incorporation	   into	   cellular	  membrane	   structures.	   The	   lipid	  
reserve	  of	  T	  cells	  is	  determined	  by	  the	  balance	  between	  lipogenesis	  and	  rate	  of	  FAO	  
[122].	  The	   low	  rate	  of	  FAO	   in	  CD28SA-­‐activated	  CD4+	  TEM	  suggested	  the	  possibility	  
that	   these	   cells	   are	   potentially	   increasing	   their	   lipid	   reserve.	   LipidTox	   staining	  
revealed	  that	  CD28SA	  stimulation	  (Figure	  4.4	  (b)	   (i))	   induces	  a	  significantly	  greater	  
accumulation	  of	  neutral	  lipids	  in	  CD4+	  TEM	  than	  when	  activated	  with	  anti-­‐CD3	  mAbs	  
(Figure	  4.4	  (b)	  (ii)).	  This	  was	  confirmed	  and	  quantified	  by	  flow	  cytometry	  (Figure	  4.4	  
(b)	  (iii)).	  	  
Lipogenesis	  requires	  the	  availability	  of	  acetyl-­‐CoA	  which	  is	  an	  essential	  substrate	  for	  
the	  endogenous	  biosynthesis	  of	  fatty	  acids.	  Increased	  glycolysis	  can	  shunt	  glucose-­‐
derived	   pyruvate	   into	   the	  mitochondria	   to	   be	   decarboxylated	   to	   acetyl-­‐CoA,	   and	  
then	  condensed	  with	  oxaloacetate	   to	   form	  citrate	   [136].	   	  Citrate	   is	   then	  exported	  
from	  the	  mitochondria	  via	  the	  malate-­‐citrate	  shuttle	  system	  and	  used	  as	  a	  substrate	  
for	   ATP-­‐citrate	   lyase	   (ACL)	   [137].	   We	   measured	   the	   acetyl-­‐CoA	   content	   and	  
demonstrate	   that	   total	   acetyl-­‐CoA	   levels	   were	   significantly	   higher	   in	   CD28SA-­‐
stimulated	   CD4+	   TEM	   than	   in	   CD3-­‐stimulated	   cells	   (Figure	   4.4	   (c)	   (i)).	   ACL	   is	   a	   key	  
cytosolic	   enzyme	   that	   catalyses	   the	   generation	   of	   acetyl-­‐coenzyme	   A	   (CoA)	   from	  
mitochondria-­‐derived	   citrate.	   Acetyl-­‐CoA	   is	   then	   carboxylated	   to	   malonyl-­‐CoA	   by	  
acetyl-­‐CoA	  carboxylase	  (ACC)	  which	  subsequently	  results	  in	  fatty	  acid	  synthesis.	  The	  
activity	  of	  ACL	  and	  ACC	  are	  increased	  by	  serine	  phosphorylation	  [138,	  139].	  	  
The	   increased	   lipogenesis	   in	   CD28SA-­‐stimulated	   cells	   is	   reflected	   by	   the	  
hyperactivity	   of	   the	   lipogenic	   enzymes,	   ACL	   and	   ACC	   as	   determined	   by	   their	  
phosphorylation	  status	  (Figure	  4.4	  (c)	  (ii)).	  CD28SA	  stimulation	  of	  T	  cells	  is	  known	  to	  
induce	  high	   IL-­‐2	  secretion	  [104].	  To	  rule	  out	  the	   influence	  of	  the	  CD28SA-­‐secreted	  
IL-­‐2	   on	   the	   de	   novo	   lipogenesis,	   we	   also	   activated	   CD4+	   TEM	   with	   anti-­‐CD3	   in	  
combination	   with	   IL-­‐2	   (aCD3+IL-­‐2),	   and	   with	   anti-­‐CD3	   in	   combination	   with	  
conventional	   anti-­‐CD28	   (aCD3+aCD28).	   Since	   ACC	   is	   the	   rate-­‐limiting	   enzyme	   in	  
regulating	  fatty	  acid	  synthesis	  [140],	  we	  measured	  its	  activity	  in	  these	  conditions.	  As	  
can	   be	   seen	   in	   the	   results,	   CD28SA-­‐stimulated	   cells	   had	   significantly	   greater	   ACC	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phosphorylation	  than	  any	  of	  the	  other	  conditions	  (Figure	  4.4	  (c)	  (iii)).	  This	  indicates	  
that	  the	  enhanced	  lipogenic	  program	  in	  CD28SA-­‐activated	  CD4+	  TEM	  is	  not	  secondary	  
to	  IL-­‐2	  effects.	  
ACL	  and	  ACC	  represent	  committed	  steps	  in	  channelling	  glucose-­‐derived	  metabolites	  
towards	  a	  lipid	  biosynthetic	  fate	  which	  is	  regulated	  by	  PI3K/Akt	  signalling	  [141].	  This	  
is	  consistent	  with	  the	  activation	  of	  the	  PI3K	  pathway	  by	  engagement	  of	  CD28	  by	  the	  
superagonistic	  mAb	  [16].	  The	  Acetyl	  CoA	  that	  feeds	  lipogenesis	  is	  primarily	  derived	  
from	  citrate	  [142].	  The	  citrate	  can	  be	  produced	  from	  glucose-­‐derived	  pyruvate	  that	  
enters	  the	  TCA	  cycle.	  A	  recent	  study	  has	  shown	  that	  in	  cancer	  cells,	  glutamine	  can	  
enter	   the	   TCA	   cycle	   and	   also	   become	   a	   source	   of	   citrate	   for	  de	   novo	   lipogenesis	  
through	  reductive	  carboxylation	  of	  glutamine-­‐derived	  α-­‐ketoglutarate	  (α-­‐KG)	  [143]	  
(Figure	   1.8).	   An	   elevated	   αKG/citrate	   ratio	  was	   shown	   to	   be	   the	   principal	   driving	  
force	  for	  reductive	  glutamine	  metabolism	  [143].	  We	  observed	  that	  CD3-­‐stimulated	  
CD4+	  TEM	  possessed	  a	  high	  relative	  αKG/citrate	  ratio	  of	  2.2±	  0.3,	  suggesting	  ongoing	  
reductive	   glutamine	   metabolism	   (Figure	   4.4	   (d)).	   In	   contrast,	   CD28SA-­‐stimulated	  
cells	   had	   a	   low	   relative	   α-­‐KG/citrate	   ratio	   of	   0.6±	   0.1	   indicative	   of	   an	   absence	   of	  
reductive	   carboxylation	   (Figure	   4.4	   (d)).	   Collectively,	   these	   results	   show	   that	  
CD28SA-­‐stimulated	  cells	  have	  a	  dominant	  program	  of	  endogenous	  biosynthesis	  of	  
fatty	   acids,	   which	   is	   not	   accompanied	   by	   preferential	   reductive	   glutamine	  
metabolism.	   Cancer	   cells	   display	   increased	   glycolytic	   flux	   where	   intermediate	  
metabolites	  are	  channelled	  towards	  acetyl-­‐CoA	  generation	  for	  use	  in	  de	  novo	  fatty	  
acid	  biosynthesis	  [144].	  We	  used	  a	  variety	  of	  different	  immortal	  cell	  lines	  to	  assess	  
the	  activity	  of	  ACL	  and	  ACC,	  markers	  of	  de	  novo	   lipogenesis.	  Figure	  4.5	  shows	  ACL	  
and	  ACC	  expression	  in	  liver	  hepatocellular	  cells	  (HepG2),	  HeLa	  cells,	  ovarian	  tumour	  
cell	   line	   A2780	   and	   the	   malignant	   melanoma	   cell	   line	   A375.	   Increased	   de	   novo	  
lipogenesis	  is	  a	  hallmark	  of	  cancer	  cells,	  and	  a	  high	  glucose-­‐to-­‐lipid	  flux	  is	  correlated	  
with	   increased	   proliferative	   capacity.	   Our	   results	   show	   that	   CD28SA	   stimulation	  
induces	   a	   similar	  metabolic	   phenotype,	  where	   increased	   glycolytic	   flux	   correlates	  
























Figure	  4.4:	  CD28SA	  activation	  induces	  de	  novo	  lipogenesis	  
(a) Oxygen	  consumption	   rates	   (OCR;	   pMoles/min)	   of	   pre-­‐activated	   human	   CD4+	   TEMs	   were	  
measured	  using	  the	  seahorse	  XF96	  extracellular	  flux	  analyser	  in	  real	  time,	  under	  basal	  conditions	  
and	  in	  response	  to	  sequential	  addition	  of	  Oligomycin	  (1	  µM),	  2,4-­‐DNP	  (160	  μM)	  and	  Antimycin	  A	  
&	  Rotenone	  (1	  µM).	  Etomoxir	  (200	  µM)	  or	  media	  was	  injected	  after	  2,4-­‐DNP	  injection.	  The	  SRC	  
(quantitative	  difference	  between	  maximal	  uncontrolled	  OCR	  [±	  etomoxir	  treatment]	  and	   initial	  
basal	  OCR)	  was	  calculated	  and	  presented	  as	   the	  percentage	  contribution	  of	  FAO	  to	  SRC	   in	  bar	  
charts.	  The	  bars	   represent	   the	  mean	  ±	  SD.	   	  The	  data	  are	   representative	  of	   three	   independent	  
experiments,	   (**	  denotes	   P-­‐value	   <	   0.01	   as	   calculated	  by	   an	  unpaired,	   two-­‐tailed	   Student’s	   t-­‐
test).	  	  	  
(b) Immunofluorescence	   images	   show	   (i)	   CD28SA-­‐	   and	   (ii)	   CD3-­‐stimulated	   CD4+	   TEM	   at	   48	   h	   post-­‐
activation	   stained	   with	   LipidTOX	   (green)	   and	   DAPI	   (blue);	   scale	   bars	   represent	   10	   μm.	   Far	  
bottom	   quadrant	   represents	   merged	   image	   of	   the	   two	   stains.	   (iii)	   LipidTOX	   staining	   was	  
quantified	   by	   flow	   cytometry.	   Data	   represent	   the	   mean	   percent	   of	   cells	   ±	   SD	   (n=3)	   staining	  
positive	  for	  neutral	  lipids.	  	  
(c) 	  (i)	  Relative	  levels	  of	  acetyl-­‐CoA	  in	  anti-­‐CD3-­‐	  and	  NIB1412-­‐stimulated	  human	  CD4+	  	  TEMs	  at	  48	  h	  
post-­‐activation;	  mean	  ±	  SD	  of	   triplicates	   (**P	   <	  0.01;	  unpaired	   two-­‐tailed	  Student’s	   t-­‐test).	   (ii)	  
Western	  blot	  analysis	  of	  p-­‐ACL	  (125kDa)	  and	  p-­‐ACC	  (250kDa),	  and	  (iii)	  p-­‐ACC	  with	  IL-­‐2	  condition,	  
in	  anti-­‐CD3-­‐	  and	  CD28SA-­‐stimulated	  CD4+	  TEM	  at	  48	  h	  post-­‐activation.	  Actin	  (45kDa)	  was	  used	  as	  
a	  loading	  control.	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(d) Alpha-­‐ketoglutarate-­‐to-­‐citrate	   ratio	   in	   CD3-­‐	   and	   CD28SA-­‐stimulated	   human	   CD4+	   TEM	   at	   48	   h	  
post-­‐activation,	  presented	  as	  bar	  charts.	  The	  bars	  represent	  the	  mean	  ±	  SD	  of	  triplicates	  (*P	  <	  
0.05;	  unpaired	  two-­‐tailed	  Student’s	  t-­‐test).	  




Figure	  4.5:	  Immortalized	  cell	  lines	  display	  markers	  for	  de	  novo	  lipogenesis	  
Western	  blot	   analysis	   of	   p-­‐ACC	   (250kDa)	   and	  p-­‐ACL	   (125kDa)	   in	   liver	   hepatocellular	   cells	   (HepG2),	  
human	  cervical	   cancer	   cells	   (HeLa),	  human	  ovarian	   tumour	  cell	   line	   (A2780)	  and	  human	  malignant	  
melanoma	  cell	  line	  (A375).	  Actin	  (45kDa)	  was	  used	  as	  a	  loading	  control.	  
	  
We	   also	   analysed	   the	   autophagy	   protein	   LC3	   to	   reveal	   the	   autophagic	   activity	   in	  
CD28SA-­‐stimulated	   cells.	   	   As	   shown	   in	   figure	   4.6,	   NIB1412-­‐stimulated	   TEMS	   had	  






Figure	  4.6:	  CD28SA	  activation	  induces	  autophagy	  	  
Western	  blot	  analysis	  of	  endogenous	  LC3	  expression	  from	  human	  CD4+	  TEMS	  activated	  with	  anti-­‐CD3	  
mAbs	  or	  NIB1412.	  The	  modification	  of	  LC3-­‐I	  (18kDa)	  to	  LC3-­‐II	  (16kDa)	  indicates	  autophagic	  activity.	  
























4.4. Discussion	  	  
Immunostimulatory	   mAbs	   are	   common	   in	   clinical	   trials	   as	   a	   strategy	   to	   increase	  
immune	   responses.	   The	   dramatic	   immunostimulatory	   activity	   comes	   with	   side	  
effects	   such	   as	   the	   induction	   of	   pro-­‐inflammatory	   mediators	   and	   organ-­‐specific	  
autoimmunity.	   Recognising	   metabolic	   patterns	   in	   immune	   cells	   treated	   with	  
therapeutic	  mAbs	  could	  serve	  as	  novel	  biomarkers	  of	  hazard.	  For	  example,	  aberrant	  
nutrient	  uptake	  and	  utilization,	   together	  with	   increased	  de	  novo	   lipid	  biosynthesis	  
could	  lead	  to	  dysregulated	  immune	  cell	  number	  and	  function.	  
Hyperactive	   cells	   such	   as	   cancer	   cells	   are	   known	   to	   undergo	   a	   metabolic	   shift	  
towards	   glycolysis	   and	   pronounced	   increase	   in	   de	   novo	   lipid	   biosynthesis,	   to	  
promote	  rapid	  cell	  proliferation	  and	  migration.	  Accumulated	  neutral	  lipid	  stores	  are	  
then	  mobilized	  to	  provide	  free	  fatty	  acids	  to	  promote	  production	  of	  signalling	  lipids,	  
for	   incorporation	   into	   cellular	   membranes	   or	   for	   the	   production	   of	   ATP	   via	   β-­‐
oxidation	   [145].	   Prior	   to	   activation,	   idle	   T	   cells	   have	   low	  metabolic	   requirements	  
and	   rely	   on	  mitochondrial	   oxidative	   pathways	   for	   basal	   energy	   generation.	   Upon	  
activation	  T	  cells	  adopt	  a	  metabolic	  profile	  typified	  by	  aerobic	  glycolysis	  and	  basal	  
OXPHOS.	  T	  cells	  use	  distinct	  metabolic	  programs	  according	   to	   their	  differentiation	  
state	   and	   immunological	   role.	   Studies	  have	   shown	   that	  CD4+	   T	  helper	   (Th)	   1,	   Th2	  
and	   Th17	   cells	   are	   highly	   glycolytic,	   while	   CD4+	   regulatory	   T	   cells	   have	   high	   lipid	  
oxidation	   rates	   [123].	   The	  metabolic	   program	   of	   CD4+	   effector	  memory	   T	   cells	   is	  
unknown.	  Here	  we	  show	  the	  bioenergetic	  profile	  adopted	  by	  TEMs	  that	  have	  been	  
activated	   via	   the	   conventional	   TCR/CD3	   pathway	   and	   through	   maximal	   CD28	  
stimulation	  using	  a	  CD28SA.	  
Previous	   studies	   have	   shown	   that	   IL-­‐2	   secreting	   CD8+	   TEMs	   store	   exogenously	  
derived	   fatty	   acids,	   while	   CD8+	   memory	   T	   cells	   use	   extracellular	   glucose	   for	   the	  
endogenous	   biosynthesis	   of	   fatty	   acids	   to	   support	   mitochondrial	   FAO	   [122].	  
Although	  the	  dynamics	  of	  fatty	  acid	  utilization	  for	  FAO	  hasn’t	  been	  shown	  in	  CD4+	  T	  
cells,	   in	   this	   report	   we	   propose	   that	   CD28SA	   stimulation	   enables	   CD4+	   TEMs	   to	  
maximize	  glucose	  utilization	  and	  promote	  endogenous	  biosynthesis	  of	   fatty	   acids.	  
The	   increased	   lipogenesis	   in	   CD28SA-­‐stimulated	   cells	   is	   reflected	   by	   the	  
hyperactivity	  of	  the	  lipogenic	  enzymes,	  ATP	  citrate	  lyase	  and	  acetyl-­‐CoA	  carboxylase	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(figure	  4.4	  (c)).	  In	  contrast	  to	  anti-­‐CD3-­‐stimulated	  cells,	  CD28SA-­‐stimulated	  cells	  had	  
accumulated	   intracellular	   levels	   of	   neutral	   lipids	   (figure	   4.4	   (b)	   iii)	   which	   further	  
support	   the	  CD28SA-­‐induced	  exacerbated	   endogenous	  biosynthesis	   of	   fatty	   acids.	  
De	  novo	  fatty	  acid	  biosynthesis	  is	  not	  only	  required	  to	  synthesize	  new	  membranes	  
for	  cell	  proliferation	  but	  also	  to	   facilitate	  the	  formation	  of	   lipid	  rafts	   for	   increased	  
signalling	  of	  cell	   surface	  receptors	  associated	  with	  pro-­‐stimulation	   [144].	  This	   is	   in	  
agreement	   with	   our	   previous	   report	   [121]	   where	   we	   showed	   an	   upregulation	   of	  
pro-­‐stimulatory	  receptors	  on	  CD28SA-­‐stimulated	  cells.	  	  
The	   irreversible	   injury	   of	   respiration	   in	   normal	   cells	   gives	   rise	   to	   the	   malignant	  
transformation	   towards	   a	   cancer	   phenotype.	   Cancer	   cells	   display	   an	   altered	  
metabolism	  characterised	  by	  increased	  rates	  of	  intracellular	  glucose	  import,	  higher	  
rate	  of	   glycolysis	   associated	  with	   reduced	  pyruvate	  oxidation	   and	   increased	   lactic	  
acid	  production.	  A	  key	  distinguishing	   feature	  of	  cancer	  cell	  metabolism	   is	   reduced	  
fatty	   acid	   oxidation	   and	   increased	  de	   novo	   fatty	   acid	   synthesis	   [146],	   to	   promote	  
rapid	   cell	   proliferation	   and	   migration	   [147].	   Although	   the	   dynamics	   of	   fatty	   acid	  
utilization	   for	  FAO	  hasn’t	  been	  shown	   in	  CD4+	  TEM,	   in	   this	   report	  we	  propose	   that	  
CD28SA	  stimulation	  enables	  CD4+	  TEM	  to	  maximize	  glucose	  utilization	  and	  promote	  
endogenous	  biosynthesis	  of	  fatty	  acids.	  	  
A	   common	   component	   of	   the	   cancer	   phenotype	   is	   adaptation	   to	   hypoxia,	   which	  
requires	   increased	   glycolysis.	   Furthermore,	   poor	   prognosis,	   increased	   tumour	  
aggressiveness	  and	  invasiveness	  are	  correlated	  with	  increased	  glucose	  uptake	  [148].	  
ACL	   and	   ACC	   expression	   in	   liver	   hepatocellular	   cells	   (HepG2),	   HeLa	   cells,	   ovarian	  
tumour	   cell	   line	   A2780	   and	   the	   malignant	   melanoma	   cell	   line	   A375	   were	   also	  
determined.	  Increased	  de	  novo	  lipogenesis	  is	  a	  hallmark	  of	  cancer	  cells,	  and	  a	  high	  
glucose-­‐to-­‐lipid	  flux	  is	  correlated	  with	  increased	  tumour	  aggressiveness.	  ACL	  is	  the	  
regulator	   of	   the	   key	   step	   that	   converts	   high	   glycolytic	   flux	   into	   increased	   lipid	  
synthesis,	   required	   for	   membrane	   production	   during	   cell	   proliferation	   [149].	   The	  
glycolytic	   phenotype	   together	   with	   upregulated	   ACL	   activity	   thus	   confers	   a	  
significant	   proliferative	   advantage	   to	   cancer	   cells.	   The	  elevated	  expression	  of	  ACL	  
and	  ACC	   in	  CD28SA-­‐activated	  T	   cells	   corresponds	  with	   their	   elevated	  proliferative	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capacity	   and	   increased	  migration/tissue	   invasion;	   characteristics	   shared	  by	   cancer	  
cells.	  	  
Autophagy	   is	   a	   cellular	   degradation	   pathway	   for	   the	   clearance	   of	   damaged	   or	  
redundant	   proteins	   and	   organelles.	   The	   degradation	   products	   of	   the	   recycled	  
intracellular	  constituents	  can	  be	  funnelled	  into	  biosynthetic	  pathways	  or	  used	  as	  an	  
alternative	  energy	  source	  to	  maintain	  cell	  viability.	  Rapidly	  proliferating	  cancer	  cells	  
have	  high	  metabolic	  demands	  and	  heavily	  rely	  on	  autophagy	  to	  supply	  biosynthetic	  
metabolites	   [150].	   Here,	   we	   show	   that	   CD28SA-­‐activated	   T	   cells	   display	   high	  
expression	   of	   the	   autophagy	   marker	   LC3-­‐II.	   Thus,	   autophagy	   significantly	  
contributes	  to	  the	  high	  metabolic	  demands	  of	  CD28SA-­‐activated	  T	  cells.	  
A	   significantly	   higher	  mitochondrial	  mass	   and	  mitoROS	  was	   observed	   in	   CD28SA-­‐
stimulated	   cells	   compared	   to	   anti-­‐CD3	   stimulated	   cells.	   MitoROS	   production	   is	  
regulated	   by	   mitochondrial	   membrane	   potential	   (Δψm),	   metabolic	   state	   of	  
mitochondria	   and	   O2	   concentration[151].	   The	   mitochondrial	   mass	   itself	   is	   not	  
positively	   correlated	  with	  mitoROS	  as	  mitochondrial	   biogenesis	   also	   increases	   the	  
expression	  of	  several	  antioxidant	  enzymes	  [152].	  Mitochondrial	  mass	  and	  Δψm	  are	  
known	  to	  be	  significantly	  increased	  in	  cells	  during	  cell	  cycle,	  particularly	  when	  they	  
are	  at	  the	  S	  phase	  [153]	  and	  we	  have	  shown	  in	  a	  previous	  study	  [121]	  that	  a	  high	  
proportion	  of	  CD28SA-­‐stimulated	  cells	  are	   in	  S-­‐phase	  at	  48hrs	  post-­‐activation	  and	  
onwards.	  Thus,	  the	  elevated	  mitochondrial	  mass	  and	  mitoROS	  might	  be	  due	  to	  the	  
rapid	  cell	  proliferation	  induced	  by	  CD28SA	  activation. 	  Studies	  have	  shown	  that	  an	  
increase	   in	   mitochondrial	   mass	   results	   in	   an	   increase	   in	   overall	   mitochondrial	  
function,	  with	  a	  boost	   in	  residual	  OXPHOS	  capacity	  and	  an	   increase	   in	  overall	  ATP	  
generating	  capacity	  [154,	  155].	  This	  concurs	  with	  the	  results	  shown	  in	  figure	  4.2	  (a);	  
elevated	   mitochondrial	   mass	   coincides	   with	   high	   basal	   respiration	   and	   high	   ATP	  
production	  in	  CD28SA-­‐stimulated	  T	  cells.	  
In	   summary,	   we	   have	   shown	   that	   CD28SA	   activation	   induces	   a	   T	   cell	   metabolic	  
program	   that	   is	   geared	   towards	   maximal	   glucose	   utilization,	   endogenous	   lipid	  
synthesis	  and	  less	  dependency	  on	  OXPHOS.	  We	  have	  also	  defined	  ACL	  and	  ACC	  as	  
the	   molecular	   components	   that	   enable	   this	   metabolic	   program	   to	   operate.	   Our	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study	  provides	  insights	  into	  the	  remarkable	  capacity	  of	  T	  cells	  to	  adopt	  a	  variety	  of	  
distinct	  metabolic	  programming	  depending	  on	  the	  pathways	  that	  are	  engaged.	  Our	  
results	  may	  also	  have	  implications	  and	  utility	  in	  drug	  development	  as	  dysregulated	  
metabolic	  patterns	   in	   immune	  cells	   treated	  with	   therapeutic	  mAbs	  could	   serve	  as	  
novel	   biomarkers	   of	   hazard	   or	   risk	   identification.	   For	   example,	   aberrant	   nutrient	  
uptake	  and	  utilization,	  together	  with	  increased	  de	  novo	   lipid	  biosynthesis	  could	  be	  
indicative	   of	   excessive	   immunostimulatory	   potential	   of	   the	   therapeutic	   mAb.	  
Metabolic	  studies	  that	  compare	  a	  number	  of	  immunostimulatory	  therapeutic	  mAbs	  
are	  required	  to	  examine	  this	  further.	  	  
Overall,	  metabolic	  patterns	  are	  important	  in	  determining	  the	  functional	  potential	  of	  
effector	   T	   cells.	   Here	   we	   have	   looked	   at	   a	   potent	   immune	   stimulant	   and	   the	  
resulting	  metabolic	   program	   adopted	   by	   effector	  memory	   CD4+	   T	   cells.	   The	   next	  
chapter	  looks	  at	  functional	  output	  and	  metabolic	  profiles	  of	  TCR-­‐activated	  cytotoxic	  
CD8+	  T	  cells	  that	  have	  suffered	  inhibition	  by	  a	  potent	  immune	  suppressant;	  TGF-­‐β.	  
We	  also	  examine	  whether	  a	  mitochondria	  localised	  antioxidant	  can	  rescue	  the	  TGF-­‐
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5. Defining	   the	   role	   of	   oxidative	   stress	   in	   TGF-­‐β-­‐
associated	   functional	  and	  metabolic	  alterations	   in	  
T	  cells	  	  
	  
5.1. Abstract	  	  
TGF-­‐β	  has	  profound	  inhibitory	  effects	  on	  the	  immune	  system	  by	  directly	  inhibiting	  T	  
cell	   proliferation	   and	   activation.	   Here	   we	   investigate	   the	   effects	   of	   the	  
mitochondrial	   ROS	   scavenger	   Tiron	   in	   mouse	   transgenic	   F5-­‐TCR	   CD8+	   T	   cells	  
activated	  in	  the	  presence	  of	  TGF-­‐β.	  T	  cells	  stimulated	  with	  NP68	  in	  the	  presence	  of	  
Tiron	   had	   significantly	   greater	  mitochondrial	   respiration	   and	   glycolysis.	   Upon	   TCR	  
re-­‐stimulation,	  T	  cells	  activated	  with	  NP68	  in	  the	  presence	  of	  Tiron	  had	  significantly	  
higher	  IFN-­‐γ	  and	  IL-­‐2	  production.	  We	  demonstrate	  that	  Tiron	  neutralizes	  the	  TGF-­‐β-­‐
mediated	  suppressive	  effects	  and	  restores	  CD8+	  effector	  functions.	  We	  propose	  that	  
immunotherapies	  targeted	  to	  counteract	  the	  immunosuppressive	  effects	  of	  tumor-­‐
derived	  TGF-­‐β	  could	  be	  supplemented	  with	  antioxidants	  to	  help	  restore	  CD8+	  T	  cell-­‐
mediated	  tumor	  eradication.	  
5.2. Introduction	  	  
The	  majority	  of	  immunomodulatory	  mAbs	  are	  aimed	  at	  enhancing	  the	  anti-­‐tumour	  
effects	  of	  T	   cells	  but	   fail	   in	   light	  of	   tumour-­‐derived	  TGF-­‐β,	   an	   immunosuppressive	  
cytokine	   that	   effectively	   inhibits	   the	   generation	   of	   a	   cytotoxic	   T	   cell	   response.	  
Interfering	   with	   TGF-­‐β-­‐induced	   immune	   suppressive	   mechanisms	   could	   maximise	  
the	   therapeutic	  effectiveness	  of	   immunomodulatory	  mAbs	   in	  eliciting	  anti-­‐tumour	  
activity.	   Tumour	   cells	   utilize	   a	   number	   of	   immune	   evasion	   strategies	   that	   take	  
advantage	  of	  the	  LAG-­‐3,	  TGF-­‐β,	  and	  cell-­‐intrinsic	  PD-­‐1	  inhibitory	  pathway	  of	  T	  cells.	  
Tumour	  cells	  express	  the	  ligands	  to	  the	  inhibitory	  receptors	  expressed	  on	  T	  cells	  and	  
evade	  elimination	  by	   the	   immune	  system.	  Tumour	  cells	   secrete	  TGF-­‐β	   to	  enhance	  
metastagenicity	   while	   inhibiting	   cytotoxic	   T	   cell-­‐mediated	   immune	   responses	   [7].	  
TGF-­‐β	  has	  profound	  inhibitory	  effects	  on	  the	  immune	  system	  by	  directly	  inhibiting	  T	  
cell	  proliferation	  and	  activation.	  The	  significance	  of	  TGF-­‐β	  is	  reflected	  in	  TGF-­‐	  β	  null	  
mice	   which	   present	   lymphocyte-­‐mediated	   multifocal	   inflammation	   [156].	   TGF-­‐β	  
exerts	   its	   functional	   effects	   by	   inducing	   prolonged	   generation	   of	   reactive	   oxygen	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species	  (ROS)	  and	  persistent	  disruption	  of	  mitochondrial	  membrane	  potential	  [157].	  
In	   addition,	   TGF-­‐β	   suppresses	   the	   transcriptional	   activity	   of	   the	   genes	   related	   to	  
mitochondrial	  biogenesis	  and	  function	  [158].	  
The	  redox	  status	  of	  a	  cell	  can	  regulate	  various	  responses	  ranging	  from	  proliferation	  
and	  activation,	  to	  cell	  death.	  Although	  there	  are	  multiple	  sources	  of	  reactive	  oxygen	  
species	  (ROS)	  in	  the	  cell,	  mitochondrial	  metabolism	  represents	  the	  major	  source	  of	  
ROS	  production	  and	  it	  has	  been	  recently	  shown	  that	  mitochondrial	  ROS	  (mitoROS)	  
directly	   stimulate	   the	   production	   of	   proinflammatory	   cytokines	   via	   distinct	  
molecular	   pathways	   [159].	   ROS	   are	   thought	   to	   modulate	   T	   cell	   reactivity	   by	  
enhancing	   and	   prolonging	   the	   antigen	   specific	   proliferative	   response	   in	   T	   cells.	  
Optimal	   ROS	   levels	   are	   required	   for	   proper	   T	   cell	   activation	   and	   are	   important	   in	  
determining	  T	  cell	  fate	  [160].	  Low	  ROS	  levels	  leads	  to	  improper	  TCR	  stimulation	  with	  
low	   activation	   and	   proliferation,	   whereas	   high	   ROS	   levels	   can	   lead	   to	   increased	  
apoptosis	  due	  DNA	  damage	  and	  activation	  of	  p53	  induced-­‐genes.	  Depending	  on	  the	  
redox	  state,	  ROS	  production	  can	  switch	  T	  cells	   towards	  a	  more	  hyporesponsive	  or	  
proliferative	   phenotype.	   	   Persistent	   and	   prolonged	   ROS	   production	   can	   lead	   to	  
oxidative	  stress	  and	  is	  thought	  to	  play	  an	  important	  role	  in	  the	  hyporesponsiveness	  
of	   T	   cells	   in	   various	   inflammatory	   conditions	   [161].	   In	   contrast,	   ROS	   production	  
shortly	   after	   TCR	   engagement	   in	   resting	   T	   cells	   can	   act	   as	   an	   amplifier	   of	   Ca2+-­‐
dependent	   steps	   in	   T	   cell	   activation	   and	   is	   essential	   for	   activation-­‐induced	   IL-­‐2	  
secretion	   [162].	   Mammalian	   cells	   have	   a	   number	   of	   antioxidant	   enzymes	   to	  
scavenge	  mitoROS.	  The	  SOD	  family	  of	  antioxidant	  enzymes	  catalyse	  the	  dismutation	  
of	   O2.-­‐	   to	   H2O2,	   which	   is	   then	   quickly	   reduced	   to	   water	   by	   two	   other	   enzymes,	  
catalase	  and	  glutathione	  peroxidase	  (GPx)	  [151].	  	  
Since	   TGF-­‐β	   deregulates	   cellular	   redox	   state	   and	   appears	   to	   inhibit	  mitochondrial	  
respiration	   and	   ATP	   synthesis,	   we	   focused	   our	   attention	   on	   the	   mitochondria-­‐
localized	   synthetic	   ROS	   scavenger	   Tiron	   (Sodium	   4,5-­‐dihydroxybenzene-­‐1,3-­‐
disulfonate),	   to	   determine	   whether	   this	   antioxidant	   can	   rescue	   the	   suppressive	  
effects	  of	  TGF-­‐β	  on	  TCR-­‐activated	  T	  cells.	  The	  present	  study	  evaluates	  the	  effect	  of	  
Tiron	   on	   T	   cell	   metabolism,	   LAG-­‐3	   and	   IL-­‐2R	   (CD25)	   receptor	   expression	   and	   its	  
effects	   on	   TCR	   re-­‐stimulation-­‐induced	   T	   cell	   proliferation	   and,	   IL-­‐2	   and	   IFNγ	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production.	  To	  induce	  antigen-­‐specific	  T	  cell	  activation	  we	  utilized	  a	  TCR	  transgenic	  
mouse	   model	   wherein	   the	   TCR	   (F5-­‐TCR)	   of	   the	   CD8+	   T	   cells	   can	   specifically	   be	  
activated	  by	  an	  antigenic	  peptide,	  NP68.	  
5.3. Results	  	  
5.3.1. TGF-­‐β	  reduces	  TCR-­‐induced	  LAG-­‐3	  and	  CD25	  expression	  
and	  inhibits	  T	  cell	  proliferation	  	  
To	  assess	  the	  effect	  of	  TGF-­‐β	  on	  the	  proliferative	  ability	  of	  mouse	  F5	  lymphocytes,	  
we	   stimulated	   T	   cells	   with	   various	   concentrations	   of	   NP68	   in	   the	   presence	   or	  
absence	  of	  TGF-­‐β.	  TGF-­‐β	  significantly	  (p<0.01)	  reduced	  TCR-­‐induced	  proliferation	  at	  
all	  concentrations	  of	  NP68	  (figure	  5.1).	  
	  
	  
Figure	  5.1:	  TGF-­‐β	  suppresses	  TCR-­‐stimulated	  T	  cell	  proliferation	  
Mouse	  F5	  CD8	  T	  cells	  were	  stimulated	  with	  the	  indicated	  concentrations	  of	  antigenic	  peptide	  NP68	  
and	   proliferation	  was	  measured	   three	   days	   post-­‐activation	   by	  3H-­‐labeled	   thymidine	   incorporation.	  
The	  vertical	  axis	  represents	  mean	  cpm	  ±	  SD	  from	  triplicate	  wells.	  The	  data	  are	  representative	  of	  four	  
independent	  experiments,	  (**p	  <	  0.01;	  unpaired	  t-­‐test).	  
	  
Upon	  T	  cell	  stimulation,	  expression	  of	  cell	  surface	  receptors	  indicates	  differentiation	  
of	  the	  naive	  CD8+	  T	  cell	  population	  into	  activated	  CTLs.	  Cytokines	  play	  a	  vital	  role	  in	  
maintaining	   the	   homeostasis	   of	   CD8+	   T	   cells.	   In	   order	   to	   assess	   whether	   TGF-­‐β	  
influences	   the	   expression	   of	   surface	   receptors,	   we	   assessed	   the	   expression	   of	   a	  
range	   of	   stimulatory	   (CD25,	   CD137	   and	   CD69)	   and	   inhibitory	   (LAG-­‐3,	   PD-­‐1,	   BTLA,	  
TIM-­‐3	   and	   TIGIT)	   receptors	   on	   CD8+	   T	   cells	   activated	   with	   a	   range	   of	   NP68	  
107	  
	  
concentrations	  (0	  to	  1μM)	  in	  the	  presence	  or	  absence	  of	  TGF-­‐β	  by	  flow	  cytometry.	  
TGF-­‐β	  was	  found	  to	  only	  influence	  the	  expression	  of	  CD25	  and	  LAG-­‐3	  receptors	  on	  T	  
cells	   activated	   with	   1nM	   NP68	   (figure	   5.2).	   NP68	   at	   1nM	   was	   shown	   to	   be	   the	  




Figure	  5.2:	  TGF-­‐β	  significantly	  reduces	  LAG-­‐3	  and	  CD25	  expression	  on	  TCR-­‐stimulated	  T	  cells	  
Mouse	  F5	  CD8	  T	  cells	  were	  stimulated	  with	  1nM	  of	  antigenic	  peptide	  NP68.	  Cells	  were	  harvested	  at	  
72hours	  post-­‐activation	  and	  stained	  with	  fluorochrome-­‐conjugated	  anti-­‐CD8	  and	  anti-­‐LAG-­‐3	  or	  anti-­‐
CD25	   antibodies	   followed	   by	   flow	   cytometric	   analysis.	   The	   mean	   percent	   of	   CD8+	   cells	   staining	  
positive	   for	   LAG-­‐3	  or	  CD25	  are	  presented	   in	  a	  bar	   graph.	  The	  bars	   represent	   the	  mean±	  SD	   (n=3).	  
(**p<	  0.01;	  unpaired	  ttest)	  
	  
In	  addition	  to	  TGF-­‐β,	  the	  influence	  of	  IL-­‐6	  and	  IL-­‐23,	  cytokines	  that	  promote	  tumor	  
growth,	   and	   the	   influence	   of	   IL-­‐2,	   a	   cytokine	   that	  mediates	   tumor	   regression,	   on	  
CD25	  and	  LAG-­‐3	  receptor	  expression	  was	  also	  examined	  (figure	  5.3).	   IL-­‐6	  has	  both	  
108	  
	  
pro-­‐inflammatory	   and	   anti-­‐inflammatory	   properties	   while	   IL-­‐23	   is	   thought	   to	   be	  




Figure	  5.3:	  Influence	  of	  other	  cytokines	  on	  LAG-­‐3	  and	  CD25	  expression	  	  
Mouse	  F5	  CD8	  T	  cells	  were	  stimulated	  with	  1nM	  of	  antigenic	  peptide	  NP68	  in	  the	  presence	  of	  IL-­‐2,	  IL-­‐
6,	   IL-­‐23	  or	  TGF-­‐β.	  Cells	  were	  harvested	  at	  72hours	  post-­‐activation	  and	   stained	  with	   fluorochrome-­‐
conjugated	   anti-­‐CD8	   and	   anti-­‐LAG-­‐3	   or	   anti-­‐CD25	   antibodies	   followed	  by	   flow	   cytometric	   analysis.	  
Populations	  of	  cells	  are	  shown	   in	  each	  quadrant	  as	  percentages	  of	   total	  T	  cells	   staining	  positive	  or	  
negative	  for	  the	  respective	  markers.	  Results	  are	  representative	  of	  four	  independent	  experiments.	  
	  
Since	   TGF-­‐β	   reduces	   LAG-­‐3	   receptor	   expression	   on	   activated	   CD8+	   T	   cell,	   we	  
assessed	  whether	   the	   functional	   output	  was	   also	   affected.	   Our	   results	   show	   that	  
IFN-­‐γ	  secretion	  of	  T	  cells	  that	  were	  stimulated	  with	  NP68	  in	  the	  presence	  of	  TGF-­‐β	  
was	  reduced	  when	  re-­‐stimulated	  at	  72hours	  with	  NP68-­‐pulsed	  dendritic	  cells	  (DCs)	  
in	   the	   presence	   of	   LAG-­‐3	   blockade	   (figure	   5.4).	   We	   used	   matured	   DC	   for	   re-­‐




Figure	  5.4:	  TGF-­‐β	  experienced	  T	  cells	  are	  less	  responsive	  to	  LAG-­‐3	  blocking	  
Matured	  mouse	  dendritic	  cells	  were	  pulsed	  with	  1nM	  of	  antigenic	  peptide	  NP68	  and	  incubated	  with	  
F5	   CD8	   T	   cells	   in	   a	   DC:	   T	   cell	   ratio	   of	   1:20	   for	   12hours.	   The	   figure	   shows	   the	   results	   of	   the	   IFN-­‐γ	  
specific	  ELISpot	  assays	  (triplicate	  means±	  SD;	  **p<	  0.01;	  unpaired	  ttest)	  
	  
To	   test	  whether	  CD25	  and	   LAG-­‐3	  are	   functionally	   important,	   a	   T	   cell	   proliferation	  
assay	   with	   IL-­‐2	   supplementation	   or	   LAG-­‐3	   blockade	   was	   done	   (figure	   5.5).	   The	  
binding	   of	   IL-­‐2	   to	   CD25	   enhances	   proliferation	   while	   addition	   of	   LAG-­‐3	   blocking	  
antibody	  also	  increases	  proliferation.	  This	  shows	  that	  CD25	  expression	  is	  important	  
for	   IL-­‐2-­‐mediated	   survival	   while	   LAG-­‐3	   expression	   inhibits	   proliferation	   under	  




Figure	  5.5:	  IL-­‐2	  supplementation	  or	  LAG-­‐3	  blockade	  increases	  T	  cell	  proliferation	  	  
Mature	   DCs	   were	   pulsed	   with	   increasing	   concentrations	   of	   NP68	   antigenic	   peptide	   and	   then	   co-­‐
cultured	  with	   F5	   CD8	   T	   cells	   for	   72	   h.	   3H-­‐labeled	   thymidine	   (3H-­‐Thy)	  was	   added	   for	   the	   last	   16	   h.	  
Proliferation	   of	   T	   cells	   was	   determined	   by	   scintillation	   counting	   of	   incorporated	   3H-­‐Thy.	   Data	   are	  
presented	  as	  mean	  3H-­‐Thy	  scintillation	  counts	  ±	  S.D.	  (*p<	  0.05;	  **p<	  0.01;	  unpaired	  ttest)	  
	  
5.3.2. MitoROS	  scavenger	  increases	  TGF-­‐β-­‐induced	  reduction	  in	  
LAG-­‐3	  and	  CD25	  expression	  	  
We	  next	   investigated	  whether	  we	   could	   rescue	   the	   reduction	   in	   LAG-­‐3	   and	   CD25	  
expression	   on	   NP68-­‐activated	   T	   cells	   that	   suffered	   inhibition	   by	   TGF-­‐β	   with	   the	  
mitochondrial	  ROS	  scavenger	  Tiron	  (added	  24hrs	  after	  T	  cell	  activation	  as	  mitoROS	  
produced	   upon	   TCR	   stimulation	   is	   essential	   for	   T	   cell	   expansion	   [164]).	   The	  
population	   of	   T	   cells	   stimulated	   with	   1nM	   NP68	   in	   the	   presence	   of	   Tiron	   had	  
significantly	  (p<0.01)	  higher	  LAG-­‐3	  and	  CD25	  expression	  than	  T	  cells	  stimulated	  with	  
NP68	  only	  at	  72	  hours	  (figure	  5.6).	  Furthermore,	  Tiron	  countered	  the	  TGF-­‐β-­‐induced	  




Figure	  5.6:	  Tiron	  supplementation	  increases	  LAG-­‐3	  and	  CD25	  expression	  on	  TCR-­‐stimulated	  T	  cells	  
Mouse	  F5	  CD8	  T	  cells	  were	  stimulated	  with	  1nM	  NP68	  ±	  TGFβ	  (5ng/ml)	  ±	  Tiron	  (250μM).	  Cells	  were	  
harvested	  at	  72hours	  post-­‐activation	  and	  stained	  with	  fluorochrome-­‐conjugated	  anti-­‐CD8	  and	  anti-­‐
LAG-­‐3	  or	  anti-­‐CD25	  antibodies	  followed	  by	  flow	  cytometric	  analysis.	  The	  mean	  percent	  of	  CD8+	  cells	  
staining	  positive	  for	  LAG-­‐3	  or	  CD25	  are	  presented	  in	  a	  bar	  graph.	  The	  bars	  represent	  the	  mean±	  SD	  
(n=3).	  (**p<	  0.01;	  unpaired	  ttest)	  
	  
5.3.3. MitoROS	  scavenger	  increases	  T	  cell	  proliferation	  of	  TGF-­‐β-­‐
experienced	  T	  cells	  upon	  TCR	  re-­‐stimulation	  	  
We	   investigated	  whether	  we	   could	   rescue	   the	   reduction	   in	  proliferation	  of	  NP68-­‐
activated	   T	   cells	   that	   suffered	   inhibition	   by	   TGF-­‐β	   with	   the	   mitochondrial	   ROS	  
scavenger	  Tiron.	  Since	  TGF-­‐β	  reduces	  the	  surface	  expression	  of	  CD25	  and	  LAG-­‐3	  on	  
T	   cells,	   we	   also	   examined	   whether	   the	   Tiron-­‐induced	   rescue	   of	   CD25	   and	   LAG-­‐3	  
expression	   has	   an	   influence	   on	   T	   cell	   proliferation	   when	   re-­‐stimulated	   in	   the	  
presence	  of	  IL-­‐2	  or	  LAG-­‐3	  blocking	  antibodies.	  T	  cells	  were	  initially	  stimulated	  with	  
1nM	  NP68	  ±	   TGFβ	   (5ng/ml)	   ±	   Tiron	   (250μM)	   for	   72hours.	  At	   the	  end	  of	   the	   time	  
point	   cells	   were	   re-­‐stimulated	   with	   1nM	   NP68	   with	   either	   IL-­‐2	   (250	   units/ml)	   or	  
LAG-­‐3	  blocking	  antibody	  (5μg/ml).	  T	  cells	  stimulated	  with	  NP68	   in	  the	  presence	  of	  
Tiron	   had	   significantly	   greater	   (p<0.01)	   proliferation	   at	   re-­‐stimulation	   than	   T	   cells	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stimulated	   with	   NP68	   only.	   Furthermore,	   Tiron	   countered	   the	   TGF-­‐β-­‐induced	  
reduction	   in	   T	   cell	   proliferation.	   The	   presence	   of	   IL-­‐2	   at	   re-­‐stimulation	   had	   a	  
significant	  (p<0.01)	  impact	  on	  T	  cell	  proliferation	  in	  all	  conditions	  (figure	  5.7).	  T	  cells	  
that	  were	  initially	  stimulated	  with	  NP68	  ±	  TGF-­‐β	  were	  unaffected	  by	  LAG-­‐3	  blocking	  
antibodies.	   The	   presence	   of	   Tiron	   at	   initial	   stimulation	   lead	   to	   higher	   T	   cell	  
proliferation	  upon	  re-­‐stimulation	  in	  the	  presence	  of	  LAG-­‐3	  blockade	  (figure	  5.7).	  
	  
	  
Figure	  5.7:	  Tiron	  supplementation	  increases	  T	  cell	  proliferation	  on	  TCR	  re-­‐stimulation	  
Mouse	  F5	  CD8	  T	  cells	  were	  stimulated	  with	  1nM	  NP68	  ±	  TGFβ	  (5ng/ml)	  ±	  Tiron	  (250μM)	  for	  72hours	  
and	  then	  re-­‐stimulated	  with	  1nM	  NP68	  in	  the	  presence	  of	  IL-­‐2	  or	  anti-­‐LAG-­‐3	  for	  72hours.	  3H-­‐labeled	  
thymidine	   (3H-­‐Thy)	   was	   added	   for	   the	   last	   16	   h.	   Proliferation	   of	   T	   cells	   was	   determined	   by	  
scintillation	  counting	  of	  incorporated	  3H-­‐Thy.	  Data	  are	  presented	  as	  mean	  3H-­‐Thy	  scintillation	  counts	  
±	  S.D.	  (*p<	  0.05;	  **p<	  0.01;	  unpaired	  ttest)	  
	  
The	  difference	   in	  LAG-­‐3	  blockade	  seen	   in	   the	  presence	  of	  Tiron	  may	  be	  due	  to	  an	  
upregulation	  of	  the	  LAG-­‐3	  ligand	  MHC	  II	  among	  the	  splenocyte	  population.	  We	  have	  
shown	  by	  flow	  cytometry	  that	  T	  cells	  activated	  with	  NP68	  ±	  TGF-­‐β	  express	  negligible	  
amounts	   of	   MHC	   II	   but	   in	   the	   presence	   of	   Tiron	   express	   significantly	   higher,	  





Figure	  5.8:	  Tiron	  induces	  MHC	  II	  expression	  on	  CD8+	  T	  cells	  
Mouse	  F5	  CD8	  T	  cells	  were	  stimulated	  with	  1nM	  NP68	  ±	  TGFβ	  (5ng/ml)	  ±	  Tiron	  (250μM).	  Cells	  were	  
harvested	  at	  72hours	  post-­‐activation	  and	  stained	  with	  fluorochrome-­‐conjugated	  anti-­‐CD8	  and	  anti-­‐
MHC	   II	   antibodies	   followed	   by	   flow	   cytometric	   analysis.	   The	  mean	   percent	   of	   CD8+	   cells	   staining	  
positive	  for	  MHC	  II	  are	  presented	  in	  a	  bar	  graph.	  The	  bars	  represent	  the	  mean±	  SD	  (n=3).	  (**p<	  0.01;	  
unpaired	  ttest)	  
	  
5.3.4. MitoROS	  scavenger	  increases	  CD8+	  IFN-­‐γ	  and	  IL-­‐2	  
production	  of	  TGF-­‐β-­‐experienced	  T	  cells	  upon	  TCR	  re-­‐
stimulation	  	  
IFN-­‐γ	  and	  IL-­‐2	  production	  are	  hallmarks	  of	  activated	  T	  cells,	  and	  the	  T	  cell	  derived	  IL-­‐
2	   in	   turn	   stimulates	  other	  T	  cells	   to	  produce	   IFN-­‐γ	   [165].	  Since	  TGF-­‐β	   is	  known	   to	  
inhibit	   IL-­‐2	   and	   IFN-­‐γ	   cytokine	   production	   in	   CD8+	   T	   cells,	   we	   examined	   whether	  
Tiron	   supplementation	   to	  NP68-­‐activated	  T	   cells	   that	   suffered	   inhibition	  by	  TGF-­‐β	  
can	  rescue	  the	  observed	  reduction	  in	  IFN-­‐γ	  and	  IL-­‐2	  production.	  As	  shown	  in	  figure	  
5.9,	   IFN-­‐γ	   and	   IL-­‐2	   production	   are	   significantly	   increased	   (p<0.01)	   upon	   NP68	   re-­‐
stimulation	   in	   T	   cells	   that	   were	   initially	   activated	   with	   Tiron	   supplementation.	   In	  
contrast,	   T	   cells	   that	   were	   initially	   activated	   with	   NP68	   and	   TGF-­‐β	   had	   lower	  
(p<0.05)	   IFN-­‐γ	  production	  compared	   to	  T	   cells	   initially	   stimulated	  with	  only	  NP68.	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Tiron	   supplementation	   after	   initial	   TCR	   stimulation	   was	   able	   to	   counter	   the	  
reduction	  in	  IFN-­‐γ	  production	  caused	  by	  TGF-­‐β.	  	  
	  
	  
Figure	  5.9:	  Tiron	  increases	  CD8+	  IFN-­‐γ	  and	  IL-­‐2	  production	  upon	  TCR	  re-­‐stimulation	  
Mouse	  F5	  CD8	  T	  cells	  were	  stimulated	  with	  1nM	  NP68	  ±	  TGFβ	  (5ng/ml)	  ±	  Tiron	  (250μM)	  for	  72hours,	  
washed	  and	  then	  re-­‐stimulated	  with	  1nM	  NP68	  for	  6hours	  with	  GolgiStop	  added	  after	  1hour.	  Cells	  
were	  harvested	  and	  stained	  with	  fluorochrome-­‐conjugated	  anti-­‐CD8,	  and	  then	  fixed	  and	  stained	  for	  
intracellular	  cytokine	  production	  with	  fluorochrome-­‐conjugated	  anti-­‐IL-­‐2	  and	  anti-­‐IFN-­‐γ	  followed	  by	  
flow	   cytometric	   analysis.	   The	   mean	   percent	   of	   CD8+	   cells	   staining	   positive	   for	   IL-­‐2	   or	   IFN-­‐γ	   are	  










5.3.5. MitoROS	  scavenger	  suppresses	  TGF-­‐β-­‐induced	  CREB	  
activation	  	  
In	  TCR-­‐activated	  CD8+	  T	  cells	  TGF-­‐β	  represses	  the	  cytotoxic	  IFN-­‐γ	  gene	  via	  activation	  
of	  the	  cAMP	  responsive	  element	  binding	  protein	  (CREB)	  [7].	  CREB	  is	  activated	  by	  a	  
number	   of	   growth	   factors,	   hormones	   and	   stress	   signals	   that	   trigger	   its	  
phosphorylation.	   In	   macrophages,	   the	   TGF-­‐β-­‐ROS-­‐CREB	  signaling	  axis	  is	   known	   to	  
trigger	   apoptosis	   as	   well	   as	   oxidative	   stress	   and	   DNA	   damage.	   The	   DNA	   damage	  
mediated	   survival	   signaling	   then	   further	   elevates	   CREB	   activation	   [60].	   Here	   we	  
show	  that	  NP68	  activated	  T	  cells	  display	  CREB	  activation,	  which	  is	  increased	  further	  
in	  the	  presence	  of	  TGF-­‐β.	  The	  addition	  of	  Tiron	  decreases	  CREB	  activation	  in	  NP68-­‐
activated	  T	  cells.	  Interestingly,	  the	  addition	  of	  Tiron	  to	  T	  cells	  activated	  with	  NP68	  in	  




Figure	  5.10:	  TGF-­‐β-­‐induced	  CREB	  is	  repressed	  by	  Tiron	  supplementation	  	  
	  Western	  blot	  analysis	  of	  phospho-­‐CREB	  (43kDa)	  in	  Mouse	  F5	  CD8+	  T	  cells	  stimulated	  with	  1nM	  NP68	  








5.3.6. MitoROS	  scavenger	  increases	  glycolysis	  and	  decreases	  
mitochondrial	  respiration	  of	  TGF-­‐β-­‐experienced	  T	  cells	  
following	  primary	  stimulation	   
To	   uncover	   the	   relative	   contribution	   of	   OXPHOS	   and	   glycolysis	   to	   the	   energy	  
demands	  of	  T	  cells	  activated	  with	  NP68	  in	  the	  presence	  of	  Tiron,	  we	  measured	  O2	  
consumption	   rates	   (OCR)	   and	  extracellular	   acidification	   rates	   (ECAR),	   respectively.	  






Figure	  5.11:	  Tiron	  supplementation	  promotes	  T	  cell	  metabolism	  
(a) O2	  consumption	  rates	  (OCR;	  pMoles/min)	  were	  measured	  using	  the	  seahorse	  XF96	  extracellular	  
flux	   analyzer	   in	   real	   time,	   under	   basal	   conditions	   and	   in	   response	   to	   sequential	   addition	   of	  
Oligomycin	   (1µM),	   2,4-­‐DNP	   (160μM)	   and	   Antimycin	   A	  &	   Rotenone	   (1	   µM).	  Mean	  OCR	   values	  
representing	   basal	   respiration,	   maximal	   respiration,	   spare	   respiratory	   capacity	   (SRC)	   and	   ATP	  
production	   are	   presented	   as	   bar	   charts.	   The	   bars	   represent	   the	   mean±	   SD.	   The	   data	   are	  
representative	  of	  three	  independent	  experiments,	  (**P<	  0.01;	  unpaired	  ttest).	  
(b) Extracellular	   acidification	   rate	   (ECAR;	   mpH/min)	   was	   measured	   using	   the	   seahorse	   XF96	  
extracellular	   flux	   analyzer	   in	   real	   time,	   under	   basal	   conditions	   and	   in	   response	   to	   sequential	  
addition	  of	  glucose	  (10mM),	  Oligomycin	  (1	  µM)	  and	  2-­‐deoxy-­‐D-­‐glucose	  (2-­‐DG)	  (100mM).	  Mean	  
ECAR	  values	  representing	  glycolysis	  and	  glycolytic	  capacity	  are	  presented	  as	  bar	  charts.	  The	  bars	  
represent	  the	  mean±	  SD.	  The	  data	  are	  representative	  of	  three	  independent	  experiments,	  (**P<	  
0.01;	  unpaired	  ttest).	  
 
We	   observed	   a	   significant	   (p<0.01)	   increase	   in	   basal	   respiration,	   maximal	  
respiration,	  spare	  respiratory	  capacity	  (SRC)	  and	  ATP	  production	  in	  T	  cells	  activated	  
with	  NP68	  in	  the	  presence	  of	  Tiron.	  In	  contrast,	  for	  T	  cells	  that	  were	  activated	  with	  
NP68	   and	   TGF-­‐β,	   Tiron	   significantly	   (p<0.01)	   reduced	   all	   of	   the	   above	  mentioned	  
metabolic	   parameters.	   T	   cells	   activated	   with	   NP68	   in	   the	   presence	   of	   Tiron	  
displayed	  significantly	  (p<0.01)	  higher	  glycolysis	  than	  T	  cells	  activated	  with	  NP68	  ±	  
TGF-­‐β	   (figure	   5.11	   (b)).	   Although	   there	   was	   no	   difference	   in	   glycolytic	   capacity	  
between	  NP68-­‐stimulated	  and	  NP68	  +	  Tiron-­‐stimulated	  T	  cells,	  Tiron	  decreased	  the	  
glycolytic	   capacity	   of	   T	   cells	   activated	  with	  NP68	   in	   the	  presence	  of	   TGF-­‐β.	   These	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results	   indicate	   that	   T	   cells	   activated	   in	   the	   presence	   of	   Tiron	   adopt	   a	  metabolic	  
program	  that	  maximizes	  basal	  glycolytic	  rate.	  
5.3.7. MitoROS	  scavenger	  increases	  glycolysis	  and	  decreases	  
mitochondrial	  respiration	  of	  TGF-­‐β-­‐experienced	  T	  cells	  
following	  secondary	  stimulation	   
Since	   elevated	   proliferation,	   IL-­‐2	   and	   IFN-­‐γ	   production	   were	   observed	   following	  
secondary	   stimulation,	   we	   investigated	   the	   relative	   contribution	   of	   OXPHOS	   and	  
glycolysis	   to	   the	   energy	   demands	   of	   TCR-­‐re-­‐stimulated	   T	   cells	   that	   experienced	   a	  
primary	  stimulation	  of	  NP68	  ±	  TGFβ	  ±	  Tiron.	  T	  cells	  were	  activated	  with	  1nM	  NP68	  ±	  
TGFβ	  (5ng/ml)	  ±	  Tiron	  (250μM)	  for	  72hours	  and	  then	  re-­‐stimulated	  with	  1nM	  NP68	  
for	  48hours	  (figure	  2.1).	  The	  OCR	  values	  of	  the	  T	  cell	  at	  the	  end	  of	  this	  time	  point	  






Figure	  5.12:	  T	  cells	  activated	  in	  the	  presence	  of	  Tiron	  display	  higher	  glycolysis	  at	  re-­‐stimulation	  
(a) O2	  consumption	  rates	  (OCR;	  pMoles/min)	  were	  measured	  using	  the	  seahorse	  XF96	  extracellular	  
flux	   analyzer	   in	   real	   time,	   under	   basal	   conditions	   and	   in	   response	   to	   sequential	   addition	   of	  
Oligomycin	   (1µM),	   2,4-­‐DNP	   (160μM)	   and	   Antimycin	   A	  &	   Rotenone	   (1	   µM).	  Mean	  OCR	   values	  
representing	   basal	   respiration,	   maximal	   respiration,	   spare	   respiratory	   capacity	   (SRC)	   and	   ATP	  
production	   are	   presented	   as	   bar	   charts.	   The	   bars	   represent	   the	   mean±	   SD.	   The	   data	   are	  
representative	  of	  three	  independent	  experiments,	  (**P<	  0.01;	  unpaired	  ttest).	  
(b) Extracellular	   acidification	   rate	   (ECAR;	   mpH/min)	   was	   measured	   using	   the	   seahorse	   XF96	  
extracellular	   flux	   analyzer	   in	   real	   time,	   under	   basal	   conditions	   and	   in	   response	   to	   sequential	  
addition	  of	  glucose	  (10mM),	  Oligomycin	  (1	  µM)	  and	  2-­‐deoxy-­‐D-­‐glucose	  (2-­‐DG)	  (100mM).	  Mean	  
ECAR	  values	  representing	  glycolysis	  and	  glycolytic	  capacity	  are	  presented	  as	  bar	  charts.	  The	  bars	  
represent	  the	  mean±	  SD.	  The	  data	  are	  representative	  of	  three	  independent	  experiments,	  (**P<	  
0.01;	  unpaired	  ttest).	  
	  
We	   observed	   a	   significant	   (p<0.01)	   increase	   in	   basal	   respiration,	   maximal	  
respiration,	  spare	  and	  ATP	  production	  in	  T	  cells	  initially	  activated	  with	  NP68	  in	  the	  
presence	  of	  Tiron.	  Interestingly,	  the	  SRC	  at	  re-­‐stimulation	  was	  significantly	  lower	  for	  
T	  cells	   initially	  activated	  with	  NP68	  +	  Tiron	  than	  cells	  activated	  with	  NP68	  only.	  All	  
other	  metabolic	  parameters	  followed	  a	  similar	  pattern	  to	  that	  shown	  in	  figure	  5.11	  
(a),	  but	  at	  higher	  OCR	  values.	  T	  cells	  with	  a	  primary	  stimulation	  of	  NP68	  ±	  TGF-­‐β	  +	  
Tiron	   displayed	   significantly	   (p<0.01)	   higher	   glycolysis	   after	   secondary	   stimulation	  
than	   T	   cells	   that	   received	   a	   primary	   stimulus	   of	   NP68	   ±	   TGF-­‐β	   (figure	   5.12	   (b)).	  
Compared	  to	  the	  metabolic	  profile	  after	  primary	  stimulation,	  re-­‐stimulation	  made	  a	  
profound	  difference	  to	  the	  glycolytic	  capacity.	  T	  cells	  with	  a	  primary	  stimulation	  of	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NP68	   ±	   TGF-­‐β	   +	   Tiron	   displayed	   significantly	   (p<0.01)	   higher	   glycolytic	   capacity	  
following	   secondary	   stimulation	   than	   T	   cells	   that	   received	   a	   primary	   stimulus	   of	  
NP68	  ±	  TGF-­‐β	   (figure	  5.12	   (b)).	  These	   results	   indicate	   that	  TCR-­‐activated	  T	  cells	   in	  
the	  presence	  of	   Tiron	  adopt	   a	  metabolic	  program	   that	  maximizes	   glycolysis	  when	  
re-­‐stimulated.	  
5.3.8. Paradoxical	  increase	  of	  mitoROS	  in	  TGF-­‐β-­‐experienced	  
activated	  T	  cells	  treated	  with	  mitoROS	  scavenger	   
Mitochondria	   are	   the	   main	   cellular	   source	   of	   energy	   and	   ROS	   in	   response	   to	  
metabolic	  demands	  and/or	  cellular	  stress.	  Although	  very	  high	  levels	  of	  mitoROS	  can	  
directly	  damage	  cellular	  components,	  mitoROS	  functions	  as	  a	  signaling	  molecule	  to	  
adapt	   to	   stress	   and	   is	   required	   for	   normal	   cell	   homeostasis.	   In	   addition,	  mitoROS	  
can	   constitutively	   promote	   cell	   proliferation	   [166].	   Since	   we	   found	   that	   Tiron	  
supplementation	  promoted	  T	  cell	  proliferation	  and	  cytokine	  production	  upon	  TCR-­‐
re-­‐stimulation,	   we	   determined	   mitoROS	   levels	   at	   48hours	   following	   Tiron	  
supplementation	  (figure	  2.1).	  The	  mitoROS	  levels	  of	  NP68	  ±	  TGF-­‐β-­‐stimulated	  T	  cells	  
significantly	  increased	  with	  Tiron	  supplementation	  (figure	  5.13	  (a)).	  Cell	  viability	  was	  
similar	  for	  NP68	  ±	  Tiron,	  but	  the	  presence	  of	  Tiron	  in	  NP68	  +	  TGFβ-­‐activated	  T	  cells	  




Figure	  5.13:	  Tiron	  supplementation	  increases	  mitoROS	  	  
(a) Mouse	  F5	  CD8	  T	  cells	  were	  stimulated	  with	  1nM	  NP68	  ±	  TGFβ	  (5ng/ml)	  ±	  Tiron	  (250μM).	  Cells	  
were	  harvested	  at	  72hours	  post-­‐activation	  and	  stained	  with	  MitoSOX™	  Red	  Mitochondrial	  
Superoxide	  Indicator	  and	  the	  staining	  intensities	  were	  quantified	  by	  flow	  cytometry.	  The	  mean	  
percent	  of	  CD8+	  cells	  staining	  positive	  for	  mitoROS	  are	  presented	  in	  a	  bar	  graph.	  The	  bars	  
represent	  the	  mean±	  SD	  (n=3).	  (*p<0.05;	  **p<	  0.01;	  unpaired	  ttest)	  
(b) Cell	  viability	  of	  F5	  CD8	  T	  cells	  stimulated	  with	  NP68	  ±	  TGFβ	  ±	  Tiron	  cultured	  for	  72hrs.	  
Percentage	  of	  viable	  cells	  determined	  using	  a	  trypan	  blue	  assay.	  The	  data	  are	  representative	  of	  









5.4. Discussion	  	  
The	  immunosuppressive	  effect	  imposed	  by	  TGF-­‐β	  on	  T	  cells	  is	  a	  determinant	  factor	  
for	   viral	   persistence	   and	   tumorigenesis.	   TGF-­‐β	   plays	   an	   active	   role	   in	   suppressing	  
anti-­‐viral	  T	  cell	  responses	  and	  inhibiting	  T	  cell-­‐mediated	  tumour	  clearance.	  Antigen-­‐
specific	  CD8+	  effector	  T	  cells	  that	  had	  undergone	  recent	  TCR	  stimulation	  are	  known	  
to	  have	  increased	  mitochondrial	  potential	  (ΔΨm)	  and	  high	  levels	  of	  ROS.	  During	  the	  
contraction	  phase	  the	  ΔΨm	  decreases	  but	  the	  superoxide	  levels	  remain	  the	  same.	  
The	   reduced	   ΔΨm	   leads	   to	   membrane	   permeability	   and	   subsequent	   caspase	  
activation	  [167].	  Mitochondrial	  ROS	  generation	  is	  required	  for	  the	  TGF-­‐β-­‐mediated	  
expression	  of	  genes	  [168].	  	  
A	  previous	  study	  investigated	  the	  effects	  of	  a	  metalloporphyrin-­‐mimetic	  compound	  
with	   superoxide	  dismutase	   activity	   on	   lymphocytic	   choriomeningitis	   virus	   (LCMV)-­‐
specific	   CD8+	   T	   cells.	   Treatment	  with	   this	   antioxidant	   reduced	   the	   expansion	   and	  
contraction	   of	   antigen-­‐specific	   CD8+	   T	   cells	   during	   primary	   activation	   and	   had	   no	  
effect	  on	  secondary	  activation	  [169].	  This	  study	  highlighted	  the	  importance	  of	  ROS	  
during	  T	  cell	  expansion	  and	  contraction	  following	  primary	  stimulation.	  The	  purpose	  
of	  the	  experiments	  presented	  here	  was	  to	  determine	  the	  effect	  of	  a	  mitochondria-­‐
localized	   antioxidant,	   Tiron,	   on	   the	   functional	   outcomes	   of	   TCR-­‐activated	   CD8+	   T	  
cells	  that	  have	  suffered	  inhibition	  by	  TGF-­‐β.	  	  
Our	   data	   shows	   that	   Tiron	   supplementation	   to	   antigen-­‐specific	   CD8+	   T	   cells	   that	  
have	   suffered	   inhibition	  by	  TGF-­‐β,	  display	   increased	   the	  proliferative	  capacity	  and	  
effector	   functions	   at	   secondary	   stimulation.	   Data	   from	   the	   present	   study	  
demonstrate	  that	  TCR-­‐stimulated	  T	  cells	  with	  Tiron	  supplementation	  have	  a	  distinct	  
functional	   response	   upon	   re-­‐stimulation.	   Tiron	   permeates	   lipid	  membranes	   freely	  
and	  preferentially	  localizes	  to	  the	  mitochondria	  where	  it	  can	  modulate	  intracellular	  
electron	  transfer	  reactions	  as	  an	  antioxidant	  by	  scavenging	  free	  radicals	  [170].	  Tiron	  
promoted	  increased	  activation	  parameters	  of	  TCR	  re-­‐stimulated	  T	  cells.	  We	  showed	  
that	   TGF-­‐β	   reduces	   the	   expression	   levels	   of	   LAG-­‐3	   and	   CD25	   receptors,	   and	   also	  
suppressed	  T	   cell	   proliferation.	  We	  demonstrated	   that	   Tiron	  was	   able	   to	   increase	  
the	   TGF-­‐β-­‐induced	   reduction	   of	   LAG-­‐3	   and	   CD25	   receptor	   expression	   levels.	  
Interestingly,	  the	  surface	  marker	  expression	  of	  CD25	  and	  LAG-­‐3	  increased	  in	  Tiron-­‐
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treated	   NP68-­‐stimulated	   T	   cells	   compared	   to	   the	   non-­‐treatment	   NP68	   only	  
condition.	   The	   changes	   in	   expression	   of	   surface	   receptors	  might	   prime	   the	   Tiron-­‐
experienced	   cells	   for	   a	   greater	   response	  upon	   re-­‐stimulation.	  Our	  data	   show	   that	  
Tiron	  also	  elevated	  activation	  parameters	  of	  re-­‐stimulated	  T	  cells	  that	  were	  initially	  
activated	   in	   the	   presence	   of	   TGF-­‐β.	   Furthermore,	  we	   showed	   that	   TGF-­‐β-­‐induced	  
CREB	  following	  primary	  stimulation	  is	  repressed	  by	  Tiron	  supplementation.	  	  
The	  mitochondrial	  respiratory	  chain	  is	  the	  major	  source	  of	  ROS.	  Excessive	  mitoROS	  
levels	   can	   induce	   cell	   death	   while	   non-­‐toxic	   levels	   serve	   as	   important	   signalling	  
molecules	  to	  regulate	  cell	  growth,	  survival	  and	  proliferation	  [171].	  It	  is	  thought	  that	  
MitoROS	  could	  possibly	  modulate	  redox	  regulated	  processes	  such	  as	  the	  activation	  
of	  growth-­‐related	  genes	  (c-­‐fos	  and	  c-­‐jun),	  the	  alterations	  of	  protein	  kinases	  activity	  
(tyrosine	  kinases,	  JNK,	  p38	  and	  ERK),	  oxidative	  inactivation	  of	  protein	  phosphatases	  
(PTEN	  and	  PP2A)	  and	  activation	  of	  transcription	  factors	  (AP-­‐1	  and	  NF-­‐kB)	  [171,	  172].	  
Any	  deregulation	  in	  mitoROS	  production	  could	  affect	  enzymes	  susceptible	  to	  redox	  
regulation	   and	   trigger	   unfavourable	   cellular	   outcomes	   including	   unwanted	   or	  
aberrant	   cell	   growth	   and/or	   proliferation.	   Several	   studies	   have	   also	   implicated	  
mitoROS	   in	   lymphocyte	   apoptosis.	   The	   involvement	   of	  mitoROS	   and	   CREB	   during	  
TCR/CD28	  activation	  of	  cytotoxic	  CD8+	  T	  cells,	  together	  with	  downstream	  signalling	  
events	  of	  LAG-­‐3,	  TGF-­‐β	  and	  IL-­‐2	  receptors	  are	  shown	  in	  the	  schematic	  below	  (figure	  
5.14).	  
Surprisingly,	   in	   contrast	   to	   T	   cells	   that	  were	   activated	  with	  NP68	   ±	   TGF-­‐β,	   T	   cells	  
activated	  with	  NP68±	   TGF-­‐β	  with	   Tiron	   supplementation	   had	   an	   elevated	   level	   of	  
mitoROS	   at	   72hrs.	   It	   is	   important	   to	   note	   that	   increased	   mitoROS	   is	   not	   always	  
equivalent	   to	   oxidative	   stress	   that	   results	   in	   cellular	   damage.	   Elevated	   ROS	   may	  
result	   in	   the	  specific	   redox-­‐dependent	  cell	   signalling	  below	  the	  required	  threshold	  
to	  induce	  oxidative	  damage	  leading	  to	  cell	  death.	  	  Re-­‐stimulation	  at	  this	  time	  point	  
enabled	  the	  Tiron-­‐experienced	  T	  cells	  to	  secrete	  more	  IL-­‐2	  cytokine	  and	  proliferate	  
at	   greater	   rates.	   Importantly,	   TCR-­‐activated	   CD8+	   T	   cells	   that	   have	   suffered	  
inhibition	   by	   TGF-­‐β	   displayed	   reduced	   proliferation	   and	   cytokine	   secretion	   at	   re-­‐
stimulation,	   which	   was	   overcome	   when	   Tiron	   was	   supplemented	   following	   the	  
primary	   TCR	   stimulation.	   This	  may	  be	  due	   to	   an	  upregulated	   antioxidant	   capacity	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that	   enables	   adaptation	   to	   higher	   intrinsic	   oxidative	   stress	   caused	   by	   the	   higher	  
mitochondrial	   activity	   to	   fuel	   the	   observed	   elevated	   functional	   outputs.	   T	   cells	  
activated	  with	  NP68	   in	   the	   presence	   of	   Tiron	   have	   an	   increased	   basal	   respiration	  
and	  higher	  rates	  of	  glycolysis	  at	  72hours.	  These	  cells	  attained	  an	  increased	  immune	  
cell	   response	   upon	   re-­‐stimulation	   as	   reflected	   by	   their	   elevated	   levels	   of	   pro-­‐
inflammatory	  cytokine	  secretion	  and	  proliferation.	  	  
	  
Figure	  5.14:	  Involvement	  of	  mitoROS	  and	  CREB	  during	  T	  cell	  activation	  	  
TCR	  triggering	  of	  CD8+	  T	  cells	  activates	  a	  number	  of	  signalling	  pathways	  that	  ultimately	  results	  in	  the	  
expression	  of	   cytotoxic	   gene	  products	   such	  as	   IFN-­‐γ,	  which	  are	   responsible	   for	  CTL-­‐mediated	  anti-­‐
tumour	  cytotoxicity.	  Downstream	  signalling	  from	  LAG-­‐3,	  TGF-­‐β	  and	  IL-­‐2	  receptors	  influence	  the	  gene	  
response	   program.	   TGF-­‐β-­‐induced	   CREB	   may	   cooperate	   with	   SMADs	   to	   repress	   IFN-­‐γ	   gene	  
expression	  in	  T	  cells.	  MitoROS	  may	  contribute	  to	  enhanced	  nuclear	   localization	  of	  the	  transcription	  
factor	  NFAT	  in	  order	  to	  increase	  IL-­‐2	  gene	  expression.	  	  
	  
In	   addition,	   we	   also	   found	   that	   Tiron-­‐treated	   NP68-­‐stimulated	   T	   cells	   express	  
detectable,	  albeit	  low	  levels	  of	  MHC	  class	  II	  molecules.	  Since	  mouse	  T	  cells	  lack	  the	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capability	   to	  synthesise	  MHC	  class	   II	  molecules	   [173],	   it	   is	   likely	   that	   the	  observed	  
expression	  was	  a	  result	  of	  MHC	  class	   II	   transfer	   from	  antigen	  presenting	  cells	   to	  T	  
cells	  [174].	  T	  cells	  that	  acquire	  MHC	  class	  II:	  peptide	  complexes	  are	  thought	  to	  act	  as	  
APCs	  and	   induce	  proliferation	  and	  IL-­‐2	  secretion	  by	  resting	  T	  cells	   [174].	  Thus,	  the	  
supplementation	  of	  Tiron	  may	  influence	  global	  effector	  functions	  by	  enabling	  T	  cells	  
to	  interact	  with	  additional	  T	  cell.	  	  
Collectively,	   these	   observations	   suggest	   that	   mitochondria-­‐localized	   antioxidants	  
may	   alter	   the	   sensitivity	   of	   T	   cells	   that	   have	   suffered	   inhibition	   by	   TGF-­‐β	   to	   TCR-­‐
induced	   secondary	   stimulation.	   Further	   studies	   are	   required	   to	   see	   whether	  
supplementation	  of	  a	  mitochondrial	  ROS	  scavenger	  following	  primary	  stimulation	  of	  
T	  cells,	  upregulates	  the	  cellular	  antioxidant	  capacity	   that	  would	  enable	  adaptation	  
to	  higher	   intrinsic	  oxidative	  stress	  caused	  by	  higher	  mitochondrial	  activity	  to	  meet	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6. Final	  Discussion	  	  
	  
Recent	   advances	   in	   immune	   mediated	   therapy	   have	   signalled	   a	   new	   era	   in	   the	  
treatment	  of	  cancer	  (as	  well	  as	  other	  indications	  such	  as	  autoimmune	  disease	  and	  
infectious	  disease),	  with	  opportunities	   for	  curative	   responses.	  These	   therapies	  are	  
largely	  based	  on	  T	  cell	   Immunomodulatory	  monoclonal	  antibodies	  (mAbs)	  that	  are	  
either	   direct	   agonists	   or	   relieve	   T	   cell	   inhibitory	   signals	   [86].	   At	   the	   same	   time,	  
however,	  these	  mAbs	  can	  be	  associated	  with	  a	  risk	  of	  serious	  adverse	  effects,	  which	  
include	   systemic	   induction	   of	   proinflammatory	   cytokines	   (cytokine	   release	  
syndrome)	   and	   organ-­‐specific	   autoimmunity,	   which	   arise	   from	   dysregulated	  
activation	  of	  the	  T	  cells	  [96].	  In	  the	  recent	  past,	  one	  such	  serious	  adverse	  event	  was	  
witnessed	   during	   a	   Phase	   I	   trial	   with	   TGN1412,	   a	   humanized	   CD28-­‐specific	  
superagonistic	  mAb	  (CD28SA)	  originally	  intended	  for	  the	  treatment	  of	  B	  cell	  chronic	  
lymphocytic	   leukaemia	   and	   rheumatoid	   arthritis,	   which	   caused	   severe	   immune-­‐
mediated	   toxicity	   (cytokine	   release	   syndrome)	   in	   healthy	   volunteers	   [92].	   The	  
underlying	   mechanism	   involved	   substantial	   proliferation	   and	   extravasation	   of	  
effector	   memory	   T	   cells	   (TEMs),	   and	   life-­‐threatening	   cytokine	   storm	   with	   highly	  
elevated	   levels	   of	   a	   number	   of	   pro-­‐inflammatory	   cytokines	   [97].	   Detailed	  
understanding	   of	   the	   target	   biology	   and	   identification	   of	   target	   specific	  
biomarkers/functional	   parameters	   for	   risk	   assessment	   would	   be	   highly	   beneficial	  
and	  aid	  our	  understanding	  of	  the	  safety	  profile	  of	  T	  cell	  modulatory	  mAbs	  in	  general	  
[87].	  While	  significant	  focus	  in	  recent	  times	  has	  been	  on	  assessing	  the	  potential	  of	  
immunomodulatory	   mAbs	   to	   induce	   enhanced	   cytokine	   release,	   much	   less	  
attention	   has	   been	   paid	   to	   other	   aspects	   of	   T	   cell	   biology	   including	   non-­‐
physiological	   activation	   phenotype/functions,	   migration	   characteristics	   and	  
metabolism.	  
Here,	  a	  humanized	  superagonistic	  anti-­‐CD28	  antibody	   (NIB1412)	  and	  conventional	  
anti-­‐CD3	  mAbs	  were	  used	  to	  demonstrate	  unlike	  conventional	  TCR/CD3	  activation	  
triggered	   by	   CD28SA.	   Activation	   by	   CD28SA	   lead	   to	   elevated	   proliferation	   with	   a	  
higher	   percentage	   of	   TEM	   (the	  main	   responding	   population	   to	   CD28SA	   activation)	  
remaining	  in	  S-­‐phase,	  reduced	  apoptosis,	  high	  secretion	  of	  IL-­‐2,	  high	  expression	  of	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TCR	  with	   fluctuating	  expression	   levels	  of	  CD28,	  elevated	  expression	  of	  stimulatory	  
markers	  GITR	  and	  CD137,	  high	  level	  expression	  of	  markers	  of	  antigen	  presentation;	  
HLA-­‐DR	  and	  CD80,	  elevated	  expression	  levels	  of	  LFA-­‐1,	  CCR5	  and	  CXCR4,	  enhanced	  
adhesion	   and	  migratory	   capacity,	   low	   level	   expression	   of	   co-­‐inhibitory	   receptors;	  
CTLA-­‐4	   and	   PD-­‐1,	   and	   finally	   in	   the	   presence	   of	   recombinant	   PD-­‐L1,	   CD28SA-­‐
activated	   TEMs	   display	   an	   absence	   of	   PD-­‐1-­‐mediated	   regulation	   together	   with	  
elevated	  expression	  of	  phospho-­‐PTEN	  and	  CK2.	  	  
Distinct	  metabolic	  profiles	  have	  been	  reported	  for	  various	  T	  cell	  subtypes	  and	  upon	  
activation	  with	  different	  agonists.	  These	  metabolic	  profiles	  are	  directly	   linked	  to	  T	  
cell	   effector	   functions	   and	   contribute	   to	   pathology	   such	   as	   cancer	   and	  
autoimmunity,	  by	  influencing	  key	  cellular	  events.	  Thus	  it	  was	  deemed	  important	  to	  
elucidate	  the	  metabolic	  profile	  of	  CD28SA-­‐activated	  cells	  to	  understand	  their	  energy	  
needs	  and	  how	   it	  may	  affect	  effector	   functions.	  The	  metabolic	  profile	  of	  CD28SA-­‐
activated	   T	   cells	   was	   found	   to	   include	   maximal	   OXPHOS	   potential	   and	   glucose	  
utilization,	   together	  with	  de	   novo	   lipogenesis	   as	   demonstrated	   by	   high	   activity	   of	  
ACL	   and	   ACC.	   CD28SA	   stimulation	   was	   also	   found	   to	   induce	   autophagy.	   	   A	   high	  
glycolytic	  flux	  into	  increased	  lipid	  synthesis,	  increased	  cell	  migration	  and	  autophagy	  
are	  characteristics	  observed	  in	  aggressive	  and	  invasive	  tumours.	  	  
The	   PD-­‐1	   co-­‐inhibitory	   receptor	   has	   been	   shown	   to	   be	   a	   powerful	   negative	  
regulator	  of	  activated	  T	  cells.	   In	  the	  absence	  of	  PD-­‐1-­‐mediated	  signals,	   there	   is	  an	  
increased	   propensity	   for	   T	   cells	   to	   expand	   with	   stronger	   accompanying	  
inflammatory	  cascades.	  Regulation	  of	  T	  cell	  activation	  by	  PD-­‐1	  therefore	  represents	  
a	   key	   characteristic	   of	   physiological	   behaviour	   and	  has	   the	  potential	   to	   report	   on	  
the	  nature	  of	  T	  cell	  activation	  induced	  by	  a	  T	  cell	  mAb.	  Given	  the	  absence	  of	  PD-­‐1-­‐
mediated	   regulation	   together	  with	   the	  distinct	  metabolic	  phenotype	  observed	   for	  
CD28SA	  activation,	  a	   framework	  for	  biomarker	  design	  to	  predict	  adverse	   immune-­‐
mediated	  effects	  that	  arise	  as	  a	  consequence	  of	  immunostimulatory	  mAbs-­‐induced	  
excessive	  T	  cell	  activation	  can	  be	  developed.	   In	  addition,	  a	  detailed	  understanding	  
of	   activation	   parameters,	   degree	   of	   regulation,	  migration	   capacity	   and	  metabolic	  
programs	   adopted	   by	   the	   target	   cell	   upon	   mAb	   action	   may	   inform	   the	   drug	  




The	  cytokine	  milieu	  in	  the	  microenvironment	  of	  affected	  tissues	  also	  influences	  the	  
functional	  outcome	  of	  immunomodulatory	  mAbs.	  The	  immunosuppressive	  cytokine	  
TGF-­‐β	  attenuates	  the	  cytotoxic	  T	  cell-­‐mediated	  anti-­‐tumour	  immune	  responses	  and	  
may	  also	  reduce	  the	  effectiveness	  of	  immunotherapy.	  Agents	  that	  block	  TGF-­‐β	  and	  
its	   signalling	   pathway	   are	   under	   development	   at	   both	   the	   pre-­‐clinical	   and	   clinical	  
stages.	  In	  the	  present	  study,	  the	  activation	  parameters	  and	  the	  metabolic	  program	  
adopted	  by	  T	  cells	   that	  have	  suffered	   inhibition	  by	  TGF-­‐β	  was	   investigated.	   It	  was	  
demonstrated	   that	   TGF-­‐β	   suppresses	   TCR-­‐stimulated	   T	   cell	   proliferation	   and	  
significantly	   reduces	   LAG-­‐3	   and	  CD25	  expression	  on	  TCR-­‐stimulated	  T	   cells.	   TGF-­‐β	  
experienced	   T	   cells	  were	   also	   found	   to	   be	   less	   responsive	   to	   LAG-­‐3	   blocking.	   The	  
relief	  of	  TGF-­‐β-­‐induced	  oxidative	  stress	  by	  supplementation	  of	  a	  mitochondrial	  ROS	  
scavenger	  was	  found	  to	  increase	  LAG-­‐3	  and	  CD25	  expression,	  proliferative	  capacity,	  
effector	  cytokine	  (IL-­‐2	  and	  IFN-­‐γ)	  production	  and	  glycolysis	  in	  TCR-­‐stimulated	  T	  cells.	  
Instead	  of	   targeting	  TGF-­‐β	  during	   immunomodulatory	  mAb-­‐based	   cancer	   therapy,	  
the	  supplementation	  of	  a	  mitochondrial	  ROS	  scavenger	  could	  negate	  the	  effects	  of	  
TGF-­‐β-­‐induced	  suppression.	  	  
The	  CD28SA	  is	  thought	  to	  induce	  maximal	  activation	  of	  the	  CD28	  receptor	  and	  thus	  
all	  observed	  parameters	  that	  were	  shown	  to	  be	  elevated	  compared	  to	  physiological	  
CD3/TCR	   activation,	   may	   be	   directly	   linked	   to	   the	   signalling	   components	   of	   the	  
CD28	  signalling	  pathway.	   	  Several	  outstanding	  questions	  remain	  regarding	  CD28SA	  
activation	   and	   how	   it	   by-­‐passes	   inhibitory	   receptor	   expression,	   and	   whether	   the	  
lack	  of	  inhibitory	  inputs	  is	  the	  cause	  behind	  the	  altered	  metabolic	  program.	  Since	  an	  
upregulation	  of	  pro-­‐stimulatory	  receptors	  (e.g.	  CD137,	  GITR,	  HLA-­‐DR	  and	  CD80)	  was	  
observed,	   each	   one	   of	   these	   receptors	   may	   also	   feed	   into	   signalling	   events	   that	  
influence	   the	  metabolic	   profile.	   Future	   investigations	   should	   be	   directed	   towards	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